

BEST AVAILABLE COPY

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 2, 2004, 19:31:09 ; Search time 16 Seconds
(without alignments)
781.761 Million cell updates/sec

Title: US-10-072-159-11
Perfect score: 708
Sequence: 1 FSVGLTETVTPNPIRFTK.....YADNDNSTGTGLLYHDTN 130

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-Processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79:*
1: Pirl:*
2: Pirl:*
3: Pirl:*
4: Pirl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	708	100.0	244	2	JC4708
2	297.5	42.0	674	2	JC23297
3	287.5	40.6	680	1	CSHUID
4	280.5	39.6	674	2	S13301
5	280.5	38.6	680	2	S13216
6	273.5	38.6	743	1	S23779
7	270.5	38.2	744	2	S15435
8	267.5	37.8	744	1	A34246
9	263.5	37.2	744	1	S23298
10	258.5	36.5	170	2	B57111
11	258.5	36.5	635	2	A57111
12	243.5	34.4	619	2	T14782
13	219	30.9	245	1	CIHUQC
14	219	30.9	423	2	A55797
15	208.5	29.4	246	2	S29328
16	186	26.3	253	2	S49158
17	184	26.0	253	2	I49560
18	182.5	25.8	253	1	CIHUQB
19	178	25.1	215	2	B48150
20	176	24.9	196	2	A48150
21	174	24.6	215	2	C48150
22	156	22.0	245	2	S19018
23	151.5	21.4	245	1	CIHUQA
24	119.5	16.9	224	2	A50032
25	116.5	16.5	193	2	A37873
26	113.5	16.0	1228	2	A57384
27	86.5	12.2	213	2	B51360
28	82	11.6	280	1	G70126
29	77	10.9	687	2	E69733

ALIGNMENTS

RESULT 1

JC4708
Gelatin-binding 28K protein precursor - human
N:Alternate names: adipose specific collagen-like factor
C:Species: Homo sapiens (man)
C>Date: 10-May-1996 #sequence_revision 19-Jul-1996 #text_change 09-Jul-2004
C:Accession: JC4708; JC4944
R:Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K.
Biochem. Biophys. Res. Commun. 221, 286-289, 1996
A>Title: cDNA cloning and expression of a novel adipose specific collagen-like factor, af
A:Reference number: JC4708; MUID:96224171; PMID:8619847
A:Accession: JC4708
A:Molecule type: mRNA
A:Residues: 1-244 <MAX>
A:Cross-references: UNIPROT:Q15848; DDBJ:D453171; NID:g871886; PIDN:BAA08227.1; PID:g871886
A:Experimental source: adipose tissue
R:Nakano, Y.; Tober, T.; Choe-Mura, N.H.; Mazda, T.; Tomita, M.
J. Biochem. 120, 803-812, 1996
A>Title: Isolation and characterization of GSP28, a novel gelatin-binding protein purified
A:Reference number: JC4944; MUID:97103474; PMID:8947845
A:Accession: JC4944
A:Molecule type: protein
A:Residues: 19-38;93-100;101-112;135-149;173-178 <MAX>
C:Comment: This protein is an endogenous factor that binds with a collagen-like domain. J

C:Genetics:
A:Gene: apMI
C:Keywords: adipose tissue; glycoprotein; hydroxyproline
F:1-18/Domain: signal sequence #status predicted <SIG>
F:19-244/Product: Gelatin-binding 28kDa protein #status experimental <MAT>
F:42-107/Region: collagen-like
F:114-241/Domain: complement C1q carboxyl-terminal homology <CIQ>
F:95/Modified site: 4-hydroxyproline (Pro) #status experimental
F:230/Binding site: carboxylate (Asn) (covalent) #status predicted

Query Match 100.0%; Score 708; DB 2; Length 244;
Best Local Similarity 100.0%; Pred. NO. 1.2e-63;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	FSVGLTETVTPNPIRFTKIFYNQNNHYDQSGTGKHCNIPGLYFYAYHTVTVMKDKVYS	60
DB	115	FSVGLTETVTPNPIRFTKIFYNQNNHYDQSGTGKHCNIPGLYFYAYHTVTVMKDKVYS	174
QY	61	LFKKDKAMLFYDQYQENNVQDQSGSVLLHLEVGDQVWLQVYGEGRNGLYADNDNSTF	120
DB	175	LFKKDKAMLFYDQYQENNVQDQSGSVLLHLEVGDQVWLQVYGEGRNGLYADNDNSTF	234
QY	121	TGFLLYHDTN	130
DB	235	TGFLLYHDTN	244

RESULT 2

S23297

collagen alpha 1(X) chain precursor - chicken

N/Alternate names: type X collagen

C/Species: Gallus gallus (chicken)

C/Date: 07-Oct-1994 #sequence revision 10-Nov-1995 #text_change 09-Jul-2004

C/Accession: S23297; A31896; S65594; S77711; I50218

R/Ninomiya, Y.; Castagnola, P.; Gerecke, D.; Gordon, M.K.; Jacenko, O.; LuValle, P.; McG

maguchi, N.; Olsen, B.R.

in Extracellular Matrix Genes, Sandell L.J. and Boyd C.D., eds., pp.79-114, Academic Pre

A/Title: The molecular biology of collagens with short triple-helical domains.

A/Reference number: S22243

A/Accession: S23297

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-674 <NIN>

A/Cross-references: UNIPROT:P08125

R/LuValle, P.; Ninomiya, Y.; Rosenblum, N.D.; Olsen, B.R.

J. Biol. Chem. 263, 18378-18385, 1988

A/Title: The type X collagen gene. Intron sequences split the 5'-untranslated region and

A/Reference number: A31896; MUID:89054019; PMID:2461368

A/Accession: A31896

A/Molecule type: mRNA

A/Residues: 1-75 <LUV>

R/Ninomiya, Y.; Gordon, M.; van der Rest, M.; Schmid, T.; Linsemmayer, T.; Olsen, B.R.

J. Biol. Chem. 261, 5041-5050, 1986

A/Title: The developmentally regulated type X collagen gene contains a long open reading

A/Reference number: I50218; MUID:86168227; PMID:3082876

A/Accession: S65594

A/Molecule type: DNA

A/Residues: 'T', '9', '11-12', 'EDQKLYILFTM', '30-31', 'TCKSGRAFTYMLQNMADLVSSHT', '48-89', 'L',

629, 'PQAVLSIRWRTKSGSCQIQNPMSIPLNMFLLSQSVLYLKSNIPITMS' <NINI>

A/Cross-references: EMBL:M13496; NID:G211699; PIDN:AAA48736.1; PID:G211700

A/Accession: S77711

A/Molecule type: protein

A/Residues: 104-112, 'X', '114-117', '453-466 <NIN>

C/Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology

C/Keywords: coiled coil; extracellular matrix; glycoprotein; homotrimer; hydroxyproline;

F1-18/Domain: signal sequence #status predicted <SIG>

F1547-673/Domain: complement C1q carboxyl-terminal homology <C1Q>

F1453-456/Modified site: hydroxyproline (Pro) #status experimental

F1611/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 42.0%; Score 297.5; DB 2; Length 674;

Best Local Similarity 47.6%; Pred. No. 6.8e-22;

Matches 59; Conservative 21; Mismatches 43; Indels 1; Gaps 1;

QY 1 FSVGLTETVTIPNPIRFTKIFYNQKHGDSGTGKFCNTPGLYFYFAYHITVYMKOVKVS 60

Db 548 FTVLRSKAYPGATVPKFDKLLYNRQHQYDPTGIFTCPGLYFSYHVAKGTNNVWA 607

QY 61 LFKKDKAMLFYDYQENNVQDAGSVLLHLVGDQVWLQVYGEGERNGLYADNDNSTF 120

Db 608 LYKNGSPVMYTYEYKGYLDQAGSAVIDLMENDQVWLQ-L-PNSENGLYSSEYVHSSF 666

QY 121 TGFL 124

Db 667 SGFL 670

RESULT 3

CGRUID

-collagen alpha 1(X) chain precursor - human

N/Alternate names: procollagen alpha 1(X) chain

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence revision 03-Nov-1995 #text_change 09-Jul-2004

C/Accession: S26396; S30086; S18249; A43901; I51870; S21856

R/Reichenberger, E.; Beier, F.; LuValle, P.; Olsen, B.R.; von der Mark, K.; Bertling, W.

FEBS Lett. 311, 305-310, 1992

A/Title: Genomic organization and full-length cDNA sequence of human collagen X.

A/Reference number: S26396; MUID:93012005; PMID:1397353

A/Accession: S26396

A/Molecule type: DNA

A/Residues: 1-680 <REI>

A/Cross-references: UNIPROT:Q03692; EMBL:X68952; EMBL:X72578; EMBL:X72579; EMBL:X72580; C

R/Apre, S.S. submitted to the EMBL Data Library, March 1992

A/Reference number: S30085

A/Accession: S30086

A/Molecule type: DNA

A/Residues: 'TTPFYGVWVCLL', '52-680 <APT>

A/Cross-references: EMBL:X65120; NID:G23129

A/Note: the initial difference is probably due to translation of an intronic sequence

R/Bate, S.; Mattai, M.G.; Olsen, B.R.

FEBS Lett. 282, 393-396, 1991

A/Title: Cloning of human alpha-1(X) collagen DNA and localization of the COL10A1 gene to

A/Reference number: S15826; MUID:91243838; PMID:2037056

A/Accession: S15826

A/Molecule type: DNA

A/Residues: '561-647', 'G', '649-666 <AP2>

A/Cross-references: EMBL:X58879; NID:G30013; PIDN:CAA41686.1; PID:G30014

R/Thomas, J.T.; Cresswell, C.J.; Rash, B.; Nicolai, H.; Jones, T.; Solomon, E.; Grant, M.

Biochem. J. 280, 617-623, 1991

A/Title: The human collagen X gene. Complete primary translated sequence and chromosomal

A/Reference number: S18249; MUID:92109659; PMID:1764025

A/Accession: S18249

A/Molecule type: DNA

A/Residues: '1-26', 'T', '28-680 <THO>

A/Cross-references: EMBL:X80392; NID:G30094; PIDN:CAA42933.1; PID:G30095

A/Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 532-Ala

R/Reichenberger, E.; Aigner, T.; von der Mark, K.; Stoss, H.; Bertling, W.

Dev. Biol. 148, 562-572, 1991

A/Title: In situ hybridization studies on the expression of type X collagen in fetal hum

A/Reference number: A43901; MUID:92077285; PMID:1743401

A/Accession: A43901

A/Molecule type: mRNA

A/Residues: '547-656 <RE2>

A/Cross-references: GB:M74050; GB:D57494; NID:G339884; PIDN:AAA61221.1; PID:G553796

A/Note: sequence extracted from NCBI backbone (NCBI:69012, NCBI:69014)

R/Wallis, G.A.; Rash, B.; Sweetman, W.A.; Thomas, J.T.; Super, M.; Evans, G.; Grant, M.E.

Am. J. Hum. Genet. 54, 169-178, 1994

A/Title: Amino acid substitutions of conserved residues in the carboxyl-terminal domain c

pe Schmid.

A/Reference number: I51870; MUID:94136476; PMID:8304336

A/Accession: I51870

A/Status: translated from GB/EMBL/DBJ

A/Molecule type: mRNA

A/Residues: '520-597', 'D', '599-650 <WAL>

A/Cross-references: GB:S8053; NID:G545180; PIDN:AAC0615.1; PID:G545181

A/Note: mutant sequence from patient with metaphyseal chondrodysplasia type Schmid

C/Comment: Prolines and lysines at the third position of the tripeptide repeating unit (C

ed and subsequently O-glycosylated.

C/Genetics:

A/Gene: GDB:COL10A1

A/Cross-references: GDB:128635; OMIM:120110

A/Map position: 6q21-6q22

A/Introns: 52/1

A/Note: a defect in this gene may cause Schmid metaphyseal chondrodysplasia

C/Complex: type X collagen may be a homotrimer

C/Function:

A/Description: structural component of extracellular fibrous polymer specifically and tr

C/Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology

C/Keywords: coiled coil; extracellular matrix; glycoprotein; homotrimer; hydroxylysine; t

F1-18/Domain: signal sequence #status predicted <SIG>

F19-680/Product: collagen alpha 1(X) chain #status predicted <MAT>

F19-567/Domain: amino-terminal nonhelical #status predicted <NC2>

F157-519/Region: interrupted helical

F1520-680/Domain: amino-terminal nonhelical #status predicted <NC1>

F1553-679/Domain: complement C1q carboxyl-terminal homology <C1Q>

F1611/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 40.6%; Score 287.5; DB 1; Length 680;

Best Local Similarity 46.4%; Pred. No. 6.9e-21;

Matches 58; Conservative 19; Mismatches 47; Indels 1; Gaps 1;


```
A:Molecule type: DNA
A:Residues: 1-743 <MUR>
A/Cross-references: UNIPROT:Q00780; EMBL:X66976; NID:G50493; PIDN:CAA47387.1; PID:g13599
C:Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology
F:616-742/Domain: complement C1q carboxyl-terminal homology <CIQ>

Query Match 38.6%; Score 273.5; DB 1; Length 743;
Best Local Similarity 45.1%; Pred. No. 2e-19;
Matches 55; Conservative 27; Mismatches 35; Indels 5; Gaps 2;

QY 9 VTIP-----NNPIRTKIFVQNNHYDGGSTGKFCNIPGLYFYFAYHTVYMKDKVKSLEKK 64
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
621 LVVFPFPGVGVKFDKLLNGRQVNPQTGFTCEVGVYFYFAYHVKGGVWVAFKFN 680

QY 65 DKAMLTYYQYQNNVDQASGVLLHLEVDQVWLQVYGEGERNGLYADNDNDSTFTGFL 124
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
681 NEPMVYTYDEYKGFDDQASGVALLRPGDQVFLQNPPE-QAAGLYAGQVHSSFSGYL 739

QY 125 LY 126
Db || 740 LY 741

RESULT 7
S15435
collagen alpha 1(VIII) chain precursor - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C:Accession: S15435
R:Muragaki, Y.; Mattei, M.G.; Yamaguchi, N.; Olsen, B.R.; Ninomiya, Y.
Eur. J. Biochem. 197, 615-622, 1991
A:Title: The complete primary structure of the human alpha-1(VIII) chain and assignment
A:Reference number: S15435; MUID:91231001; PMID:2025894
A:Accession: S15435
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-744 <MUR>
A/Cross-references: UNIPROT:P27658; EMBL:X57527; NID:G30081; PIDN:CAA40748.1; PID:g30082
C:Genetics:
A:Gene: GDB:COL8A1
A/Cross-references: GDB:128104; OMIM:120251
A:Map position: 3q11.1-3q13.2
C:Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-744/Product: collagen alpha 1(VIII) chain #status predicted <MAT>
F:21-117/Region: amino-terminal nonhelical
F:118-571/Region: interrupted helical
F:572-744/Region: carboxyl-terminal nonhelical
F:617-743/Domain: complement C1q carboxyl-terminal homology <CIQ>

Query Match 38.2%; Score 270.5; DB 2; Length 744;
Best Local Similarity 45.5%; Pred. No. 3.9e-19;
Matches 51; Conservative 28; Mismatches 32; Indels 1; Gaps 1;

QY 15 PIRTKIFVQNNHYDGGSTGKFCNIPGLYFYFAYHTVYMKDKVKSLEKKAMLTYYDQ 74
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
632 PVKFNLLYNGRQVNPQTGFTCEVGVYFYFAYHVKGGVWVAFKFNPEVMTYDE 691

QY 75 YOENNVDQASGVLLHLEVDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY 126
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
692 YKGFDDQASGVALLRPGDQVFLQNPSE-QAAGLYAGQVHSSFSGYLLY 742

RESULT 8
A34246
collagen alpha 1(VIII) chain precursor - rabbit
C:Species: Oryctolagus cuniculus (domestic rabbit)
C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C:Accession: A34246
R:Yamaguchi, N.; Benya, P.D.; van der Rest, M.; Ninomiya, Y.
J. Biol. Chem. 264, 16022-16029, 1989
A:Title: The cloning and sequencing of alpha1(VIII) collagen cDNAs demonstrate that type
X chains similar to those of type X collagen.

A:Molecule type: DNA
A:Residues: 1-744 <YAM>
A/Cross-references: UNIPROT:P14282; GB:J05042; NID:G164895; PIDN:AAA31204.1; PID:g164896
C:Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-744/Product: collagen alpha 1(VIII) chain #status predicted <MAT>
F:21-117/Region: amino-terminal nonhelical
F:118-571/Region: interrupted helical
F:572-744/Region: carboxyl-terminal nonhelical
F:617-743/Domain: complement C1q carboxyl-terminal homology <CIQ>

Query Match 37.8%; Score 267.5; DB 1; Length 744;
Best Local Similarity 45.5%; Pred. No. 7.9e-19;
Matches 51; Conservative 28; Mismatches 32; Indels 1; Gaps 1;

QY 15 PIRTKIFVQNNHYDGGSTGKFCNIPGLYFYFAYHTVYMKDKVKSLEKKAMLTYYDQ 74
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
632 PIKFDLLYNGRQVNPQTGFTCEVGVYFYFAYHVKGGVWVAFKFNPEVMTYDE 691

QY 75 YOENNVDQASGVLLHLEVDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY 126
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
692 YKGFDDQASGVALLRPGDQVFLQNPSE-QAAGLYAGQVHSSFSGYLLY 742

RESULT 9
S23298
collagen alpha 1(VIII) chain - chicken
C:Species: Gallus gallus (chicken)
C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C:Accession: S23298
R:Ninomiya, Y.; Castagnola, P.; Gerscke, D.; Gordon, M.K.; Jacenko, O.; LuValle, P.; McCa-
maguchi, N.; Olsen, B.R.
in Extracellular Matrix Genes, Sandell L.J. and Boyd C.D., eds., pp.79-114, Academic Pres
A:Title: The molecular biology of collagens with short triple-helical domains.
A:Reference number: S23298
A:Accession: S23298
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-744 <NIN>
A/Cross-references: UNIPROT:Q7L2R2.
C:Superfamily: collagen alpha 1(VIII) chain; complement C1q carboxyl-terminal homology
F:617-743/Domain: complement C1q carboxyl-terminal homology <CIQ>

Query Match 37.2%; Score 263.5; DB 1; Length 744;
Best Local Similarity 45.5%; Pred. No. 2e-18;
Matches 51; Conservative 27; Mismatches 33; Indels 1; Gaps 1;

QY 15 PIRTKIFVQNNHYDGGSTGKFCNIPGLYFYFAYHTVYMKDKVKSLEKKAMLTYYDQ 74
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
632 PIKFDLLYNGRQVNPQTGFTCEVGVYFYFAYHVKGGVWVAFKFNPEVMTYDE 691

QY 75 YOENNVDQASGVLLHLEVDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY 126
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
692 YKGFDDQASGVALLRPGDQVFLQNPSE-QAAGLYAGQVHSSFSGYLLY 742

RESULT 10
B57131
collagen alpha 2(VIII) chain - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 03-Nov-1995 #sequence_revision 03-Nov-1995 #text_change 09-Jul-2004
C:Accession: B57131
R:Muragaki, Y.; Jacenko, O.; Apre, S.; Mattei, M.G.; Ninomiya, Y.; Olsen, B.R.
J. Biol. Chem. 266, 7721-7727, 1991
A:Title: The alpha2(VIII) collagen gene. A novel member of the short chain collagen faml]
A:Reference number: A57131; MUID:91210292; PMID:2019595
A:Accession: B57131
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-170 <MUR>
A/Cross-references: UNIPROT:P25318; GB:M60833
```


BEST AVAILABLE COPY

C;Superfamily: collagen alpha 1(VIII) chain; complement Clq carboxyl-terminal homology
F;43-169/Domain: complement Clq carboxyl-terminal homology <ClQ>
Query Match 36.5%; Score 258.5; DB 2; Length 170;
Best Local Similarity 40.8%; Pred. No. 1.1e-18;
Matches 51; Conservative 27; Mismatches 46; Indels 1; Gaps 1;
QY 1 FSVGLETVTIPNMPRTFKIFPNQNHVDGSGKPHCNIPGLYFAYHITVYMKDVKVS 60
DB 44 FTAVLTSPPASGMPVRFDRTLNGHSGVNPATGIFSCPVGGVYFAYHVVKGTVNWVA 103
QY 61 LFKDKAMLFYDQYQENNVDQASGVLLHLEVDGQVWLQVYGEGERNGLYADNDNDSTF 120
DB 104 LYKXNVPATYDYBYKKGYLDQASGGAVQLQRENDQVWQMPSD-QANGLYSTYETHSSP 162
QY 121 TGFLL 125
DB 163 SGFLL 167
RESULT 11
A57131
collagen alpha 2(VIII) chain - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 03-Nov-1995 #sequence_revision 03-Nov-1995 #text_change 09-Jul-2004
C;Accession: A57131
R;Muragaki, Y.; Jacenko, O.; Apte, S.; Mattei, M.G.; Ninomiya, Y.; Olsen, B.R.
J. Biol. Chem. 266, 7721-7727, 1991
A;Title: The alpha2(VIII) collagen gene. A novel member of the short chain collagen fami
A;Reference number: A57131; MUID:91210292; PMID:2019595
A;Accession: A57131
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-635 <MUR>
A;Cross-references: UNIPROT:P25067; GB:M60832; NID:g177178; PID:AAA62822.1; PID:g177178
C;Genetics:
A;Gene: GDB:COL8A2
A;Cross-references: GDB:127812; OMIM:120252
A;Map position: 1p34.3-p32.3
C;Superfamily: collagen alpha 1(VIII) chain; complement Clq carboxyl-terminal homology
F;1-11/Domain: amino-terminal nonhelical (fragment) #status predicted <NC2>
F;12-468/Region: interrupted helical
F;469-635/Domain: carboxyl-terminal nonhelical #status predicted <NC7>
F;508-634/Domain: complement Clq carboxyl-terminal homology <ClQ>
Query Match 36.5%; Score 258.5; DB 2; Length 635;
Best Local Similarity 40.8%; Pred. No. 5.2e-18;
Matches 50; Conservative 29; Mismatches 45; Indels 1; Gaps 1;
QY 1 FSVGLETVTIPNMPRTFKIFPNQNHVDGSGKPHCNIPGLYFAYHITVYMKDVKVS 60
DB 509 FTAVLTSPLASGMPVRFDRTLNGHSGVNPATGIFTCPVGGVYFAYHVVKGTVNWVA 568
QY 61 LFKDKAMLFYDQYQENNVDQASGVLLHLEVDGQVWLQVYGEGERNGLYADNDNDSTF 120
DB 569 LYKXNVPATYDYBYKKGYLDQASGGAVQLQRENDQVWQIPSD-QANGLYSTYETHSSP 627
QY 121 TGFLL 125
DB 628 SGFLL 632
RESULT 12
T14782
hypotheical protein DKFZp586B0621.1 - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C;Accession: T14782
R;Ottewaelder, B.; Obermaier, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, August 1999
A;Reference number: Z18184
A;Accession: T14782
A;Status: preliminary

A;Molecule type: mRNA
A;Residues: 1-219 <OTT>
A;Cross-references: UNIPROT:Q9XKJ0; EMBL:AL110261
A;Experimental source: adult uterus; clone DKFZp586B0621
C;Genetics:
A;Note: DKFZp586B0621.1
Query Match 34.4%; Score 243.5; DB 2; Length 219;
Best Local Similarity 42.18; Pred. No. 4.7e-17;
Matches 53; Conservative 23; Mismatches 45; Indels 5; Gaps 4;
QY 6 ETVYVIP-NMIRTKIFPNQNHVDGSGKPHCNIPGLYFAYHITVYMKDVKVSLEKK 64
DB 88 ESRVPPSPDAPLEDRVLVNEQGHYDAVTGKFTQVPGVYFAYHATVYRASLQFDLVKN 147
QY 65 DKAMLFYDQYQENNVDQ--SGSVLLHLEVDGQVWLQVYGEGERNGLYADNDNDSTFTG 122
DB 148 GES-IASFFQFGGWKXPASLSGGAMVRLPEQDQWVQV-GVGDIYIGIYASIKTDSIFSG 205
QY 123 FLLYHD 128
DB 206 FLVYSD 211
RESULT 13
CIHUQC
complement subcomponent Clq chain C precursor - human
N;Alternate names: complement subcomponent Clq gamma chain
C;Species: Homo sapiens (man)
C;Date: 22-May-1991 #sequence_revision 31-May-1996 #text_change 09-Jul-2004
C;Accession: S14351; A03207
R;Sellar, G.C.; Blake, D.J.; Reid, K.B.M.
Biochem. J. 274, 481-490, 1991
A;Title: Characterization and organization of the genes encoding the A-, B- and C-chains
A;Reference number: S14350; MUID:91174759; PMID:1706597
A;Accession: S14351
A;Status: not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-245 <SEL>
A;Cross-references: UNIPROT:P02747
R;Reid, K.B.M.
Biochem. J. 179, 367-371, 1979
A;Title: Complete amino acid sequences of the three collagen-like regions present in sub
A;Reference number: A90304; MUID:60020137; PMID:486087
A;Accession: A03207
A;Molecule type: protein
A;Residues: 29-56; P;58-65; K;73-83; K;85-86; D;88-89; N;91-122 <REI>
C;Comment: The first component of complement is a calcium-dependent complex of the three
ivation of C1r (enzyme), C1s (proenzyme), and the other eight components of complement.
C;Comment: The C1q subcomponent is composed of nine subunits, six of which are disulfide-
dimers of the C chain. Equimolar amounts of the A, B, and C chains are found after reduc
C;Genetics:
A;Gene: GDB:CIQO
A;Cross-references: GDB:128132; OMIM:120575
A;Map position: 1p36.3-1p34.1
A;Intons: 60/3
C;Superfamily: complement subcomponent Clq chain A; complement Clq carboxyl-terminal hom
C;Keywords: complement pathway; glycoprotein; homodimer; hydroxylsine; hydroxyproline; I
F;1-28/Domain: signal sequence #status predicted <SIG>
F;29-245/Product: complement subcomponent Clq chain B #status predicted <NAR>
F;31-114/Domain: collagenous, triple helix <COL>
F;121-244/Domain: complement Clq carboxyl-terminal homology <ClQ>
F;32/Disulfide bonds: interchain #status experimental
F;36,39,42,45,54,63,81,93,95,99,105/Modified site: 4-hydroxyproline (Pro) #status experin
F;57,72,75/Modified site: 5-hydroxylsine (Lys) #status experimental
F;75/Binding site: carbonylate (Lys) (covalent) #status experimental
Query Match 30.9%; Score 219; DB 1; Length 245;
Best Local Similarity 40.8%; Pred. No. 1.6e-14;
Matches 53; Conservative 22; Mismatches 47; Indels 8; Gaps 5;
QY 1 FSVGLETV-VTFNMPRTFKIFPNQNHVDGSGKPHCNIPGLYFAYHITVYMKDVKV 59

Db 122 FTVTRQTHOPPAPNSLIRNAVLNTPQGDYDSTGKFTCKVGLYFYVTHAS-HTANLCV 180
QY 60 SLFKD-KAMLFYDYQYQNNVDQAGSVLLHLEVGQVWLQVYGEGERGLYADNDNDS 118
Db 181 LLYRSGVKVTVTCGHTSKTNQVN--SGGVLLRLQVGEVWLAVNDYDMVGI---QGSDS 235
QY 119 TFGGLLYHD 128
Db 236 VFGGLLFPD 245

RESULT 14

A55797
collagen precursor, sacculle-specific - bluegill
C:Species: Lepomis macrochirus (bluegill)
C>Date: 23-Mar-1995 #sequence_revision 23-Mar-1995 #text_change 15-Sep-2003
C/Accession: A55797
R/Davis, J.G.; Oberholtzer, J.C.; Burns, F.R.; Greene, M.I.
Science 267, 1031-1034, 1995
A>Title: Molecular cloning and characterization of an inner ear-specific structural protein
A/Reference number: A55797; MUID:95167486; PMID:7863331
A/Accession: A55797
A>Status: Preliminary
A/Molecule type: mRNA
A/Residues: 1-423 <DAV>
A/Cross-references: GB:U17431; NID:9687605; PIDN:AAA69978.1; PID:9687606
F:58-271/Domain: collagenous, triple helix #status predicted <COL>
F:281-410/Domain: complement Clq carboxyl-terminal homology <Clq>

Query Match 30.9%; Score 219; DB 2; Length 423;
Best Local Similarity 43.1%; Pred. No. 3e-14;
Matches 44; Conservative 17; Mismatches 39; Indels 2; Gaps 1;
QY 1 FSVGL--ETVTPNMPIRFTKIFYNQNNHYDGTGKFKHCNIPGLYFYFAYHITVYMKDVK 58
Db 282 FSVGLFPSSPPPLPVKFKVFNKGCHNDPTLNKENVTPGVLYFSYHITVRNRPV 341
QY 59 VSLFKDKAMLFYDYQYQNNVDQAGSVLLHLEVGQVWLQ 100
Db 342 AALVNVGVRLTRDSLYQDIDQASNLALLHLTDGQVWLE 383

RESULT 15

S29328
complement subcomponent Clq chain C - mouse
C:Species: Mus musculus (house mouse)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C/Accession: S29328
R/Petry, F.; Reid, K.B.M.; Loos, M.
Eur. J. Biochem. 209, 129-134, 1992
A>Title: Isolation, sequence analysis and characterization of cDNA clones coding for the
ecerebellin.
A/Reference number: S29328; MUID:93011118; PMID:1396691
A/Accession: S29328
A>Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-246 <PET>
A/Cross-references: UNIPROT:Q02105; EMBL:X66295; NID:950228; PIDN:CAA46993.1; PID:950229
C/Superfamily: complement subcomponent Clq chain A; complement Clq carboxyl-terminal hom
F:122-245/Domain: complement Clq carboxyl-terminal homology <Clq>

Query Match 29.4%; Score 208.5; DB 2; Length 246;
Best Local Similarity 38.8%; Pred. No. 1.8e-13;
Matches 45; Conservative 23; Mismatches 43; Indels 5; Gaps 3;
QY 13 NMPTRFTKIFYNQNNHYDGTGKFKHCNIPGLYFYFAYHITVYMKDVKSLFKDKAMLFY 72
Db 136 NALVRFSVNTNPGQHYNPSTGKFTCEVPGLYFVY--TSHTANLCVHL-NLNLRVAGF 193
QY 73 DQYQNNVDQAGSVLLHLEVGQVWLQVYGEGERGLYADNDNDSTFTGGLLYHD 128
Db 194 CDHFNKQVSSGGALLRLRGDEVWLSV---NDYNGWIGEGNSVFGGLLFPD 246

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 2, 2004, 19:26:59 ; Search time 68 Seconds
(without alignments)
685.806 Million cell updates/sec

Title: US-10-072-159-11
Perfect score: 708
Sequence: 1 FSVGLTFTVTPNPPIRFTK.....YADNDNSTGTGFLYHDTN 130

Scoring table: BLOSUM62
Gapop 10.0., Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-Processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04.*
1: Geneseq1980s.*
2: Geneseq1990s.*
3: Geneseq2000s.*
4: Geneseq2001s.*
5: Geneseq2002s.*
6: Geneseq2003as.*
7: Geneseq2003bs.*
8: Geneseq2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	708	100.0	130	2	AA01485
2	708	100.0	130	7	AD93609 Human adi
3	708	100.0	137	7	AD93608 Human adi
4	708	100.0	144	7	AD93607 Human adi
5	708	100.0	145	7	AD93613 Human adi
6	708	100.0	157	7	AD93606 Human adi
7	708	100.0	163	7	AD93612 Human adi
8	708	100.0	163	7	AD93655 Human adi
9	708	100.0	187	7	AD93615 Human adi
10	708	100.0	193	7	AD93614 Human adi
11	708	100.0	203	7	AD93605 Human adi
12	708	100.0	226	7	AD93604 Human adi
13	708	100.0	231	2	AA01480
14	708	100.0	231	4	AB060347
15	708	100.0	233	7	AD93630
16	708	100.0	244	3	AA014807
17	708	100.0	244	3	AA014807
18	708	100.0	244	3	AA014807
19	708	100.0	244	3	AA014807
20	708	100.0	244	4	AB05828 Human adi
21	708	100.0	244	4	AB05829 Human adi
22	708	100.0	244	4	AB05829 Human adi
23	708	100.0	244	4	AB05829 Human adi
24	708	100.0	244	4	AB05829 Human adi
25	708	100.0	244	5	AB08223 Human adi

26	708	100.0	244	5	AAG80254
27	708	100.0	244	6	ABP70915
28	708	100.0	244	6	ABR42035
29	708	100.0	244	6	ABU98378
30	708	100.0	244	6	ABP70905
31	708	100.0	244	6	ABP70905
32	708	100.0	244	6	ABP70905
33	708	100.0	244	6	ABR40088
34	708	100.0	244	6	ABR40249
35	708	100.0	244	6	AAO30071
36	708	100.0	244	6	AAE37142
37	708	100.0	244	6	ABR40221
38	708	100.0	244	6	ABR39850
39	708	100.0	244	6	ABR44306
40	708	100.0	244	6	ABP70910
41	708	100.0	244	6	ABP70910
42	708	100.0	244	6	ABP70910
43	708	100.0	244	6	ABR43906
44	708	100.0	244	6	ABU08790
45	708	100.0	244	6	ABP98485

ALIGNMENTS

RESULT 1
AA01485
ID AA01485 standard; peptide; 130 AA.
XX
AC AA01485;
XX
DT 21-MAY-1999 (first entry)
XX
DE ApM1 protein fragment (residues 115-244).
XX
KW Dietary lipid; liver; peripheral tissue; medicament; C1q complement;
KW partitioning; lipolysis stimulated receptor; LSR; hypertension; G1q,R;
KW obesity; atherosclerosis; insulin resistance; obesity-related disease;
KW microangiopathy; Type II diabetes; ocular lesion; renal lesion; cachexia;
KW neoplastic; eating disorder; ApM1.
XX
OS Homo sapiens.
XX
PN WO9907736-A2.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98WO-IB001256.
XX
PR 06-AUG-1997; 97FR-00010088.
PR 22-APR-1998; 98FR-00005032.
XX
PA (GEST) GENSET.
PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI Bihaun B, Bougueleret L, Yen-Potin F;
XX
DR WPI; 1999-167364/14.
XX
PT Use of lipolysis stimulated receptor - for developing agents for
PT modulating partitioning of dietary lipids between the liver and
PT peripheral tissues, e.g. for treating obesity.
XX
PS Claim 6; Page 70; 77pp; English.
XX
CC The invention relates to agents which influence the partitioning of
CC dietary lipids between the liver and peripheral tissues for use as
CC medicaments. Sequences shown in AA01481-488 that relate to C1q
CC complement family and two consensus sequences (AA01499-500) are
CC potentially useful as such agents. Compounds that influence the
CC partitioning of dietary lipids between the liver and peripheral tissues
CC can be used in medicament for treating a condition in which the
CC partitioning of dietary lipids to the liver is abnormal. A polypeptide

CC having binding specificity for a gamma subunit of the lipolysis
 CC stimulated receptor (LSR) or a GCLG.R or GCLG.R homologue can be used for
 CC treatment of obesity, where the polypeptide is not a subunit of the LSR.
 CC The agents which increase partitioning of dietary lipids to the liver can
 CC be used for treating obesity-related atherosclerosis, obesity-related
 CC insulin resistance, obesity-related hypertension, microangiopathic lesions
 CC resulting from obesity-related Type II diabetes, ocular lesions caused by
 CC microangiopathy in obese individuals with Type II diabetes, and renal
 CC lesions caused by microangiopathy in obese individuals with Type II
 CC diabetes. Agents which decrease the partitioning of dietary lipids to the
 CC liver can be used for treating cachexia in subjects with neoplastic or
 CC para-neoplastic syndrome or eating disorders. The present sequence
 CC represents a claimed peptide fragment of ApM1
 XX
 SQ Sequence 130 AA;

Query Match 100.0%; Score 708; DB 2; Length 130;
 Best Local Similarity 100.0%; Pred. No. 3.4e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FSVGLETVYTPNMPRTKIFYNQNHQYDGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 60
 Db 1 FSVGLETVYTPNMPRTKIFYNQNHQYDGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 60
 Qy 61 LFKKDKAMLFYDQYQENNVQASGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Db 61 LFKKDKAMLFYDQYQENNVQASGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Qy 121 TGFLLYHDTN 130
 Db 121 TGFLLYHDTN 130

RESULT 2
 ADE93609
 ID ADE93609 standard; protein; 130 AA.

AC ADE93609;
 DT 12-FEB-2004 (first entry)
 DE Human adiponectin apM1 (115-244) protein.

XX adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
 KW antirheumatic; antibacterial; antilipemic; dermatological;
 KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 KW atherosclerosis; cardiovascular disease; dyslipidaemia;
 KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 KW Sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 KW myocardial infarction; inflammation; gene therapy; human; apM1;
 KW wild-type.

XX Homo sapiens.
 XX WO2003055916-A2.
 XX 10-JUL-2003.

XX 20-DEC-2002; 2002WO-DK000897.
 XX 21-DEC-2001; 2001DK-00001952.
 XX 21-DEC-2001; 2001US-0343482P.
 XX 25-APR-2002; 2002DK-00000527.
 XX 25-APR-2002; 2002US-0375492P.
 XX 03-JUL-2002; 2002DK-00001036.
 XX 03-JUL-2002; 2002US-0394117P.
 XX 20-SEP-2002; 2002DK-00001385.
 XX 20-SEP-2002; 2002US-0412169P.

XX (MAXY-) MAXYGEN APS.
 XX (MAXY-) MAXYGEN HOLDINGS LTD.

PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;

PI Bogness A;
 XX NPI; 2003-598262/56.
 XX New conjugate comprising an adiponectin polypeptide and a first non-
 PT polypeptide moiety, useful for preparing a composition for treating a
 PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 XX Claim 14; SEQ ID NO 7; 184pp; English.

XX The invention relates to a novel conjugate comprising an adiponectin
 CC polypeptide and a first non-polypeptide moiety covalently attached to the
 CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 CC acid residue having an attachment group for the first non-polypeptide
 CC moiety which has been introduced in a position where the parent
 CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiarteriosclerotic,
 CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipemic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, Sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1 protein of the
 CC invention.

XX Sequence 130 AA;

Query Match 100.0%; Score 708; DB 7; Length 130;
 Best Local Similarity 100.0%; Pred. No. 3.4e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FSVGLETVYTPNMPRTKIFYNQNHQYDGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Db 1 FSVGLETVYTPNMPRTKIFYNQNHQYDGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Qy 61 LFKKDKAMLFYDQYQENNVQASGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Db 61 LFKKDKAMLFYDQYQENNVQASGSVLLHLEVDQVWLVQVYGERNGLYADNDNSTF 120
 Qy 121 TGFLLYHDTN 130
 Db 121 TGFLLYHDTN 130

RESULT 3
 ADE93608
 ID ADE93608 standard; protein; 137 AA.

XX ADE93608;
 XX 12-FEB-2004 (first entry)
 XX Human adiponectin apM1 (108-244) protein.

XX adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
 KW antirheumatic; antibacterial; antilipemic; dermatological;
 KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 KW atherosclerosis; cardiovascular disease; dyslipidaemia;
 KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 KW Sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 KW myocardial infarction; inflammation; gene therapy; human; apM1;
 KW wild-type.

XX Homo sapiens.
 XX WO2003055916-A2.
 XX 10-JUL-2003.

XX 20-DEC-2002; 2002WO-DK000897.

XX 21-DEC-2001; 2001DK-00001952.
PR 21-DEC-2001; 2001US-0343482P.
PR 25-APR-2002; 2002DK-00000627.
PR 25-APR-2002; 2002US-0375492P.
PR 03-JUL-2002; 2002DK-00001036.
PR 03-JUL-2002; 2002US-0394117P.
PR 20-SEP-2002; 2002DK-00001385.
PR 20-SEP-2002; 2002US-0412169P.
XX (MAXY-) MAXYGEN APS.
FA (MAXY-) MAXYGEN HOLDINGS LTD.
XX Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
PI Bogsnes A;
XX WPI; 2003-598262/56.
XX New conjugate comprising an adiponectin polypeptide and a first non-
PT polypeptide moiety, useful for preparing a composition for treating a
PT polypeptide moiety, useful for preparing a composition for treating a
PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
XX Claim 14; SEQ ID NO 6; 184pp; English.
XX The invention relates to a novel conjugate comprising an adiponectin
CC polypeptide and a first non-polypeptide moiety covalently attached to the
CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
CC acid residue having an attachment group for the first non-polypeptide
CC moiety which has been introduced in a position where the parent
CC adiponectin is occupied by a surface exposed amino acid residue. The
CC conjugate of the invention demonstrates antiarteriosclerotic,
CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipæmic,
CC dermatological, immunosuppressive, immunomodulator and anorectic
CC activities and may be useful for treating diabetes, obesity,
CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
CC infarction and destructive processes related to activation of the
CC inflammatory system, as well as during gene therapy procedures. The
CC current sequence is that of the human adiponectin apM1 protein of the
CC invention.
XX Sequence 137 AA;

Query Match 100.0%; Score 708; DB 7; Length 137;
Best Local Similarity 100.0%; Pred. No. 3.6e-78;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FSVGLETVYVTPNNPIRFTKIFYNQNNHYDGTGKFCNCIPGLYFYFAYHITVYMKDVKVS 60
DB 8 FSVGLETVYVTPNNPIRFTKIFYNQNNHYDGTGKFCNCIPGLYFYFAYHITVYMKDVKVS 67
QY 61 LFKKDKAMLFYDQYQENNVQAGSVLLHLEVGQWLVQYGEGERNGLYADNDNSTF 120
DB 68 LFKKDKAMLFYDQYQENNVQAGSVLLHLEVGQWLVQYGEGERNGLYADNDNSTF 127
QY 121 TGFLLYHDTN 130
DB 128 TGFLLYHDTN 137

RESULT 4
ADE93607
ID ADE93607 standard; protein; 144 AA.
XX ADE93607;
AC ADE93607;
XX 12-FEB-2004 (first entry)
DT Human adiponectin apM1(101-244) protein.
DE adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
KW antirheumatic; antibacterial; antilipæmic; dermatological;
XX

KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
KW atherosclerosis; cardiovascular disease; dyslipidaemia;
KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
KW sjogren syndrome; cachexia; septic shock; myasthenia gravis;
KW myocardial infarction; inflammation; gene therapy; human; apM1;
KW wild-type.
XX Homo sapiens.
OS WO2003055916-A2.
XX 10-JUL-2003.
XX 20-DEC-2002; 2002WO-DK000897.
XX 21-DEC-2001; 2001DK-00001952.
PR 21-DEC-2001; 2001US-0343482P.
PR 25-APR-2002; 2002DK-00000627.
PR 25-APR-2002; 2002US-0375492P.
PR 03-JUL-2002; 2002DK-00001036.
PR 03-JUL-2002; 2002US-0394117P.
PR 20-SEP-2002; 2002DK-00001385.
PR 20-SEP-2002; 2002US-0412169P.
XX (MAXY-) MAXYGEN APS.
FA (MAXY-) MAXYGEN HOLDINGS LTD.
XX Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
PI Bogsnes A;
XX WPI; 2003-598262/56.
XX New conjugate comprising an adiponectin polypeptide and a first non-
PT polypeptide moiety, useful for preparing a composition for treating a
PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
XX Claim 44; SEQ ID NO 5; 184pp; English.
XX The invention relates to a novel conjugate comprising an adiponectin
CC polypeptide and a first non-polypeptide moiety covalently attached to the
CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
CC acid residue having an attachment group for the first non-polypeptide
CC moiety which has been introduced in a position where the parent
CC adiponectin is occupied by a surface exposed amino acid residue. The
CC conjugate of the invention demonstrates antiarteriosclerotic,
CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipæmic,
CC dermatological, immunosuppressive, immunomodulator and anorectic
CC activities and may be useful for treating diabetes, obesity,
CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
CC infarction and destructive processes related to activation of the
CC inflammatory system, as well as during gene therapy procedures. The
CC current sequence is that of the human adiponectin apM1 protein of the
CC invention.
XX Sequence 144 AA;

Query Match 100.0%; Score 708; DB 7; Length 144;
Best Local Similarity 100.0%; Pred. No. 3.9e-78;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FSVGLETVYVTPNNPIRFTKIFYNQNNHYDGTGKFCNCIPGLYFYFAYHITVYMKDVKVS 60
DB 15 FSVGLETVYVTPNNPIRFTKIFYNQNNHYDGTGKFCNCIPGLYFYFAYHITVYMKDVKVS 74
QY 61 LFKKDKAMLFYDQYQENNVQAGSVLLHLEVGQWLVQYGEGERNGLYADNDNSTF 120
DB 75 LFKKDKAMLFYDQYQENNVQAGSVLLHLEVGQWLVQYGEGERNGLYADNDNSTF 134
QY 121 TGFLLYHDTN 130
DB 135 TGFLLYHDTN 144

RESULT 5
ADE93613
ID ADE93613 standard; protein; 145 AA.
XX AC ADE93613;
XX DE 12-FEB-2004 (first entry)
XX DE Human adiponectin apM1(100-244) protein.
XX KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
KW antirheumatic; antibacterial; antilipaeamic; dermatological;
KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
KW atherosclerosis; cardiovascular disease; dyslipidaemia;
KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
KW sjogren syndrome; cachexia; septic shock; myasthenia gravis;
KW myocardial infarction; inflammation; gene therapy; human; apM1;
XX wild-type.
XX OS Homo sapiens.
XX PN WO2003055916-A2.
XX PD 10-JUL-2003.
XX PF 20-DEC-2002; 2002WO-DK000897.
XX PR 21-DEC-2001; 2001DK-00001952.
XX PR 21-DEC-2001; 2001US-0343482P.
XX PR 25-APR-2002; 2002DK-00000627.
XX PR 25-APR-2002; 2002US-0375492P.
XX PR 03-JUL-2002; 2002DK-00001036.
XX PR 03-JUL-2002; 2002US-0394117P.
XX PR 20-SEP-2002; 2002DK-00001385.
XX PR 20-SEP-2002; 2002US-0412169P.
XX (MAXY-) MAXYGEN APS.
XX PA (MAXY-) MAXYGEN HOLDINGS LTD.
XX PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
XX PI Bognes A;
XX DR WPI; 2003-598262/56.
XX PT New conjugate comprising an adiponectin polypeptide and a first non-
XX PT polypeptide moiety, useful for preparing a composition for treating a
XX PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
XX PS Claim 44; SEQ ID NO 11; 184pp; English.
XX CC The invention relates to a novel conjugate comprising an adiponectin
XX CC polypeptide and a first non-polypeptide moiety covalently attached to the
XX CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
XX CC acid residue having an attachment group for the first non-polypeptide
XX CC moiety which has been introduced in a position where the parent
XX CC adiponectin is occupied by a surface exposed amino acid residue. The
XX CC conjugate of the invention demonstrates antiarteriosclerotic,
XX CC antidiabetic, cardiant, antirheumatic, immunomodulator and anorectic,
XX CC dermatological, immunosuppressive, immunomodulator and anorectic
XX CC activities and may be useful for treating diabetes, obesity,
XX CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
XX CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
XX CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
XX CC infarction and destructive processes related to activation of the
XX CC inflammatory system, as well as during gene therapy procedures. The
XX CC current sequence is that of the human adiponectin apM1 protein of the
XX CC invention.
XX SQ Sequence 145 AA;
XX Query Match 100.0%; Score 708; DB 7; Length 145;

Best Local Similarity 100.0%; Pred. No. 3.9e-78;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FSVGLETVVTPNNPIRFTKIFYNQNHQYDGTGCKFKHCNIFGLYYPAYHITVYMKDKVKS 60
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DB 16 FSVGLETVVTPNNPIRFTKIFYNQNHQYDGTGCKFKHCNIFGLYYPAYHITVYMKDKVKS 75
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVDQVWLVQVYGERNGLYADNDSTF 120
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
76 LFKKDKAMLFYDQYQENNVQASGVLLHLEVDQVWLVQVYGERNGLYADNDSTF 135
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 121 TGFLLYHDTN 130
DB 136 TGFLLYHDTN 145
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESULT 6
ADE93606
ID ADE93606 standard; protein; 157 AA.
XX AC ADE93606;
XX DE 12-FEB-2004 (first entry)
XX DE Human adiponectin apM1(88-244) protein.
XX KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
KW antirheumatic; antibacterial; antilipaeamic; dermatological;
KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
KW atherosclerosis; cardiovascular disease; dyslipidaemia;
KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
KW sjogren syndrome; cachexia; septic shock; myasthenia gravis;
KW myocardial infarction; inflammation; gene therapy; human; apM1;
XX wild-type.
XX OS Homo sapiens.
XX PN WO2003055916-A2.
XX PD 10-JUL-2003.
XX PF 20-DEC-2002; 2002WO-DK000897.
XX PR 21-DEC-2001; 2001DK-00001952.
XX PR 21-DEC-2001; 2001US-0343482P.
XX PR 25-APR-2002; 2002DK-00000627.
XX PR 25-APR-2002; 2002US-0375492P.
XX PR 03-JUL-2002; 2002DK-00001036.
XX PR 03-JUL-2002; 2002US-0394117P.
XX PR 20-SEP-2002; 2002DK-00001385.
XX PR 20-SEP-2002; 2002US-0412169P.
XX (MAXY-) MAXYGEN APS.
XX PA (MAXY-) MAXYGEN HOLDINGS LTD.
XX PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
XX PI Bognes A;
XX DR WPI; 2003-598262/56.
XX PT New conjugate comprising an adiponectin polypeptide and a first non-
XX PT polypeptide moiety, useful for preparing a composition for treating a
XX PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
XX PS Claim 44; SEQ ID NO 4; 184pp; English.
XX CC The invention relates to a novel conjugate comprising an adiponectin
XX CC polypeptide and a first non-polypeptide moiety covalently attached to the
XX CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
XX CC acid residue having an attachment group for the first non-polypeptide
XX CC moiety which has been introduced in a position where the parent
XX CC adiponectin is occupied by a surface exposed amino acid residue. The
XX CC conjugate of the invention demonstrates antiarteriosclerotic,
XX CC antidiabetic, cardiant, antirheumatic, immunomodulator and anorectic,
XX CC dermatological, immunosuppressive, immunomodulator and anorectic
XX CC activities and may be useful for treating diabetes, obesity,
XX CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
XX CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
XX CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
XX CC infarction and destructive processes related to activation of the
XX CC inflammatory system, as well as during gene therapy procedures. The
XX CC current sequence is that of the human adiponectin apM1 protein of the
XX CC invention.
XX SQ Sequence 145 AA;
XX Query Match 100.0%; Score 708; DB 7; Length 145;

CC anti-diabetic, cardiant, antirheumatic, antibacterial, antilipaeamic, antidiabetic, cardiant, antirheumatic, antibacterial, antilipaeamic, dermatological, immunosuppressive, immunomodulator and anorectic activities and may be useful for treating diabetes, obesity, atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, Sjogren syndrome, cachexia, septic shock, myasthenia gravis, myocardial infarction and destructive processes related to activation of the inflammatory system, as well as during gene therapy procedures. The current sequence is that of the human adiponectin apM1 protein of the invention.

XX SQ Sequence 157 AA;

Query Match 100.0%; Score 708; DB 7; Length 157;
Best Local Similarity 100.0%; Pred. No. 4.4e-78;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 60
DB 28 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 87
QY 61 LFKDKKAMLFYDQYQENNVDAQSGVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
DB 88 LFKDKKAMLFYDQYQENNVDAQSGVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 147
QY 121 TGFLLYHDTN 130
DB 148 TGFLLYHDTN 157

RESULT 7
ADE93612
ID ADE93612 standard; protein; 163 AA.
AC ADE93612;
DT 12-FEB-2004 (first entry)
DE Human adiponectin apM1 (82-244) protein.
KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant; antirheumatic; antibacterial; antilipaeamic; dermatological; immunosuppressive; immunomodulator; anorectic; diabetes; obesity; atherosclerosis; cardiovascular disease; dyslipidaemia; rheumatoid arthritis; Crohn's; systemic lupus erythematosus; Sjogren syndrome; cachexia; septic shock; myasthenia gravis; myocardial infarction; inflammation; gene therapy; human; apM1; wild-type.
OS Homo sapiens.
XX WO2003055916-A2.
XX 10-JUL-2003.
XX 20-DEC-2002; 2002WO-DK000897.
XX 21-DEC-2001; 2001DK-00001952.
XX 21-DEC-2001; 2001US-0343482P.
XX 25-APR-2002; 2002DK-00000627.
XX 25-APR-2002; 2002US-0375492P.
XX 03-JUL-2002; 2002DK-00001036.
XX 03-JUL-2002; 2002US-0394117P.
XX 20-SEP-2002; 2002DK-00001385.
XX 20-SEP-2002; 2002US-0412169P.
XX (MAXY-) MAXYGEN APS.
PA (MAXY-) MAXYGEN HOLDINGS LTD.
XX Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T, Bognes A;
XX WPI; 2003-598262/56.

DR N-PSDB; ADE93618.
XX New conjugate comprising an adiponectin polypeptide and a first non-polypeptide moiety, useful for preparing a composition for treating a mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
PS Claim 44; SEQ ID NO 10; 184pp; English.
CC The invention relates to a novel conjugate comprising an adiponectin polypeptide and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide. The adiponectin polypeptide comprises an amino acid residue having an attachment group for the first non-polypeptide moiety which has been introduced in a position where the parent adiponectin is occupied by a surface exposed amino acid residue. The conjugate of the invention demonstrates antiarteriosclerotic, antidiabetic, cardiant, antirheumatic, antibacterial, antilipaeamic, dermatological, immunosuppressive, immunomodulator and anorectic activities and may be useful for treating diabetes, obesity, atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, Sjogren syndrome, cachexia, septic shock, myasthenia gravis, myocardial infarction and destructive processes related to activation of the inflammatory system, as well as during gene therapy procedures. The current sequence is that of the human adiponectin apM1 protein of the invention.

XX SQ Sequence 163 AA;

Query Match 100.0%; Score 708; DB 7; Length 163;
Best Local Similarity 100.0%; Pred. No. 4.6e-78;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 60
DB 34 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 93
QY 61 LFKDKKAMLFYDQYQENNVDAQSGVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
DB 94 LFKDKKAMLFYDQYQENNVDAQSGVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 153
QY 121 TGFLLYHDTN 130
DB 154 TGFLLYHDTN 163

RESULT 8
ADE93655
ID ADE93655 standard; protein; 163 AA.
AC ADE93655;
XX 12-FEB-2004 (first entry)
DT Human adiponectin Y11N-apM1 (82-244) mutant protein.
DE
XX
KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant; antirheumatic; antibacterial; antilipaeamic; dermatological; immunosuppressive; immunomodulator; anorectic; diabetes; obesity; atherosclerosis; cardiovascular disease; dyslipidaemia; rheumatoid arthritis; Crohn's; systemic lupus erythematosus; Sjogren syndrome; cachexia; septic shock; myasthenia gravis; myocardial infarction; inflammation; gene therapy; human; apM1; mutant; mutein.
OS Synthetic.
OS Homo sapiens.
XX WO2003055916-A2.
XX 10-JUL-2003.
XX 20-DEC-2002; 2002WO-DK000897.

PR 21-DEC-2001; 2001DK-00001952.
 PR 21-DEC-2001; 2001US-0343482P.
 PR 25-APR-2002; 2002DK-00000627.
 PR 25-APR-2002; 2002US-0375492P.
 PR 03-JUL-2002; 2002DK-00001036.
 PR 03-JUL-2002; 2002US-0394117P.
 PR 20-SEP-2002; 2002DK-00001385.
 PR 20-SEP-2002; 2002US-0412169P.
 XX
 PA (MAXY-) MAXYGEN APS.
 PA (MAXY-) MAXYGEN HOLDINGS LTD.
 XX
 PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
 PI Bogsnes A;
 XX
 DR WPI; 2003-598262/56.
 DR N-PSDB; ADE93667.
 XX
 PT New conjugate comprising an adiponectin polypeptide and a first non-
 PT polypeptide moiety, useful for preparing a composition for treating a
 PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 XX
 PS Claim 38; SEQ ID NO 53; 184pp; English.
 XX
 CC The invention relates to a novel conjugate comprising an adiponectin
 CC polypeptide and a first non-polypeptide moiety covalently attached to the
 CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 CC acid residue having an attachment group for the first non-polypeptide
 CC moiety which has been introduced in a position where the parent
 CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiarteriosclerotic,
 CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipaeamic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1(82-244) mutant
 CC protein of the invention.
 XX
 SQ Sequence 163 AA;
 Query Match 100.0%; Score 708; DB 7; Length 163;
 Best Local Similarity 100.0%; Pred. No. 4.6e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 60
 DB 34 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 93
 QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 120
 DB 94 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 153
 QY 121 TGFLLYHDTN 130
 DB 154 TGFLLYHDTN 163
 RESULT 9
 ADE93615
 ID ADE93615 standard; protein; 187 AA.
 XX
 AC ADE93615;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human adiponectin apM1(58-244) protein.
 XX
 KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
 KW antirheumatic; antibacterial; antilipaeamic; dermatological;

immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 atherosclerosis; cardiovascular disease; dyslipidaemia;
 rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 myocardial infarction; inflammation; gene therapy; human; apM1;
 wild-type.
 XX
 OS Homo sapiens.
 XX
 PN WO2003055916-A2.
 XX
 PD 10-JUL-2003.
 XX
 PF 20-DEC-2002; 2002WO-DK000897.
 XX
 PR 21-DEC-2001; 2001DK-00001952.
 PR 21-DEC-2001; 2001US-0343482P.
 PR 25-APR-2002; 2002DK-00000627.
 PR 25-APR-2002; 2002US-0375492P.
 PR 03-JUL-2002; 2002DK-00001036.
 PR 03-JUL-2002; 2002US-0394117P.
 PR 20-SEP-2002; 2002DK-00001385.
 PR 20-SEP-2002; 2002US-0412169P.
 XX
 PA (MAXY-) MAXYGEN APS.
 PA (MAXY-) MAXYGEN HOLDINGS LTD.
 XX
 PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
 PI Bogsnes A;
 XX
 DR WPI; 2003-598262/56.
 DR N-PSDB; ADE93617.
 XX
 PT New conjugate comprising an adiponectin polypeptide and a first non-
 PT polypeptide moiety, useful for preparing a composition for treating a
 PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 XX
 PS Claim 44; SEQ ID NO 13; 184pp; English.
 XX
 CC The invention relates to a novel conjugate comprising an adiponectin
 CC polypeptide and a first non-polypeptide moiety covalently attached to the
 CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 CC acid residue having an attachment group for the first non-polypeptide
 CC moiety which has been introduced in a position where the parent
 CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiarteriosclerotic,
 CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipaeamic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1 protein of the
 CC invention.
 XX
 SQ Sequence 187 AA;
 Query Match 100.0%; Score 708; DB 7; Length 187;
 Best Local Similarity 100.0%; Pred. No. 5.5e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 60
 DB 58 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 117
 QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 120
 DB 118 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQYGERNGLYADNDNSTF 177
 QY 121 TGFLLYHDTN 130
 |||||

178 TGFLLYHDTN 187

Query Match 100.0%; Score 708; DB 7; Length 193;
 Best Local Similarity 100.0%; Pred. No. 5,8e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVTIPNMPIRFTKIFYNQNNHYDGSVKFKFCNTPGLYYFAYHITVTYMKDKVKS 60
 DB 64 FSVGLETVTIPNMPIRFTKIFYNQNNHYDGSVKFKFCNTPGLYYFAYHITVTYMKDKVKS 123

QY 61 LFKDKKAMLFYDQYQENNVDOASGVSLLHLEVDQVWLVQYGEGERNGLYADNDNDSTF 120
 DB 124 LFKDKKAMLFYDQYQENNVDOASGVSLLHLEVDQVWLVQYGEGERNGLYADNDNDSTF 183

QY 121 TGFLLYHDTN 130
 DB 184 TGFLLYHDTN 193

RESULT 11
 ADE93605
 ID ADE93605 standard; protein; 203 AA.
 XX ADE93605;
 AC ADE93605;
 XX XX
 XX 12-FEB-2004 (first entry)
 XX XX
 XX Human adiponectin apM1(42-244) protein.
 XX XX
 KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
 KW antirheumatic; antibacterial; antilipemic; dermatological;
 KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 KW atherosclerosis; cardiovascular disease; dyslipidaemia;
 KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 KW sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 KW myocardial infarction; inflammation; gene therapy; human; apM1;
 KW wild-type.
 XX Homo sapiens.
 OS Homo sapiens.
 XX XX
 XX WO2003055916-A2.
 XX XX
 XX 10-JUL-2003.
 XX XX
 XX 20-DEC-2002; 2002WO-DK000897.
 XX XX
 XX 21-DEC-2001; 2001DK-00001952.
 XX XX
 XX 21-DEC-2001; 2001US-0343482P.
 XX XX
 XX 25-APR-2002; 2002DK-00000627.
 XX XX
 XX 25-APR-2002; 2002US-0375492P.
 XX XX
 XX 03-JUL-2002; 2002DK-00001036.
 XX XX
 XX 03-JUL-2002; 2002US-0394117P.
 XX XX
 XX 20-SEP-2002; 2002DK-00001385.
 XX XX
 XX 20-SEP-2002; 2002US-0412169P.
 XX XX
 XX (MAXY-) MAXYGEN APS.
 XX (MAXY-) MAXYGEN HOLDINGS LTD.
 XX XX
 XX Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
 XX Bogsgnes A;
 XX XX
 XX WPI; 2003-598262/56.
 XX N-PSDB; ADE93616.
 XX XX
 XX New conjugate comprising an adiponectin polypeptide and a first non-
 XX polypeptide moiety, useful for preparing a composition for treating a
 XX mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 XX Claim 44; SEQ ID NO 12; 184pp; English.
 XX XX
 XX The invention relates to a novel conjugate comprising an adiponectin
 XX polypeptide and a first non-polypeptide moiety covalently attached to the
 XX adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 XX acid residue having an attachment group for the first non-polypeptide
 XX moiety which has been introduced in a position where the parent
 XX adiponectin is occupied by a surface exposed amino acid residue. The
 XX conjugate of the invention demonstrates antiarteriosclerotic.
 XX antidiabetic, cardiant, antirheumatic, antibacterial, antilipemic,
 XX dermatological, immunosuppressive, immunomodulator and anorectic
 XX activities and may be useful for treating diabetes, obesity,
 XX atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 XX arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
 XX syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 XX infarction and destructive processes related to activation of the
 XX inflammatory system, as well as during gene therapy procedures. The
 XX current sequence is that of the human adiponectin apM1 protein of the
 XX invention.
 XX Sequence 193 AA;
 XX SQ

Sequence 193 AA;

CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiarteriosclerotic.
 CC anti-diabetic, cardiant, anti-rheumatic, antibacterial, antilipemic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1 protein of the
 CC invention.

XX Sequence 203 AA;

Query Match 100.0%; Score 708; DB 7; Length 203;
 Best Local Similarity 100.0%; Pred. No. 6.2e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 60
 DB 74 FSVGLETYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 133

QY 61 LFKKDKAMLFYDQYQENNVDDASGSVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 120
 DB 134 LFKKDKAMLFYDQYQENNVDDASGSVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 193

QY 121 TGFLLYHDTN 130
 DB 194 TGFLLYHDTN 203

RESULT 12

AD93604
 ID ADE93604 standard; protein; 226 AA.

XX AC ADE93604;

DT 12-FEB-2004 (first entry)

XX Human adiponectin apM1 (19-244) protein.

XX adiponectin conjugate; antiarteriosclerotic; anti-diabetic; cardiant;
 KW anti-rheumatic; antibacterial; antilipemic; dermatological;
 KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 KW atherosclerosis; cardiovascular disease; dyslipidaemia;
 KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 KW sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 KW myocardial infarction; inflammation; gene therapy; human; apM1;
 KW wild-type.

XX Homo sapiens.

XX WO2003055916-A2.

PN 10-JUL-2003.

PF 20-DEC-2002; 2002WO-DK000897.

XX 21-DEC-2001; 2001DK-00001952.

PR 21-DEC-2001; 2001US-0343482P.

PR 25-APR-2002; 2002DK-00000627.

PR 25-APR-2002; 2002US-0375492P.

PR 03-JUL-2002; 2002DK-00001036.

PR 03-JUL-2002; 2002US-0394117P.

PR 20-SEP-2002; 2002DK-00001385.

PR 20-SEP-2002; 2002US-0412169P.

XX (MAXY-) MAXYGEN APS.

PA (MAXY-) MAXYGEN HOLDINGS LTD.

XX Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;

PI Bogsgnes A;

XX DR WPI; 2003-598262/56.
 XX New conjugate comprising an adiponectin polypeptide and a first non-
 PT polypeptide moiety, useful for preparing a composition for treating a
 PT mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 XX Claim 14; SEQ ID NO 2; 184pp; English.

CC The invention relates to a novel conjugate comprising an adiponectin
 CC polypeptide and a first non-polypeptide moiety covalently attached to the
 CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 CC acid residue having an attachment group for the first non-polypeptide
 CC moiety which has been introduced in a position where the parent
 CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiarteriosclerotic,
 CC anti-diabetic, cardiant, anti-rheumatic, antibacterial, antilipemic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1 protein of the
 CC invention.

XX Sequence 226 AA;

Query Match 100.0%; Score 708; DB 7; Length 226;
 Best Local Similarity 100.0%; Pred. No. 7.2e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 60
 DB 97 FSVGLETYVTIPNMPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 156

QY 61 LFKKDKAMLFYDQYQENNVDDASGSVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 120
 DB 157 LFKKDKAMLFYDQYQENNVDDASGSVLLHLEVDQVWLVQVYGEGRNGLYADNDSTF 216

QY 121 TGFLLYHDTN 130
 DB 217 TGFLLYHDTN 226

RESULT 13

AA21808
 ID AAY21808 standard; protein; 231 AA.

XX AC AAY21808;

DT 10-SEP-1999 (first entry)

XX Adipose most abundant gene transcription product 1 (apM1) fragment.

XX Smooth muscle proliferation; secretion factor; apM1; adipose;

XX adipose most abundant gene transcription product 1; obesity;

XX arteriosclerosis; restenosis; angina pectoris; myocardial infarction.

XX Unidentified.

XX WO9921577-A1.

XX 06-MAY-1999.

XX 27-OCT-1998; 98WO-JP004862.

XX 29-OCT-1997; 97JP-00297569.

XX (SAXA) OTSUKA PHARM CO LTD.

XX Matsuzawa Y, Ohmoto Y;

PI

XX WPI; 1999-418412/35.
 XX Inhibition of smooth muscle proliferation using secretion factor apM1.
 PT Example; Page 59-60; 65pp; Japanese.
 XX Then invention relates to the inhibition of smooth muscle proliferation
 CC using a composition containing secretion factor apM1 (adipose most
 CC abundant gene transcript product 1), together with a suitable carrier.
 CC apM1 is expressed specifically in adipose tissue and the composition is
 CC used for the prevention and treatment of arteriosclerosis; restenosis
 CC following vascular reconstruction; and treatment and diagnosis of
 CC diseases related to obesity, and disorders associated with it such as
 CC angina pectoris and myocardial infarction. The present sequence
 CC represents a fragment of apM1 isolated from abdominal fat tissue of myoma
 CC uteri
 XX
 SQ Sequence 231 AA;
 Query Match 100.0%; Score 708; DB 2; Length 231;
 Best Local Similarity 100.0%; Pred. No. 7.4e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FSVGLETVYTIENPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 60
 DB 102 FSVGLETVYTIENPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 161
 QY 61 LFKKDKAMLFYDQVQENNVDAQSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 120
 DB 162 LFKKDKAMLFYDQVQENNVDAQSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 221
 QY 121 TGFLLYHDTN 130
 DB 222 TGFLLYHDTN 231
 RESULT 14
 AAB60347
 ID AAB60347 standard; protein; 231 AA.
 XX
 AC AAB60347;
 DT 06-APR-2001 (first entry)
 XX
 DE Recombinant human apM1 protein (residues 15-244 + Met1), SEQ ID NO:3.
 XX
 KW Antigenic protein detection; sodium sulphate; ELISA;
 KW enzyme-linked immunosorbent assay; human apM1; recombinant expression;
 KW Escherichia coli; adipose most abundant gene transcript 1;
 KW adipose-specific collagen-like factor.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN JP2000304748-A.
 XX
 PD 02-NOV-2000.
 XX
 PF 21-APR-1999; 99JP-00114170.
 XX
 PR 21-APR-1999; 99JP-00114170.
 XX
 XX (SAKA) OTSUKA PHARM CO LTD.
 XX
 DR WPI; 2001-127687/14.
 XX
 PT Detection of an antigenic protein comprises use of enzyme linked
 PT immunosorbent assay.
 XX
 PS Example 1; Page 7-8; 10pp; Japanese.
 XX
 CC The invention relates to a method for detecting an antigenic protein. The

CC method comprises boiling the sample containing the antigenic protein in
 CC the presence of sodium sulphate, diluting it in buffer, and detecting the
 CC enzyme by enzyme-linked immunosorbent assay (ELISA). In an
 CC exemplification of the invention, residues 15-244 (plus an initial Met
 CC residue) of human apM1 (adipose most abundant gene transcript 1;
 CC AAB60347), an adipose-specific collagen-like factor, was recombinantly
 CC expressed in Escherichia coli. Using the method of the invention, it was
 CC found that apM1 was expressed mainly in the inclusion body fragment as an
 CC approximately 30 kd protein. The present sequence represents the
 CC recombinantly expressed human apM1
 XX
 SQ Sequence 231 AA;
 Query Match 100.0%; Score 708; DB 4; Length 231;
 Best Local Similarity 100.0%; Pred. No. 7.4e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FSVGLETVYTIENPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 60
 DB 102 FSVGLETVYTIENPIRFTKIFYNQNHVDGSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 161
 QY 61 LFKKDKAMLFYDQVQENNVDAQSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 120
 DB 162 LFKKDKAMLFYDQVQENNVDAQSGVLLHLEVDQVWLQVYGEGERNGLYADNDNSTF 221
 QY 121 TGFLLYHDTN 130
 DB 222 TGFLLYHDTN 231
 RESULT 15
 ADD93530
 ID ADD93530 standard; protein; 233 AA.
 XX
 AC ADD93530;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Novel NOV2e, homologous to human adiponectin.
 XX
 KW NOV2e; human; adiponectin; gene therapy.
 KW
 OS Homo sapiens.
 XX
 PN WO2003078572-A2.
 XX
 PD 25-SEP-2003.
 XX
 XX 06-MAR-2003; 2003WO-US006859.
 XX
 PR 15-MAR-2002; 2002US-0365034P.
 PR 19-MAR-2002; 2002US-0365477P.
 PR 21-MAR-2002; 2002US-0366420P.
 PR 05-MAR-2003; 2003US-00379747.
 XX
 XX (CURA-) CURAGEN CORP.
 XX
 XX Burges CE, Chant JS, Chaudhuri A, Edinger SR, Gangolli EA;
 PI Malyankar UM, Miller CE, Cui CE, Ort T, Patturajan M, Rastelli L;
 PI Rieger DK, Shimkets RA, Zernhosen BD;
 XX
 DR WPI; 2003-779122/73.
 DR N-PSDB; ADD93529.
 XX
 XX New isolated NOVX polypeptides and polynucleotides, useful for
 PT preventing, diagnosing or treating NOVX-associated disorders, e.g.
 PT osteoarthritis, obesity, atherosclerosis, cancer, Parkinson's disease,
 PT asthma, or infections.
 XX
 PS Claim 1; Page 108; 205pp; English.
 XX
 CC The present sequence is the protein sequence of a novel polypeptide,
 CC designated NOV2e, that shows amino acid sequence homology to the human

CC adiponectin (adipose most abundant gene transcript 1, APM1). The
 CC adiponectin gene is the most abundant gene transcript in adipose cells
 CC that regulates lipid metabolism. An interaction between adiponectin and
 CC calcium modulating ligand was identified, indicating a novel pathway by
 CC which adiponectin may induce lipid breakdown in muscle cells and
 CC adipocytes. The invention is based on the identification of proteins and
 CC polypeptides, and the nucleic acids encoding them, that are
 CC differentially modulated in a pathological state, disease or an abnormal
 CC condition or state. These are targets for therapeutic agents and can be
 CC used in screening methodologies to identify candidate therapeutic agents
 CC which interact with the target and thereby exert a desired or favourable
 CC effect, e.g. in neurogenesis, cell differentiation, cell proliferation,
 CC haematopoiesis, wound healing and angiogenesis. Methods for diagnosis,
 CC treatment and prevention of disorders involving the novel human nucleic
 CC acids and proteins are provided. The polypeptides are also used to raise
 CC antibodies, useful in therapy and diagnosis.

XX ^ Sequence 233 AA;
 SQ

Query Match 100.0%; Score 708; DB 7; Length 233;
 Best Local Similarity 100.0%; Pred. No. 7.5e-78;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FSVGLETYVTIPNMPIRFTKIFYNQNNHYDGTGKFCNIPGLYFYFAHYITVYMKDKVVS 60
 Db 104 FSVGLETYVTIPNMPIRFTKIFYNQNNHYDGTGKFCNIPGLYFYFAHYITVYMKDKVVS 163
 QY 61 LFKKDXAMLFYDQYQENNVDQASGVLLHLEVGQDWLQVYGEGERNGLYADNDNSTF 120
 Db 164 LFKKDXAMLFYDQYQENNVDQASGVLLHLEVGQDWLQVYGEGERNGLYADNDNSTF 223
 QY 121 TGFLLYHDTN 130
 Db 224 TGFLLYHDTN 233

Search completed: December 2, 2004, 19:33:35
 Job time : 71 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 2, 2004, 19:32:25 ; Search time 144 Seconds

(without alignments)
321.951 Million cell updates/sec

Title: US-10-072-159-11

Perfect score: 708

Sequence: 1 FSVGLTYVTIPNPIRFTK.....YADNDNDSTFTGFLLYHDTN 130

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1582122 seqs, 356623098 residues

Total number of hits satisfying chosen parameters: 1582122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	708	100.0	130	13	US-10-072-159-11
2	708	100.0	130	13	Sequence 11, Appl
3	708	100.0	130	14	Sequence 11, Appl
4	708	100.0	137	14	Sequence 7, Appl
5	708	100.0	144	14	Sequence 6, Appl
6	708	100.0	144	14	Sequence 5, Appl
7	708	100.0	145	14	Sequence 11, Appl
8	708	100.0	157	14	Sequence 4, Appl
9	708	100.0	163	14	Sequence 10, Appl
10	708	100.0	163	14	Sequence 53, Appl
11	708	100.0	187	14	Sequence 13, Appl
12	708	100.0	193	14	Sequence 12, Appl
13	708	100.0	203	14	Sequence 3, Appl
			226	14	Sequence 2, Appl

14	708	100.0	231	14	US-10-189-493-2
15	708	100.0	233	15	US-10-379-747-14
16	708	100.0	244	9	US-09-776-976-6
17	708	100.0	244	9	US-09-758-055-6
18	708	100.0	244	9	US-09-909-547-6
19	708	100.0	244	9	US-09-911-176B-48
20	708	100.0	244	14	US-10-180-762-51
21	708	100.0	244	14	US-10-231-814-6
22	708	100.0	244	14	US-10-234-000-4
23	708	100.0	244	14	US-10-360-186-51
24	708	100.0	244	14	US-10-321-164-3
25	708	100.0	244	14	US-10-376-460-6
26	708	100.0	244	14	US-10-189-493-1
27	708	100.0	244	14	US-10-197-293-3
28	708	100.0	244	14	US-10-325-717-1
29	708	100.0	244	14	US-10-411-120-67
30	708	100.0	244	15	US-10-379-747-6
31	708	100.0	244	15	US-10-379-747-8
32	708	100.0	244	15	US-10-379-747-10
33	708	100.0	244	15	US-10-621-787-3
34	708	100.0	244	15	US-10-285-833-6
35	708	100.0	250	15	US-10-379-747-12
36	703	99.3	145	14	US-10-325-717-27
37	703	99.3	163	14	US-10-325-717-18
38	703	99.3	163	14	US-10-325-717-55
39	703	99.3	163	14	US-10-325-717-60
40	703	99.3	187	14	US-10-325-717-33
41	703	99.3	193	14	US-10-325-717-30
42	703	99.3	203	14	US-10-325-717-21
43	702	99.2	144	14	US-10-325-717-25
44	702	99.2	145	14	US-10-325-717-26
45	702	99.2	145	14	US-10-325-717-28

ALIGNMENTS

RESULT 1

US-10-072-159-11
; Sequence 11, Application US/10072159
; Publication No. US20020151498A1
; GENERAL INFORMATION:
; APPLICANT: Bihain, Bernard
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Yen-Potin, Frances
; TITLE OF INVENTION: Lipoprotein-regulating medicaments
; FILE REFERENCE: GENSET.036APC
; CURRENT APPLICATION NUMBER: US/10/072,159
; CURRENT FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: 09/485,316
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: FR 98/05032
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: PCT IB98/01256
; PRIOR FILING DATE: 1998-08-06
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: Patent.pm
; SEQ ID NO 11
; LENGTH: 130
; TYPE: PRI
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIMILAR
; LOCATION: 1..130
; OTHER INFORMATION: fragment 115..244 of translation from ref Genbank D45371
US-10-072-159-11

Query Match 100.0%; Score 708; DB 13; Length 130;
Best Local Similarity. 100.0%; .Pred. No. 6.2e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FSVGLTYVTIPNPIRFTKIFVNOQHYDGSFGKPHCNIGLYFAVHITVYMKDKVYS 60
|||||

Db 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGTKFHCNIPGLYFYFAYHITVYMKDKVKS 60
QY 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
Db 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
QY 121 TGFLLYHDTN 130
Db 121 TGFLLYHDTN 130

RESULT 2

US-10-060-845-11
; Sequence 11, Application US/10060845
; Publication No. US20020165154A1
; GENERAL INFORMATION:
; APPLICANT: Bihain, Bernard
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Yen-Potin, Frances
; TITLE OF INVENTION: Lipoprotein-regulating medicaments
; FILE REFERENCE: GENSET.038APC
; CURRENT APPLICATION NUMBER: US/10/060,845
; CURRENT FILING DATE: 2002-01-29
; PRIOR APPLICATION NUMBER: U.S. 09/485,316
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: FR 97/10088
; PRIOR FILING DATE: 1997-08-06
; PRIOR APPLICATION NUMBER: FR 98/05032
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: PCT 1B98/01256
; PRIOR FILING DATE: 1998-08-06
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: Patent.pm
; SEQ ID NO 11
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: SIMILAR
; LOCATION: 1..130
; OTHER INFORMATION: fragment 115...244 of translation from ref Genbank D45371
US-10-060-845-11

Query Match 100.0%; Score 708; DB 13; Length 130;
Best Local Similarity 100.0%; Pred. No. 6.2e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGTKFHCNIPGLYFYFAYHITVYMKDKVKS 60
Db 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGTKFHCNIPGLYFYFAYHITVYMKDKVKS 60
QY 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
Db 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
QY 121 TGFLLYHDTN 130
Db 121 TGFLLYHDTN 130

RESULT 3

US-10-325-717-7
; Sequence 7, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610

; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apM1(115-244)
US-10-325-717-7

Query Match 100.0%; Score 708; DB 14; Length 130;
Best Local Similarity 100.0%; Pred. No. 6.2e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGTKFHCNIPGLYFYFAYHITVYMKDKVKS 60
Db 1 FSVGLTYVTIPNMPIRFTKIFYNQNHVDGSGTKFHCNIPGLYFYFAYHITVYMKDKVKS 60
QY 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
Db 61 LFKKDKAMLFYDQYQENNVDSAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNDSTF 120
QY 121 TGFLLYHDTN 130
Db 121 TGFLLYHDTN 130

RESULT 4

US-10-325-717-6
; Sequence 6, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 137
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apM1(108-244)
US-10-325-717-6

Query Match 100.0%; Score 708; DB 14; Length 137;
Best Local Similarity 100.0%; Pred. No. 6.6e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 100.0%; Score 708; DB 14; Length 157;
Best Local Similarity 100.0%; Pred. No. 7.8e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 60
DB 28 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 87

QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 120
DB 88 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 147

QY 121 TGFLLYHDTN 130
DB 148 TGFLLYHDTN 157

RESULT 8

US-10-325-717-10
; Sequence 10, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; PRIOR FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 163
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apm1(82-244)
US-10-325-717-10

Query Match 100.0%; Score 708; DB 14; Length 163;
Best Local Similarity 100.0%; Pred. No. 8.2e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 60
DB 34 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 93

QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 120
DB 94 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 153

QY 121 TGFLLYHDTN 130
DB 154 TGFLLYHDTN 163

RESULT 9

US-10-325-717-53
; Sequence 53, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:

; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; PRIOR FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 163
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct Y11N-APM1(82-244)
US-10-325-717-53

Query Match 100.0%; Score 708; DB 14; Length 163;
Best Local Similarity 100.0%; Pred. No. 8.2e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 60
DB 34 FSVGLETVYTIPIPNPIRFTKIFYNQNHVDGSGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 93

QY 61 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 120
DB 94 LFKKDKAMLFYDQYQENNVQASGVLLHLEVGQVWLVQVYGEGERNGLYADNDNDSTF 153

QY 121 TGFLLYHDTN 130
DB 154 TGFLLYHDTN 163

RESULT 10

US-10-325-717-13
; Sequence 13, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; PRIOR FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 187
; TYPE: PRT

```
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apm1(58-244)
US-10-325-717-13

Query Match      100.0%; Score 708; DB 14; Length 187;
Best Local Similarity 100.0%; Pred. No. 9.7e-70; Indels 0; Gaps 0;
Matches 130; Conservative 0; Mismatches 0;

QY 1 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 60
DB 58 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 117
QY 61 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120
DB 118 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 177
QY 121 TGFLLYHDTN 130
DB 178 TGFLLYHDTN 187

RESULT 11
US-10-325-717-12
; Sequence 12, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 193
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apm1(52-244)
US-10-325-717-12

Query Match      100.0%; Score 708; DB 14; Length 193;
Best Local Similarity 100.0%; Pred. No. 1e-69; Indels 0; Gaps 0;
Matches 130; Conservative 0; Mismatches 0;

QY 1 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 60
DB 64 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 123
QY 61 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120
DB 124 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 183
QY 121 TGFLLYHDTN 130
DB 184 TGFLLYHDTN 193

RESULT 12
```

```
US-10-325-717-3
; Sequence 3, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 203
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apm1(42-244)
US-10-325-717-3

Query Match      100.0%; Score 708; DB 14; Length 203;
Best Local Similarity 100.0%; Pred. No. 1.1e-69; Indels 0; Gaps 0;
Matches 130; Conservative 0; Mismatches 0;

QY 1 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 60
DB 74 FSVGLETVVTPNMPIRFTKIFYNQNHVDGSGKFGHCNIPGLYFYFAYHITVYMKDVKS 133
QY 61 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120
DB 134 LFKDKAMLFYDQYQENNVDQASGVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 193
QY 121 TGFLLYHDTN 130
DB 194 TGFLLYHDTN 203

RESULT 13
US-10-325-717-2
; Sequence 2, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
```

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 226

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: apM1(19-244)

US-10-325-717-2

Query Match

Best Local Similarity 100.0%; Score 708; DB 14; Length 226;

Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 60

Db 97 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 156

QY 61 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120

Db 157 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 216

QY 121 TGFLLYHDTN 130

Db 217 TGFLLYHDTN 226

RESULT 14

US-10-189-493-2

; Sequence 2, Application US/10189493

; Publication No. US20030166551A1

; GENERAL INFORMATION:

; APPLICANT: Otsuka Pharmaceutical Co., Ltd.

; TITLE OF INVENTION: Smooth muscle growth inhibitory composition, a

; TITLE OF INVENTION: diagnostic method for arteriosclerosis and a kit

; FILE REFERENCE: P98-51

; CURRENT APPLICATION NUMBER: US/10/189,493

; CURRENT FILING DATE: 2002-07-08

; PRIOR APPLICATION NUMBER: US/09/530,423

; PRIOR FILING DATE: 2000-05-01

; NUMBER OF SEQ ID NOS: 4

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 2

; LENGTH: 231

; TYPE: PRT

; ORGANISM: Abdominal fat tissue from myoma uteri

US-10-189-493-2

Query Match

Best Local Similarity 100.0%; Score 708; DB 14; Length 231;

Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 60

Db 102 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 161

QY 61 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120

Db 162 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 221

QY 121 TGFLLYHDTN 130

Db 222 TGFLLYHDTN 231

RESULT 15

US-10-379-747-14

; Sequence 14, Application US/10379747

; Publication No. US20040023874A1

; GENERAL INFORMATION:

; APPLICANT: Burgess, Catherine E.;

; APPLICANT: Chant, John S.;

; APPLICANT: Chaudhuri, Amitabha ;

; APPLICANT: Edinger, Shlomit R.;

; APPLICANT: Gangolli, Esha A.;

; APPLICANT: Malvankar, Uriel M.;

; APPLICANT: Miller, Charles E.;

; APPLICANT: Ooi, Chean Eng;

; APPLICANT: Ort, Tatiana A.;

; APPLICANT: Patturajan, Meera ;

; APPLICANT: Rastelli, Luca ;

; APPLICANT: Rieger, Daniel K.;

; APPLICANT: Shimkets, Richard A.;

; APPLICANT: Zerhusen, Bryan D.

; TITLE OF INVENTION: THEAPRUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS

; FILE REFERENCE: 21402-568B

; CURRENT APPLICATION NUMBER: US/10/379,747

; CURRENT FILING DATE: 2003-03-05

; PRIOR APPLICATION NUMBER: 60/365,034

; PRIOR FILING DATE: 2002-03-15

; PRIOR APPLICATION NUMBER: 60/366,420

; PRIOR FILING DATE: 2002-03-21

; PRIOR APPLICATION NUMBER: 60/365,477

; PRIOR FILING DATE: 2002-03-19

; NUMBER OF SEQ ID NOS: 45

; SOFTWARE: CuraseqList, version 0.1

; SEQ ID NO 14

; LENGTH: 233

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-379-747-14

Query Match

Best Local Similarity 100.0%; Score 708; DB 15; Length 233;

Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 60

Db 104 FSVGLETVYTIENMPIRFTKIFYNQNHVDGSGKFCNIPGLYFYFAYHITVYMKDVKS 163

QY 61 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 120

Db 164 LFKDKKAMLFYDQYQENNVDOAGSVLLHLEVGQVWLQVYGEGERNGLYADNDNSTF 223

QY 121 TGFLLYHDTN 130

Db 224 TGFLLYHDTN 233

Search completed: December 2, 2004, 19:38:04

Job time : 145 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: December 3, 2004, 09:18:03 ; Search time 399 Seconds

(without alignments)
1710.338 Million cell updates/sec

Title: US-10-072-159-11

Perfect score: 708

Sequence: 1 FVSGEYTYIENPIRFTK.....YADNDSTFTGFLLYHDTN 130

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DSV=xlp
-Q=/cgn2/1/USPTO.spool_P/US10072159/runat_02122004_142304_1552/app_query.fasta_1.327
-DB=N Geneseg 23Sep04 -QFW=fastap -SUFFIX=p2n.rng -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFW=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US10072159 @CGN 1 1 708 @runat_02122004_142304_1552 -NCPU=6 -ICPU=3
-NO MWAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N Geneseg 23Sep04:*

- 1: geneseg1980s:*
- 2: geneseg1990s:*
- 3: geneseg2000s:*
- 4: geneseg2001as:*
- 5: geneseg2001bs:*
- 6: geneseg2002as:*
- 7: geneseg2002bs:*
- 8: geneseg2003as:*
- 9: geneseg2003bs:*
- 10: geneseg2003cs:*
- 11: geneseg2003ds:*
- 12: geneseg2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	708	100.0	492	10	ADE93618 Human adi
2	708	100.0	537	10	ADE93667 Human adi
3	708	100.0	564	10	ADE93617 Human adi
4	708	100.0	582	10	ADE93616 Human adi
5	708	100.0	735	8	AAD56155 Human APM
6	708	100.0	735	10	ADC21966 Human ing

7	708	100.0	735	10	ADF16357	Adf16357 Human alb
8	708	100.0	735	10	ADF16359	Adf16359 Human alb
9	708	100.0	735	10	ADF16358	Adf16358 Human alb
10	708	100.0	735	10	AD93611	Ad93611 Human adi
11	708	100.0	735	10	AD93611	Ad93611 Human adi
12	708	100.0	735	10	AD93611	Ad93611 Human adi
13	708	100.0	735	10	AD93611	Ad93611 Human adi
14	708	100.0	735	12	AD93611	Ad93611 Human adi
15	708	100.0	735	12	AD93611	Ad93611 Human adi
16	708	100.0	735	12	AD93611	Ad93611 Human adi
17	708	100.0	735	12	AD93611	Ad93611 Human adi
18	708	100.0	735	12	AD93611	Ad93611 Human adi
19	708	100.0	735	12	AD93611	Ad93611 Human adi
20	708	100.0	735	12	AD93611	Ad93611 Human adi
21	708	100.0	735	12	AD93611	Ad93611 Human adi
22	708	100.0	735	12	AD93611	Ad93611 Human adi
23	708	100.0	735	12	AD93611	Ad93611 Human adi
24	708	100.0	735	12	AD93611	Ad93611 Human adi
25	708	100.0	735	12	AD93611	Ad93611 Human adi
26	708	100.0	735	12	AD93611	Ad93611 Human adi
27	708	100.0	735	12	AD93611	Ad93611 Human adi
28	708	100.0	735	12	AD93611	Ad93611 Human adi
29	708	100.0	735	12	AD93611	Ad93611 Human adi
30	708	100.0	735	12	AD93611	Ad93611 Human adi
31	708	100.0	735	12	AD93611	Ad93611 Human adi
32	708	100.0	735	12	AD93611	Ad93611 Human adi
33	708	100.0	735	12	AD93611	Ad93611 Human adi
34	708	100.0	735	12	AD93611	Ad93611 Human adi
35	708	100.0	735	12	AD93611	Ad93611 Human adi
36	708	100.0	735	12	AD93611	Ad93611 Human adi
37	708	100.0	735	12	AD93611	Ad93611 Human adi
38	708	100.0	735	12	AD93611	Ad93611 Human adi
39	708	100.0	735	12	AD93611	Ad93611 Human adi
40	708	100.0	735	12	AD93611	Ad93611 Human adi
41	708	100.0	735	12	AD93611	Ad93611 Human adi
42	708	100.0	735	12	AD93611	Ad93611 Human adi
43	708	100.0	735	12	AD93611	Ad93611 Human adi
44	708	100.0	735	12	AD93611	Ad93611 Human adi
45	708	100.0	735	12	AD93611	Ad93611 Human adi

ALIGNMENTS

RESULT 1	
AD93618	
ID	AD93618 standard; cDNA; 492 BP.
XX	
AC	AD93618;
XX	
DT	12-FEB-2004 (first entry)
XX	
DE	Human adiponectin apM1 (82-244) cDNA.
XX	
KW	adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;
KW	antirheumatic; antibacterial; antilipemic; dermatological;
KW	immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
KW	atherosclerosis; cardiovascular disease; dyslipidaemia;
KW	rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
KW	sjogren syndrome; cachexia; septic shock; myasthenia gravis;
KW	myocardial infarction; inflammation; gene therapy; human; apM1; ss; gene;
XX	wild-type.
OS	Homo sapiens.
XX	
PN	W02003055916-A2.
XX	
PD	10-JUL-2003.
XX	
XX	20-DEC-2002; 2002WO-DK000897.
XX	
PF	21-DEC-2001; 2001DK-00001952.
XX	
PR	21-DEC-2001; 2001US-0343482P.
XX	
PR	25-APR-2002; 2002DK-00005627.
XX	

CC current sequence is that of the human adiponectin apM1(82-244) mutant
 CC cDNA of the invention.

XX
 SQ Sequence 537 BP; 135 A; 139 C; 132 G; 131 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	8,9e-86	Length:	537
Score:	708.00	Matches:	130
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	10	Gaps:	0

US-10-072-159-11 (1-130) x ADE93667 (1-537)

QY	1	PheSerValGlyLeuGluThrTyrrValThrIleProAsnMetProIleArgPheThrLys	20
DB	145	TTTCAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG	204
QY	21	IlePheTyrrAsnGlnAsnHisTyrrAspGlySerThrGlyLysPheHisCysAsnIle	40
DB	205	ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATCCACTGCAACATT	264
QY	41	ProGlyLeuTyrrPheAlaTyrrHisIleThrValTyrrMetLysAspValLysValSer	60
DB	265	CCTGGGCTGTACTTGGCTTGCCTACCAATCAGCTATATGAAGGATGTGAAGGTCCAGC	324
QY	61	LeuPheLysAspLysAlaMetLeuPheThrTyrrAspGlnTyrrGlnGluAsnVal	80
DB	325	CTCTTCAAGAGGACAGGCTATGCTTCACCTATGATCAGTACCAGGAATAATATGTG	384
QY	81	AspGlnAlaSerGlySerValLeuLeuHisIleGluValGlyAspGlnValTrpLeuGln	100
DB	385	GACCAAGGCTCCGGCTCTGTGCTCTGCTGATGGAGGTGGCGCAACCAAGTCTGGCTCCAG	444
QY	101	ValTyrrGlyGluGlyGluArgAsnGlyLeuTyrrAlaAspAsnAspAspSerThrPhe	120
DB	445	GTGTATGGGAGGAGAGCGTAATGACTCTATGCTGATATGACATGACTCCACCTTC	504
QY	121	ThrGlyPheLeuLeuTyrrHisAspThrAsn	130
DB	505	ACAGGCTTCTCTCTACCATGACACCAAC	534

RESULT 3

ADE93617

ID ADE93617 standard; cDNA; 564 BP.

AC ADE93617;

XX

XX 12-FEB-2004 (first entry)

DT Human adiponectin apM1(58-244) cDNA.

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PR 25-APR-2002; 2002US-0375492P.
 PR 03-JUL-2002; 2002DK-00001036.
 PR 03-JUL-2002; 2002US-0394117P.
 PR 20-SEP-2002; 2002DK-00001385.
 PR 20-SEP-2002; 2002US-0412169P.
 XX
 PA (MAXY-) MAXYGEN APS.
 PA (MAXY-) MAXYGEN HOLDINGS LTD.
 XX
 XX Rasmussen PS, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
 PI Bogsges A;
 XX
 DR WPI: 2003-598262/56.
 DR P-PSDB; ADE93615.
 XX

XX
 PS Claim 63; SEQ ID NO 15; 184pp; English.
 XX
 CC The invention relates to a novel conjugate comprising an adiponectin
 CC polypeptide and a first non-polypeptide moiety covalently attached to the
 CC adiponectin polypeptide. The adiponectin polypeptide comprises an amino
 CC acid residue having an attachment group for the first non-polypeptide
 CC moiety which has been introduced in a position where the parent
 CC adiponectin is occupied by a surface exposed amino acid residue. The
 CC conjugate of the invention demonstrates antiatherosclerotic,
 CC antidiabetic, cardiant, antirheumatic, antibacterial, antilipemic,
 CC dermatological, immunosuppressive, immunomodulator and anorectic
 CC activities and may be useful for treating diabetes, obesity,
 CC atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid
 CC arthritis, Crohn's disease, systemic lupus erythematosus, Sjogren
 CC syndrome, cachexia, septic shock, myasthenia gravis, myocardial
 CC infarction and destructive processes related to activation of the
 CC inflammatory system, as well as during gene therapy procedures. The
 CC current sequence is that of the human adiponectin apM1 cDNA of the
 CC invention.

XX
 SQ Sequence 564 BP; 150 A; 140 C; 145 G; 129 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	9,53e-86	Length:	564
Score:	708.00	Matches:	130
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	10	Gaps:	0

US-10-072-159-11 (1-130) x ADE93617 (1-564)

QY	1	PheSerValGlyLeuGluThrTyrrValThrIleProAsnMetProIleArgPheThrLys	20
DB	172	TTTCAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG	231
QY	21	IlePheTyrrAsnGlnAsnHisTyrrAspGlySerThrGlyLysPheHisCysAsnIle	40
DB	232	ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTCAACATT	291
QY	41	ProGlyLeuTyrrPheAlaTyrrHisIleThrValTyrrMetLysAspValLysValSer	60
DB	292	CCTGGGCTGTACTTGGCTTGCCTACCAATCAGTCTATATGAAGGATGTGAAGGTCCAGC	351
QY	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrrAspGlnTyrrGlnGluAsnVal	80
DB	352	CTCTTCAAGAGGACAAAGGCTATGCTCTCTGATCTGGAGGTGGCGCAACCAAGTCTGGCTCCAG	411
QY	81	AspGlnAlaSerGlySerValLeuLeuHisIleGluValGlyAspGlnValTrpLeuGln	100
DB	412	GACCAAGGCTCCGGCTCTGTGCTCTGATCTGGAGGTGGCGCAACCAAGTCTGGCTCCAG	471
QY	101	ValTyrrGlyGluGlyGluArgAsnGlyLeuTyrrAlaAspAsnAspAspSerThrPhe	120


```
RESULT 6
ADC21966
ID      ADC
XX
AC      ADC
XX
```


PF 23-DEC-2002; 2002WO-US040891.
 XX 21-DEC-2001; 2001US-0341811P.
 PR 24-JAN-2002; 2002US-0350358P.
 PR 26-FEB-2002; 2002US-0351360P.
 PR 28-FEB-2002; 2002US-0359370P.
 PR 28-FEB-2002; 2002US-0360000P.
 PR 27-MAR-2002; 2002US-0367500P.
 PR 08-APR-2002; 2002US-0370227P.
 PR 10-MAY-2002; 2002US-0378950P.
 PR 24-MAY-2002; 2002US-0382617P.
 PR 28-MAY-2002; 2002US-0383123P.
 PR 05-JUN-2002; 2002US-0385708P.
 PR 10-JUL-2002; 2002US-0394625P.
 PR 24-JUL-2002; 2002US-0398008P.
 PR 09-AUG-2002; 2002US-0402131P.
 PR 13-AUG-2002; 2002US-0402708P.
 PR 18-SEP-2002; 2002US-0411355P.
 PR 18-SEP-2002; 2002US-0411426P.
 PR 02-OCT-2002; 2002US-0414984P.
 PR 11-OCT-2002; 2002US-0417611P.
 PR 23-OCT-2002; 2002US-0420246P.
 PR 05-NOV-2002; 2002US-0423623P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (DELZ) DELTA BIOTECHNOLOGY LTD.
 PA (PRIN-) PRINCIPIA PHARM CORP.
 XX Ballance DJ, Turner AJ, Rosen CA, Haseltine WA,
 PI WPI; 2003-598517/56.
 XX P-PSDB; ADF16685.
 DR New albumin fusion protein, useful for preparing a composition for
 XX treating diabetes mellitus.
 XX Example 4; SEQ ID NO 1451; 24pp; English.
 CC This invention relates to a novel albumin fusion protein having albumin
 CC or biological activity. Human serum albumin is responsible for a
 CC significant proportion of the osmotic pressure of serum and also
 CC functions as a carrier of endogenous and exogenous ligands. The fusion of
 CC albumin to a therapeutic protein may increase shelf-life and stability of
 CC the therapeutic protein. The albumin fusion protein of the invention may
 CC allow production of compositions with antidiabetic activity whilst the
 CC nucleotide sequence which encodes it may be useful for gene therapy. The
 CC albumin fusion protein is useful for preparing a composition for treating
 CC diabetes mellitus. The present sequence is a DNA sequence which encodes a
 CC therapeutic protein which was fused with human albumin to create a novel
 CC albumin fusion protein of the invention. Note: The sequence data for this
 CC patent did not form part of the printed specification, but was obtained
 CC in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/publishedpct_sequences
 XX SQ Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,388-85 Length: 735
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 10 Gaps: 0
 US-10-072-159-11 (1-130) x ADF16359 (1-735)
 QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 DB 343 TTCAGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATCGCTTTTACCAAG 402
 QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 DB 403 ATCTTCTCAATCAGCAAAACCATGATGATGCTCCATGGTAATTCCTTCGCAACTT 462

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 DB 463 CTTGGCTGTACTTCTTTCCTACCATCACAGTCTATATGAAGGATGTGAGGTCAGC 522
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 DB 523 CTCTTCAAGAGGAGCAAGGCTATGCTTTCACCTATGATCAGTACCCAGAAATAATGTG 582
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 DB 583 GACCAAGGCTCCGGCTCTGTCTCTGCACTCTGGAGGTGGGGACCAAGTCTGGCTCCAG 642
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
 DB 643 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGATATGATGATGATGATGATGATG 702
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 DB 703 ACAGGCTTCTCTCTACCATGACACCAAC 732
 RESULT 9
 ADF16358
 ID ADF16358 standard; DNA; 735 BP.
 XX ADF16358;
 XX ADF16358;
 DT 12-FEB-2004 (first entry)
 XX Human albumin fusion protein-related DNA sequence SeqID1450.
 XX albumin fusion protein; albumin activity; human serum albumin;
 KW serum osmotic pressure; shelf-life; stability; antidiabetic;
 KW gene therapy; diabetes mellitus; human; gene; ds.
 XX Homo sapiens.
 OS
 XX WC2003060071-A2.
 XX 24-JUL-2003.
 XX 23-DEC-2002; 2002WO-US040891.
 XX 21-DEC-2001; 2001US-0341811P.
 PR 24-JAN-2002; 2002US-0350358P.
 PR 28-JAN-2002; 2002US-0351360P.
 PR 28-FEB-2002; 2002US-0359370P.
 PR 28-FEB-2002; 2002US-0360000P.
 PR 27-MAR-2002; 2002US-0367500P.
 PR 08-APR-2002; 2002US-0370227P.
 PR 10-MAY-2002; 2002US-0378950P.
 PR 24-MAY-2002; 2002US-0382617P.
 PR 28-MAY-2002; 2002US-0383123P.
 PR 05-JUN-2002; 2002US-0385708P.
 PR 10-JUL-2002; 2002US-0394625P.
 PR 24-JUL-2002; 2002US-0398008P.
 PR 09-AUG-2002; 2002US-0402131P.
 PR 13-AUG-2002; 2002US-0402708P.
 PR 18-SEP-2002; 2002US-0411355P.
 PR 18-SEP-2002; 2002US-0411426P.
 PR 02-OCT-2002; 2002US-0414984P.
 PR 11-OCT-2002; 2002US-0417611P.
 PR 23-OCT-2002; 2002US-0420246P.
 PR 05-NOV-2002; 2002US-0423623P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (DELZ) DELTA BIOTECHNOLOGY LTD.
 PA (PRIN-) PRINCIPIA PHARM CORP.
 XX Ballance DJ, Turner AJ, Rosen CA, Haseltine WA,
 PI WPI; 2003-598517/56.
 DR P-PSDB; ADF16684.

XX New albumin fusion protein, useful for preparing a composition for
 PT treating diabetes mellitus.
 XX
 XX Example 4; SEQ ID NO 1450; 24pp; English.
 XX
 XX This invention relates to a novel albumin fusion protein having albumin
 CC or biological activity. Human serum albumin is responsible for a
 CC significant proportion of the osmotic pressure of serum and also
 CC functions as a carrier of endogenous and exogenous ligands. The fusion of
 CC albumin to a therapeutic protein may increase shelf-life and stability of
 CC the therapeutic protein. The albumin fusion protein of the invention may
 CC allow production of compositions with antidiabetic activity whilst the
 CC nucleotide sequence which encodes it may be useful for gene therapy. The
 CC albumin fusion protein is useful for preparing a composition for treating
 CC diabetes mellitus. The present sequence is a DNA sequence which encodes a
 CC therapeutic protein which was fused with human albumin to create a novel
 CC albumin fusion protein of the invention. Note: The sequence data for this
 CC patent did not form part of the printed specification, but was obtained
 CC in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/publishedpat_sequences
 XX
 SQ Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.38e-85 Length: 735
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 10 Gaps: 0

US-10-072-159-11 (1-130) x ADF16358 (1-735)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 343 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 402
 QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 403 ATCTTCAATACAGCAACCAACCACTATGATGCTCCATGTTAAATTCATTCGCAACATT 462
 QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 463 CCTGGGCTGTACTACTTTCCTCCATCCACATCATCAGTCTATATCAAGGATGTGAAGTCAGC 522
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnLysAsnVal 80
 Db 523 CTCCTTCAAGAGGACAGAGCTATGCTCTTCCTTACCTATGATCAGGAAATAATGTG 582
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 583 GACCAGGCTCTCGGCTCTGTCTCTGCTATCGATCTGGAGGTGGCGACCAAGTCTGCTCCAG 642
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
 Db 643 GTGTATGGGAGGAGGAGCGTAATGGACTCTATGCTGATAATGCAATGACTCCACCTTC 702
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 703 ACAGGCTTCTCTCTACCATGACACCAAC 732

RESULT 10
 ADE93611
 ID ADE93611 standard; cDNA; 735 BP.
 XX
 AC ADE93611;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human adiponectin apM1 (1-244) cDNA.
 XX
 KW adiponectin conjugate; antiarteriosclerotic; antidiabetic; cardiant;

antirheumatic; antibacterial; antilipaeamic; dermatological;
 KW immunosuppressive; immunomodulator; anorectic; diabetes; obesity;
 KW atherosclerosis; cardiovascular disease; dyslipidaemia;
 KW rheumatoid arthritis; Crohn's; systemic lupus erythematosus;
 KW Sjogren syndrome; cachexia; septic shock; myasthenia gravis;
 KW myocardial infarction; inflammation; gene therapy; human; apM1; ss; gene;
 KW wild-type.
 XX
 OS Homo sapiens.
 PN WO2003055916-A2.
 XX
 PD 10-JUL-2003.
 XX
 PF 20-DEC-2002; 2002WO-DK000897.
 XX
 PR 21-DEC-2001; 2001DK-00001952.
 PR 21-DEC-2001; 2001US-0343482P.
 PR 25-APR-2002; 2002DK-00000627.
 PR 03-JUL-2002; 2002US-0375492P.
 PR 03-JUL-2002; 2002DK-00001036.
 PR 20-SEP-2002; 2002US-0394117P.
 PR 20-SEP-2002; 2002DK-00001385.
 PR 20-SEP-2002; 2002US-0412169P.
 XX
 PA (MAXY-) MAXYGEN APS.
 PA (MAXY-) MAXYGEN HOLDINGS LTD.
 XX
 PI Rasmussen PB, Andersen KV, Pedersen AH, Schambye HT, Halkier T;
 PI Bogsgnes A;
 DR
 DR WPI; 2003-598262/56.
 DR P-PSDB; ADE93603.
 XX

New conjugate comprising an adiponectin polypeptide and a first non-polypeptide moiety, useful for preparing a composition for treating a mammal having e.g., diabetes, atherosclerosis or cardiovascular disease.
 Disclosure; SEQ ID NO 9; 184pp; English.

The invention relates to a novel conjugate comprising an adiponectin polypeptide and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide. The adiponectin polypeptide comprises an amino acid residue having an attachment group for the first non-polypeptide moiety which has been introduced in a position where the parent adiponectin is occupied by a surface exposed amino acid residue. The conjugate of the invention demonstrates antiarteriosclerotic, antidiabetic, cardiant, antirheumatic, antibacterial, antilipaeamic, dermatological, immunosuppressive, immunomodulator and anorectic activities and may be useful for treating diabetes, obesity, atherosclerosis, cardiovascular diseases, dyslipidaemia, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, Sjogren syndrome, cachexia, septic shock, myasthenia gravis, myocardial infarction and destructive processes related to activation of the inflammatory system, as well as during gene therapy procedures. The current sequence is that of the human adiponectin apM1 cDNA of the invention.

SQ Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.38e-85 Length: 735
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 10 Gaps: 0

US-10-072-159-11 (1-130) x ADE93611 (1-735)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 343 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 402

QY	21	IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle	40	
DB	403	ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCAGTGGTAATTCCTCACTGCACATT	462	
QY	41	ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer	60	
DB	463	CCTGGGCTGTACTACTTGGCTTCCACCATCACAGTCTATATGAAGATGTGAAGGTCCAGC	522	
QY	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80	
DB	523	CTCTTCAAGAGGACGAGGTATGCTCTTCCATATGATCAGTACCAAGAAATAATGTG	582	
QY	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln	100	
DB	583	GACCAGGCTCCGGCTCTGTGCTCTCCATCTGGAGGTGGGACCAAGTCTGGCTCCAG	642	
QY	101	ValTyrGlyGluGlyGluAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	120	
DB	643	GTGTATGGGAAGGAGAGCGTAATGACTCTATGCTGATAATGACATGACTCCACTTC	702	
QY	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130	
DB	703	ACAGGCTTTCTTCTTACCATGACACCAAC	732	
XX	RESULT 12			
ID	ADH21734			
XX	ADH21734 standard; DNA; 735 BP.			
XX				
AC	ADH21734;			

QY	21	IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle	40	
DB	403	ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCAGTGGTAATTCCTCACTGCACATT	462	
QY	41	ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer	60	
DB	463	CCTGGGCTGTACTACTTGGCTTCCACCATCACAGTCTATATGAAGATGTGAAGGTCCAGC	522	
QY	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80	
DB	523	CTCTTCAAGAGGACGAGGTATGCTCTTCCATATGATCAGTACCAAGAAATAATGTG	582	
QY	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln	100	
DB	583	GACCAGGCTCCGGCTCTGTGCTCTCCATCTGGAGGTGGGACCAAGTCTGGCTCCAG	642	
QY	101	ValTyrGlyGluGlyGluAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	120	
DB	643	GTGTATGGGAAGGAGAGCGTAATGACTCTATGCTGATAATGACATGACTCCACTTC	702	
QY	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130	
DB	703	ACAGGCTTTCTTCTTACCATGACACCAAC	732	
XX	RESULT 11			
ID	ADH21732			
XX	ADH21732 standard; DNA; 735 BP.			
AC	ADH21732;			
XX	11-MAR-2004 (first entry)			
DE	Human adiponectin-encoding DNA, SEQ ID NO:529.			
XX	Fusion protein; human serum albumin; HSA; therapeutic protein;			
KW	shelf-life; in vitro biological activity; in vivo biological activity;			
KW	metabolic disorder; endocrine disorder; diabetes; type 1; type 2;			
KW	diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;			
KW	retinopathy; cardiovascular disorder; heart disease; renal disorder;			
KW	obesity; glucose level maintenance; weight loss; antidiabetic; cardiand;			
XX	anorectic; ophthalmological; gene therapy; gene; ds.			
OS	Homo sapiens.			
XX	WO2003059934-A2.			
XX	24-JUL-2003.			
XX	23-DEC-2002; 2002WO-US040892.			
PR	21-DEC-2001; 2001US-0341811P.			
PR	24-JAN-2002; 2002US-0350358P.			
PR	26-FEB-2002; 2002US-0359370P.			
PR	28-FEB-2002; 2002US-0360000P.			
PR	27-MAR-2002; 2002US-0367500P.			
PR	08-APR-2002; 2002US-0370227P.			
PR	10-MAY-2002; 2002US-0378950P.			
PR	24-JUL-2002; 2002US-0398008P.			
PR	09-AUG-2002; 2002US-0402131P.			
PR	13-AUG-2002; 2002US-0402708P.			
PR	18-SEP-2002; 2002US-0411355P.			
PR	02-OCT-2002; 2002US-0414984P.			
PR	11-OCT-2002; 2002US-0417611P.			
PR	23-OCT-2002; 2002US-0420246P.			
PR	05-NOV-2002; 2002US-0423623P.			
XX	(HUMA-) HUMAN GENOME SCI INC.			
XX	Rosen CA, Haseltine WA;			
XX	WPI; 2003-598501/56.			
DR	P-PSDB; ADH21884.			
DR				
XX	New albumin fusion protein, useful for preparing a composition for			
PT	treating diabetes mellitus.			
XX	Disclosure; SEQ ID NO 529; 1086pp; English.			
XX	The invention relates to fusion proteins comprising human serum albumin			
CC	(ADH21530) and a therapeutic polypeptide such as a therapeutic protein,			
CC	antibody or peptide or their variants or fragments, the therapeutic			
CC	protein may be fused to the N-terminus, the C-terminus or both termini of			
CC	albumin via a linker. The albumin component of the fusion proteins			
CC	prolongs the shelf-life and the in vitro and vivo biological activity of			
CC	the proteins compared with those of the corresponding therapeutic			
CC	proteins on their own. The invention also relates to nucleic acids			
CC	encoding albumin fusion proteins, vectors and host cells comprising an			
CC	albumin fusion protein, nucleic acid, compositions and kits comprising an			
CC	albumin fusion protein, the method of extending the shelf-life of a			
CC	therapeutic protein by fusion with albumin, and the treatment of disease			
CC	using an albumin fusion protein. The albumin fusion proteins may be used			
CC	in the treatment of metabolic/endocrine disorders, diabetes and diabetes-			
CC	related conditions. Specifically the albumin fusion proteins may be used			
CC	to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders			
CC	(especially neuropathy), retinopathy, cardiovascular disorders			
CC	(especially heart disease, renal disorders and obesity. The proteins may			
CC	also be used in a method of maintaining a basal glucose level in a			
CC	patient and in a method for losing weight. The present sequence is			
CC	related to the invention.			
XX	Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;			
XX				
Alignment Scores:				
Pred. No.:	1.38e-85	Length:	735	
Score:	708.00	Matches:	130	
Percent Similarity:	100.00%	Conservative:	0	
Best Local Similarity:	100.00%	Mismatches:	0	
Query Match:	100.00%	Indels:	0	
DB:	10	Gaps:	0	
US-10-072-159-11 (1-130) x ADH21732 (1-735)				
QY	1	PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys	20	
DB	343	TTCAAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG	402	
QY	21	IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle	40	
DB	403	ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAATTCCTCACTGCACATT	462	
QY	41	ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer	60	
DB	463	CCTGGGCTGTACTACTTTCCTACCAATCAGTCTATATGAAGATGTGAAGGTCCAGC	522	
QY	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80	
DB	523	CTCTTCAAGAGGACGAGGTATGCTCTTCCATATGATCAGTACCAAGAAATAATGTG	582	
QY	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln	100	
DB	583	GACCAGGCTCCGGCTCTGTGCTCTCCATCTGGAGGTGGGACCAAGTCTGGCTCCAG	642	
QY	101	ValTyrGlyGluGlyGluAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	120	
DB	643	GTGTATGGGAAGGAGAGCGTAATGACTCTATGCTGATAATGACATGACTCCACTTC	702	
QY	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130	
DB	703	ACAGGCTTTCTTCTTACCATGACACCAAC	732	
RESULT 12				
ID	ADH21734			
XX	ADH21734 standard; DNA; 735 BP.			
XX				
AC	ADH21734;			

XX DT 11-MAR-2004 (first entry)
 XX DE Human HDALV07-encoding DNA, SEQ ID NO:531.
 XX KW Fusion protein; human serum albumin; HSA; therapeutic protein;
 XX KW shelf-life; in vitro biological activity; in vivo biological activity;
 XX KW metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
 XX KW diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
 XX KW retinopathy; cardiovascular disorder; heart disease; renal disorder;
 XX KW obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
 XX KW anorectic; ophthalmological; gene therapy; gene; ds.
 XX OS Homo sapiens.
 XX PN WO2003059934-A2.
 XX PD 24-JUL-2003.
 XX PF 23-DEC-2002; 2002WO-US040892.
 XX PR 21-DEC-2001; 2001US-034181P.
 XX PR 24-JAN-2002; 2002US-0350358P.
 XX PR 26-FEB-2002; 2002US-0359370P.
 XX PR 28-FEB-2002; 2002US-0360000P.
 XX PR 27-MAR-2002; 2002US-0367500P.
 XX PR 08-APR-2002; 2002US-0370227P.
 XX PR 10-MAY-2002; 2002US-0378950P.
 XX PR 24-JUL-2002; 2002US-0398008P.
 XX PR 09-AUG-2002; 2002US-0402131P.
 XX PR 13-AUG-2002; 2002US-0402708P.
 XX PR 18-SEP-2002; 2002US-0411355P.
 XX PR 02-OCT-2002; 2002US-0414984P.
 XX PR 11-OCT-2002; 2002US-0417611P.
 XX PR 23-OCT-2002; 2002US-0420246P.
 XX PR 05-NOV-2002; 2002US-0423623P.
 XX FA (HUMA-) HUMAN GENOME SCI INC.
 XX PI Rosen CA, Haseltine WA;
 XX DR WPI: 2003-598501/56.
 XX DR P-PSDB; ADH21886.
 XX PT New albumin fusion protein, useful for preparing a composition for
 XX PT treating diabetes mellitus.
 XX PS Disclosure; SEQ ID NO 531; 1086pp; English.
 XX CC The invention relates to fusion proteins comprising human serum albumin
 XX CC (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
 XX CC antibody or peptide or their variants or fragments. The therapeutic
 XX CC protein may be fused to the N-terminus, the C-terminus or both termini of
 XX CC albumin via a linker. The albumin component of the fusion proteins
 XX CC prolongs the shelf-life and the in vitro and vivo biological activity of
 XX CC the proteins compared with those of the corresponding therapeutic
 XX CC proteins on their own. The invention also relates to nucleic acids
 XX CC encoding albumin fusion proteins, vectors and host cells comprising an
 XX CC albumin fusion protein nucleic acid, compositions and kits comprising an
 XX CC albumin fusion protein, the method of extending the shelf-life of a
 XX CC therapeutic protein by fusion with albumin, and the treatment of disease
 XX CC in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
 XX CC related conditions. Specifically the albumin fusion proteins may be used
 XX CC to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders
 XX CC (especially neuropathy), retinopathy, cardiovascular disorders
 XX CC (especially heart disease, renal disorders and obesity. The proteins may
 XX CC also be used in a method of maintaining a basal glucose level in a
 XX CC patient and in a method for losing weight. The present sequence is
 XX CC related to the invention.
 XX SQ Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.38e-85 Length: 735
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 10 Gaps: 0
 US-10-072-159-11 (1-130) x ADH21734 (1-735)
 QY 1 PheSerValGlyLeuGluThrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 343 TTCAGTGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 402
 QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 403 ATCTTCTACCAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCACTGCCAATT 462
 QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 463 CCTGGGCTGTACTTTCCTTACCACATCAGTCTATATGAAGGATGTGAAGGTCAGC 522
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 523 CTCTTCAGGAAGGACCAAGGCTATGCTCTTACCTATGATCAGTACCAAGGAAATATATGTG 582
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 583 GACCAGGCTCCGGCTCTGTGCTCTGCTCATCTGGAGTGGGGAGCCCAAGTCTGGCTCCAG 642
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
 Db 643 GTGTATGGGGAAGGAGAGGCGTAAATGGACTCTATGCTGATAATGACAATGACTCCACTTC 702
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 703 ACAGGCTTCTTCTTACCATGACACCAAC 732
 RESULT 13
 ADH21733
 ID ADH21733 standard; DNA; 735 BP.
 XX AC ADH21733;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human HDALV07(GD)/adiponectin-encoding DNA, SEQ ID NO:530.
 XX KW Fusion protein; human serum albumin; HSA; therapeutic protein;
 XX KW shelf-life; in vitro biological activity; in vivo biological activity;
 XX KW metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
 XX KW diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
 XX KW retinopathy; cardiovascular disorder; heart disease; renal disorder;
 XX KW obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
 XX KW anorectic; ophthalmological; gene therapy; gene; ds.
 XX OS Homo sapiens.
 XX PN WO2003059934-A2.
 XX PD 24-JUL-2003.
 XX PF 23-DEC-2002; 2002WO-US040892.
 XX PR 21-DEC-2001; 2001US-034181P.
 XX PR 24-JAN-2002; 2002US-0350358P.
 XX PR 26-FEB-2002; 2002US-0359370P.
 XX PR 28-FEB-2002; 2002US-0360000P.
 XX PR 27-MAR-2002; 2002US-0367500P.
 XX PR 08-APR-2002; 2002US-0370227P.
 XX PR 10-MAY-2002; 2002US-0378950P.
 XX PR 24-JUL-2002; 2002US-0398008P.
 XX PR 09-AUG-2002; 2002US-0402131P.

PR	13-AUG-2002; 2002US-0402708P.	
PR	18-SEP-2002; 2002US-0411355P.	
PR	02-OCT-2002; 2002US-0414984P.	
PR	11-OCT-2002; 2002US-0417611P.	
PR	23-OCT-2002; 2002US-0420246P.	
PR	05-NOV-2002; 2002US-0423623P.	
XX	(HUWA-) HUMAN GENOME SCI INC.	
XX		
XX	Rosen CA, Haseltine WA;	
XX	WPI; 2003-598501/56.	
XX	P-PSDB; ADH21885.	
DR		
DR	New albumin fusion protein, useful for preparing a composition for	
PT	treating diabetes mellitus.	
PT		
XX	Disclosure; SEQ ID NO 530; 1086pp; English.	
XX		
CC	The invention relates to fusion proteins comprising human serum albumin	
CC	(ADH21530) and a therapeutic polypeptide such as a therapeutic protein,	
CC	antibody or peptide or their variants or fragments. The therapeutic	
CC	protein may be fused to the N-terminus, the C-terminus or both termini of	
CC	albumin via a linker. The albumin component of the fusion proteins	
CC	prolongs the shelf-life and the in vitro and vivo biological activity of	
CC	the proteins compared with those of the corresponding therapeutic	
CC	proteins on their own. The invention also relates to nucleic acids	
CC	encoding albumin fusion proteins, vectors and host cells comprising an	
CC	albumin fusion protein nucleic acid, compositions and kits comprising an	
CC	albumin fusion protein, the method of extending the shelf-life of a	
CC	therapeutic protein by fusion with albumin, and the treatment of disease	
CC	using an albumin fusion protein. The albumin fusion proteins may be used	
CC	in the treatment of metabolic/endocrine disorders, diabetes and diabetes-	
CC	related conditions. Specifically the albumin fusion proteins may be used	
CC	to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders	
CC	(especially neuropathy), retinopathy, cardiovascular disorders	
CC	(especially heart disease), renal disorders and obesity. The proteins may	
CC	also be used in a method of maintaining a basal glucose level in a	
CC	patient and in a method for losing weight. The present sequence is	
CC	related to the invention.	
XX		
XX	Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;	
XX		
Alignment Scores:		
Prod. No.:	1,38e-85	Length: 735
Score:	708.00	Matches: 130
Percent Similarity:	100.00%	Conservative: 0
Best Local Similarity:	100.00%	Mismatches: 0
Query Match:	100.00%	Indels: 0
DB:	10	Gaps: 0
US-10-072-159-11 (1-130) x ADH21733 (1-735)		
QY	1	PheSerValGlyLeuGluThrTyxValThrIleProAsnMetProIleArgPheThrLys 20
Db	343	TTTCAGTGGGATTCGAGACTTACGTGTACTATCCCAACATGCCCATTCGCTTTACCAAG 402
QY	21	IlePheTyxAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db	403	ACCTTCTCAATCAGCAAAACACCATATGATGGCTCCACTGGTAAATTCCACTGCAACATT 462
QY	41	ProGlyLeuTyxTyrPhealaTyxHisIleThrValTyrMetLysAspValLysValSer 60
Db	463	CTGGGGCTGTACTTTGGCTTACCACATCACAGTCTATATGAAGGATGGAAGGTGAGC 522
QY	61	LeuPheLysIleAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnIleAsnAsnVal 80
Db	523	CTCTTCAGAGGACRAGGCTATGCTCTTCACCTATGATCATGATCACCAGGAAATAATGTG 582
QY	81	AspGlnAlaSerGlySerValLeuLeuHisIleGluValGlyAspGlnValTyrLeuGln 100
Db	583	GACCAGGCTCCGGCTGTGTGCTCTGATCTGGAGTGGGGCGACCAAGTTGGCTCCAG 642

QY	101	VallTyGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe
Db	643	GGTATGGGGAAGAGACCGTAATGGACTCTATGCTGATATGACATGCCACCTTC
QY	121	ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db	703	ACAGGCTTTCTCTCACCATTGACACCAAC 732
RESULT 14		
ADFI4853		
ID	ADFI4853 standard; DNA; 735 BP.	
XX	AC	
AC	ADF14853;	
DT	26-FEB-2004 (first entry)	
XX		
DE	Human arteriosclerosis-related protein coding sequence, SEQ ID 1.	
XX		
KW	Arteriosclerosis; adiponectin; scavenger receptor A ;	
KX	antiarteriosclerotic; human; gene; ds.	
XX		
OS	Homo sapiens.	
XX		
PH	Key Location/Qualifiers	
CDS	1..735	
FT	/*tag= a	
FT	/product= "Human arteriosclerosis-related protein"	
XX		
PN	WO2003099319-A1.	
XX		
PD	04-DEC-2003.	
XX		
PF	26-MAY-2003; 2003WO-JP006518.	
XX		
PR	24-MAY-2002; 2002JP-00151220.	
XX		
PA	(NISC-) JAPAN SCI & TECHNOLOGY CORP.	
PI	Kadowaki T, Yamauchi T, Kubota N, Terauchi Y, Kubota T, Noda T;	
PI	Nagai R, Imai Y;	
XX		
DR	WPI; 2004-023231/02.	
DR	P-PSDB; ADFI4854.	
XX		
PT	Preventives or remedies for arteriosclerosis containing agents for	
PT	regulating scavenger receptor A expression in arterial walls to inhibit	
PT	lipid accumulation in macrophages and to prevent its onset and	
PT	progression.	
XX		
PS	Disclosure; SEQ ID NO 1; 46pp; Japanese.	
XX		
CC	The present invention relates to preventives or remedies for	
CC	arteriosclerosis, which contain as active ingredient a spherical region	
CC	in the C-terminal side of adiponectin, adiponectin or their gene. Such	
CC	drugs contain agents for regulating scavenger receptor A expression in	
CC	arterial wall to inhibit lipid accumulation in macrophages and to prevent	
CC	onset and progression of arteriosclerosis with direct stoppage of	
CC	endangium form thickening. The present sequence was used to illustrate	
CC	the invention.	
XX		
SQ	Sequence 735 BP; 179 A; 193 C; 201 G; 162 T; 0 U; 0 Other;	
Alignment Scores:		
Fred. No.:	1.38e-85	Length: 735
Score:	708.00	Matches: 130
Percent Similarity:	100.00%	Conservative: 0
Best Local Similarity:	100.00%	Mismatches: 0
Query Match:	100.00%	Indels: 0
DB:	12	Gaps: 0

US-10-072-159-11 (1-130) x ADF14853 (1-735)

Qy 1 pheservalGlyLeuGluThrTyrrValThrIleProAsnMetProIleArgPheThrLys 20

Db 343 TTCCAGTGGGATTCGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 402
 QY 21 ILlePheTyRAsnGlnGlnAsnHisTyRAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 403 ATCTTCTACATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTACTGCAACATT 462
 QY 41 ProGlyLeuTyRtyrPheAlaTyRHisIleThrValTyRMetLysAspValLysValSer 60
 Db 463 CTGGGCTGTACTACTTTGCTTCCACATCAGATCTATATGAGAGATGTGAGGTCCAGC 522
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyRAspGlnTyRGlnGluAsnVal 80
 Db 523 CTCCTTCARAGAGACAAAGCTATGCTCTTCACCTATGATCAGTACCAAGGAAATAATGTG 582
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 583 GACCAGGCTCCGGCTCTGCTCTGCTGATCTGGAGTGGGCGACCAAGTCTGGCTCCAG 642
 QY 101 ValTyRGlyGluGlyGluArgAsnGlyLeuTyRAlaAspAsnAspSerThrPhe 120
 Db 643 GTGTATGGGGAAGAGAGAGCTTAATGAGCTCTATGCTGATATGACATGACTCCACCTTC 702
 QY 121 ThrGlyPheLeuLeuTyRHisAspThrAsn 130
 Db 703 ACAGGCTTCTCTTCTTACCATGACCAAC 732

RESULT 15

ADD93529
 ID ADD93529 standard; cDNA; 742 BP.

XX AC ADD93529;

XX DT 29-JAN-2004 (first entry)

XX DE Novel nucleic acid NOV2e, homologous to human adiponectin.
 XX KW NOV2e; human; adiponectin; gene therapy; gene; ss.
 XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 XX CDS 11..712
 XX FT /*tag= a
 XX FT /partial
 XX FT /product= "Human NOV2e"
 XX FT /note= "No start codon"

XX WO2003078572-A2.

XX PN 25-SEP-2003.

XX PD 06-MAR-2003; 2003WO-US006859.

XX PF 15-MAR-2002; 2002US-0365034P.

XX PR 19-MAR-2002; 2002US-0365477P.

XX PR 21-MAR-2002; 2002US-0366420P.

XX PR 05-MAR-2003; 2003US-00379747.

XX (CURA-) CURAGEN CORP.

XX PI Burgess CE, Chant JS, Chaudhuri A, Edinger SR, Gangolli EA;

XX PI Malyankar UM, Miller CE, Ooi CE, Ort T, Patturajan M, Rastelli L;

XX PI Rieger DK, Shimkets RA, Zerhusen BD;

XX DR WPI; 2003-779122/73.

XX DR P-PSDB; ADD93530.

XX XX New isolated NOVX polypeptides and polynucleotides, useful for

XX PT preventing, diagnosing or treating NOVX-associated disorders, e.g.

XX PT osteoarthritis, obesity, atherosclerosis, cancer, Parkinson's disease,

XX PT asthma, or infections.

XX XX

Claim 20; Page 108; 205pp; English.

PS The present sequence is that of a novel polynucleotide encoding novel
 XX NOV2e, a polypeptide that shows amino acid sequence homology to the human
 CC adiponectin (adipose most abundant gene transcript 1, APM1). The
 CC adiponectin gene is the most abundant gene transcript in adipose cells
 CC that regulates lipid metabolism. An interaction between adiponectin and
 CC calcium modulating lipid was identified, indicating a novel pathway by
 CC which adiponectin may induce lipid breakdown in muscle cells and
 CC adipocytes. The invention is based on the identification of proteins and
 CC polypeptides, and the nucleic acids encoding them, that are
 CC differentially modulated in a pathological state, disease or an abnormal
 CC condition or state. These are targets for therapeutic agents and can be
 CC used in screening methodologies to identify candidate therapeutic agents
 CC which interact with the target and thereby exert a desired or favourable
 CC effect, e.g. in neurogenesis, cell differentiation, cell proliferation,
 CC haematopoiesis, wound healing and angiogenesis. Methods for diagnosis,
 CC treatment and prevention of disorders involving the novel human nucleic
 CC acids and proteins are provided. The nucleic acids are further used in
 CC gene therapy, as hybridization probes and primers, in chromosome mapping,
 CC tissue typing, preventive medicine, and pharmacogenomics.

SQ Sequence 742 BP; 189 A; 204 C; 197 G; 152 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.4e-85 Length: 742
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 10 Gaps: 0

US-10-072-159-11 (1-130) x ADD93529 (1-742)

QY 1 PheSerValGlyLeuGluThrTyRValThrIleProAsnMetProIleArgPheThrLys 20
 Db 320 TTCAGTGGGATTCGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 379
 QY 21 ILlePheTyRAsnGlnGlnAsnHisTyRAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 380 ATCTTCTACATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTACTCAACATT 439
 QY 41 ProGlyLeuTyRtyrPheAlaTyRHisIleThrValTyRMetLysAspValLysValSer 60
 Db 440 CTGGGCTGTACTACTTTGCCCTACCACATCAGTCTATATGAGGATGTGAGGTCCAGC 499
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyRAspGlnTyRGlnGluAsnVal 80
 Db 500 CTCCTTCAGAGGACAAAGGCTATGCTCTTCACCTATGATCAGTACCAAGAAATAATGTG 559
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 560 GACCAGGCTCCGGCTCTGCTCTGCTCTGCTATGAGGTGGGCGACCAAGTCTGGCTCCAG 619

QY 101 ValTyRGlyGluGlyGluArgAsnGlyLeuTyRAlaAspAsnAspAspSerThrPhe 120
 Db 620 GTGTATGGGGAAGGAGAGCGTAATGAGCTCTATGCTGATATGACAAATGACTCCACCTTC 679

QY 121 ThrGlyPheLeuLeuTyRHisAspThrAsn 130
 Db 680 ACAGGCTTCTTCTCTTACCATGACACCAAC 709

Search completed: December 3, 2004, 11:01:11

Job time : 405 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: December 3, 2004, 09:58:48 ; Search time 2353 Seconds

(without alignments)
2612.691 Million cell updates/sec

Title: US-10-072-159-11

Perfect score: 708

Sequence: 1 FSVGLETYTIPNPIRFTK.....YADNDNDSTFGTGLLYHDTN 130

Scoring table:

BLOSUM62	Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5	
Fgapop 6.0 , Fgapext 7.0	
Delop 6.0 , Delext 7.0	

Searched: 4526729 segs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+p2n.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/US10072159/runat_02122004_142305_15562/app_query.fasta_1.327
-DB=GenEmbl -QFMT=fastap -SUFFIX=p2n.rge -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -NATFIX=blotsum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEADSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US10072159@cgn 1 1 5600 @runat_02122004_142305_15562 -NCPU=6 -ICPU=3
-NO_WMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=10 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

GenEmbl.*

1: gb_ba.*

2: gb_btg.*

3: gb_in.*

4: gb_om.*

5: gb_ov.*

6: gb_pat.*

7: gb_ph.*

8: gb_pl.*

9: gb_pr.*

10: gb_ro.*

11: gb_sts.*

12: gb_sy.*

13: gb_un.*

14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	708	100.0	492	6	AX800356 Sequence
2	708	100.0	521	9	HL131461 Homo sapi
3	708	100.0	537	6	AX800405 Sequence
4	708	100.0	564	6	AX800355 Sequence

5	708	100.0	582	6	AX800354 Sequence
6	708	100.0	735	6	AX752056 Sequence
7	708	100.0	735	6	AX800349 Sequence
8	708	100.0	1313	6	AF034253 Sequence
9	708	100.0	4510	6	CQ715267 Sequence
10	708	100.0	4517	6	AR138194 Sequence
11	708	100.0	4517	6	AR255755 Sequence
12	708	100.0	4517	6	AR337311 Sequence
13	708	100.0	4517	6	AR343651 Sequence
14	708	100.0	4517	6	AX195211 Sequence
15	708	100.0	4517	6	AX335029 Sequence
16	708	100.0	4517	6	AX358521 Sequence
17	708	100.0	4517	6	AX767959 Sequence
18	708	100.0	4517	6	AX951629 Sequence
19	708	100.0	4517	6	AX960544 Sequence
20	708	100.0	4517	6	BD074783 Homolog O
21	708	100.0	4517	9	HOMUFS12
22	708	100.0	4537	9	AB012163S3
23	708	100.0	4545	6	BD238086 Genome se
24	708	100.0	4545	6	AR344520 Sequence
25	708	100.0	4545	6	AX134174 Sequence
26	708	100.0	13001	9	AC072018 Homo sapi
27	708	100.0	20966	6	BD238082 Sequence
28	708	100.0	20966	6	AR337312 Sequence
29	708	100.0	20966	6	AR343652 Sequence
30	708	100.0	20966	6	AR344516 Sequence
31	708	100.0	20966	6	AX134170 Sequence
32	708	100.0	20966	6	AX195213 Sequence
33	708	100.0	20966	6	AX358523 Sequence
34	708	100.0	20966	6	AX767961 Sequence
35	708	100.0	20966	6	AX960548 Sequence
36	708	100.0	176155	2	AC012149 Homo sapi
37	708	100.0	195323	2	AC026612 Homo sapi
38	707	99.9	734	9	AF404407 Macaca mu
39	703	99.3	537	6	AX800403 Sequence
40	703	99.3	537	6	AX800408 Sequence
41	702	99.2	537	6	AX800402 Sequence
42	702	99.2	537	6	AX800404 Sequence
43	700	98.9	537	6	AX800407 Sequence
44	699	98.7	537	6	AX800406 Sequence
45	699	98.7	537	6	AX800409 Sequence

ALIGNMENTS

RESULT 1	AX800356	492 bp	DNA	linear	PAT 13-OCT-2003
LOCUS	Sequence 16 from Patent WO03055916.				
DEFINITION	AX800356				
ACCESSION	AX800356.1	GI:37653576			
VERSION					
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1				
AUTHORS	Rasmussen,P.B., Andersen,K.V., Pedersen,A.H., Schambye,H.T., Halkier,T. and Bogshes,A.				
TITLE	Adiponectin fragments and conjugates				
JOURNAL	Patent: WO 03055916-A 16 10-JUL-2003;				
	Maxygen Aps (DK) ; Maxygen Holdings Ltd. c/o Close Brothers				
	(Cayman) Limited (KY)				
FEATURES	Location/Qualifiers				
source	1..492				
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
	/note="apM1 (82-244) coding sequence"				

ORIGIN

Alignment Scores:

Pred. No.: 2.42e-74

Length: 492

Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AX800356 (1-492)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrIys 20
 DB 100 TTCAAGTGGGATTGGAGACTTACGTACTATCCCAACATGCCCATTCGTTTACCAAG 159
 QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 DB 160 ATCTTCTACATCAGCAAAACCACTATGATGCTCCACTGGTAAATTCCTGCAACATT 219
 QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 DB 220 CTGGGCTGTACTCTTGGCTTACCACATCAGCTCTATATGAAGGATGTGAAGGTGAGC 279
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 DB 280 CTCCTTCAAGAGGACCAAGCTATGCTCTTCACTATGATCAGTACCAAGGAAAAATAATGTG 339
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
 DB 340 GACCAAGCTCCGGCTCTGTGCTCTGCACTGGAGGTGGGACCAAGTCTGGCTCCAG 399
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnAspSerThrPhe 120
 DB 400 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGTAATGACAATGACTCCACCTTC 459
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 DB 460 ACAGGCTTCTCTCTACATGACACCAAC 489

RESULT 2
 HSAL131461 521 bp DNA linear PRI 21-OCT-1999
 LOCUS Homo sapiens apM-1 gene, exon 3.
 DEFINITION
 ACCESSION AJ131461
 VERSION AJ131461.1 GI:5725240
 KEYWORDS adipocyte-specific secretory protein; apM-1 gene.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Schaffler, A., Orso, E., Palitzsch, K.D., Buchler, C., Drobnik, W., Furst, A., Scholmerich, J., and Schmitz, G.
 TITLE The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21.3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH)
 JOURNAL Biochem. Biophys. Res. Commun. 260 (2), 416-425 (1999)
 MEDLINE 99333693
 PUBMED 10403784
 REFERENCE 2 (bases 1 to 521)
 AUTHORS Schaffler, A.J.
 TITLE Direct Submission
 JOURNAL Submitted (09-DEC-1998) Schaffler A.J., University of Regensburg, Germany, Institute for Clinical Chemistry and Laboratory Medicine, Franz-Josef-Strauss-Allee 11, D-93042, GERMANY

FEATURES
 source

1..521
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="1"
 /map="1q21.3-q23"
 1..521
 /gene="apM-1"
 1..>521

gene
 exon

ORIGIN
 /gene="apM-1"
 /number=3
 /usedin=AJ131460:apM1_CDS

Alignment Scores:

Pred. No.: 2,58e-74 Length: 521
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 9 Gaps: 0

US-10-072-159-11 (1-130) x HSAL131461 (1-521)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrIys 20
 DB 129 TTCAAGTGGGATTGGAGACTTACGTACTATCCCAACATGCCCATTCGTTTACCAAG 188
 QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 DB 189 ATCTTCTACATCAGCAAAACCACTATGATGCTCCACTGGTAAATTCCTGCAACATT 248
 QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 DB 249 CTGGGCTGTACTCTTGGCTTACCACATCAGCTCTATATGAAGGATGTGAAGGTGAGC 308
 QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 DB 309 CTCCTTCAAGAGGACCAAGCTATGCTCTTCACTATGATCAGTACCAAGGAAAAATAATGTG 368
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
 DB 369 GACCAAGCTCCGGCTCTGTGCTCTGCACTGGAGGTGGGACCAAGTCTGGCTCCAG 428
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnAspSerThrPhe 120
 DB 429 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGTAATGACAATGACTCCACCTTC 488
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 DB 489 ACAGGCTTCTCTCTACATGACACCAAC 518

RESULT 3

AX800405 537 bp DNA linear PAT 13-OCT-2003
 LOCUS AX800405
 DEFINITION Sequence 65 from Patent WO03055916.
 ACCESSION AX800405
 VERSION AX800405.1 GI:37653580
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Rasmussen, P.B., Andersen, K.V., Pedersen, A.H., Schambye, H.T., Halkier, F., and Bogsnes, A.
 TITLE Adiponectin fragments and conjugates
 JOURNAL Patent: WO 03055916-A 65 10-JUL-2003;
 Maxygen Aps (DK); Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited (KY)

FEATURES
 source

1..537
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic construct encoding Villin-apM1 (82-244)"

ORIGIN

Alignment Scores:
 Pred. No.: 2,68e-74 Length: 537
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0


```

Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0
US-10-072-159-11 (1-130) x AX800405 (1-537)

QY 1 PheSerValGlyLeuGluThrTyValThrIleProAsnMetProIleArgPheThrLys 20
DB 145 TTCAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 204
QY 21 IlePheTyAsnGlnAsnHisTyAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 205 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGTTAAATTCCTGCAACATT 264
QY 41 ProGlyLeuTyTyPheAlaTyHisIleThrValTyMetLysAspValValSer 60
DB 265 CTTGGCTGTACTACTTTGCCCTACCATCATCAGCTCTATATGAAGGATGTGAAGGTCAGC 324
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyAspGlnTyGlnGluAsnVal 80
DB 325 CTCTTCAAGAGGACCAAGGCTATGCTCTTCACTATGATCAGTACCAAGAAATATATGTG 384
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 385 GACCAGGCTCGGCTCTGTCTCTGCTCATCTGAGGTGGCGGACCAAGTCTGGCTCCAG 444
QY 101 ValTyGlyGluGlyGluArgAsnGlyLeuTyTyAspGlnTyGlnGluAsnVal 120
DB 445 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGTAATGACATGATCCTCCACTTC 504
QY 121 ThrGlyPheLeuLeuTyTyHisAspThrAsn 130
DB 505 ACAGGCTTCTCTCTACCATGACACCAAC 534

RESULT 4
LOCUS AX800355 564 bp DNA linear PAT 13-OCT-2003
DEFINITION Sequence 15 from Patent WO03055916.
ACCESSION AX800355
VERSION AX800355.1 GI:37653575
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Rasmussen,P.B., Andersen,K.V., Pedersen,A.H., Schambye,H.T.,
Haikier,T. and Bogness,A.
TITLE Adiponectin fragments and conjugates
JOURNAL Patent: WO 03055916-A 15 10-JUL-2003;
Maxygen Aps (DK) ; Maxygen Holdings Ltd. c/o Close Brothers
(Cayman) Limited (KY)
FEATURES
Location/Qualifiers
source 1..564
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="apM1(58-244) coding sequence"

ORIGIN
Alignment Scores:
Pred. No.: 2,848-74 Length: 564
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0
US-10-072-159-11 (1-130) x AX800355 (1-564)

QY 1 PheSerValGlyLeuGluThrTyValThrIleProAsnMetProIleArgPheThrLys 20
DB 172 TTCAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 231

Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0
US-10-072-159-11 (1-130) x AX800405 (1-537)

QY 21 IlePheTyAsnGlnAsnHisTyAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 232 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGTTAAATTCCTGCAACATT 291
QY 41 ProGlyLeuTyTyPheAlaTyHisIleThrValTyMetLysAspValValSer 60
DB 292 CTTGGCTGTACTACTTTGCCCTACCATCATCAGCTCTATATGAAGGATGTGAAGGTCAGC 351
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyAspGlnTyGlnGluAsnVal 80
DB 352 CTCTTCAAGAGGACCAAGGCTATGCTCTTCACTATGATCAGTACCAAGAAATATATGTG 411
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 412 GACCAGGCTCGGCTCTGTCTCTGCTCATCTGAGGTGGCGGACCAAGTCTGGCTCCAG 471
QY 101 ValTyGlyGluGlyGluArgAsnGlyLeuTyTyAspGlnTyGlnGluAsnVal 120
DB 472 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGTAATGACATGATCCTCCACTTC 531
QY 121 ThrGlyPheLeuLeuTyTyHisAspThrAsn 130
DB 532 ACAGGCTTCTCTCTACCATGACACCAAC 561

RESULT 5
LOCUS AX800354 582 bp DNA linear PAT 13-OCT-2003
DEFINITION Sequence 14 from Patent WO03055916.
ACCESSION AX800354
VERSION AX800354.1 GI:37653574
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Rasmussen,P.B., Andersen,K.V., Pedersen,A.H., Schambye,H.T.,
Haikier,T. and Bogness,A.
TITLE Adiponectin fragments and conjugates
JOURNAL Patent: WO 03055916-A 14 10-JUL-2003;
Maxygen Aps (DK) ; Maxygen Holdings Ltd. c/o Close Brothers
(Cayman) Limited (KY)
FEATURES
Location/Qualifiers
source 1..582
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="apM1(52-244) coding sequence"

ORIGIN
Alignment Scores:
Pred. No.: 2,958-74 Length: 582
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0
US-10-072-159-11 (1-130) x AX800354 (1-582)

QY 1 PheSerValGlyLeuGluThrTyValThrIleProAsnMetProIleArgPheThrLys 20
DB 190 TTCAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 249
QY 21 IlePheTyAsnGlnAsnHisTyAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 250 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGTTAAATTCCTGCAACATT 309
QY 41 ProGlyLeuTyTyPheAlaTyHisIleThrValTyMetLysAspValValSer 60
DB 310 CTTGGCTGTACTACTTTGCCCTACCATCATCAGCTCTATATGAAGGATGTGAAGGTCAGC 369
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyAspGlnTyGlnGluAsnVal 80

```


QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 703 ACAGGCTTTCTCTACCATGACCAAC 732

RESULT 8
LOCUS AR034253 1313 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 6 from patent US 5869330.
ACCESSION AR034253
VERSION AR034253.1 GI:5949858
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1313)
AUTHORS Scherer,P.E. and Iodish,H.F.
TITLE DNA encoding a novel serum protein produced exclusively in adipocytes
JOURNAL Patent: US 5869330-A 6 09-FEB-1999;
FEATURES Location/Qualifiers
source 1. .1313
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Alignment Scores:
Pred. No.: 7.68e-74 Length: 1313
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AR034253 (1-1313)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
Db 415 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 474
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db 475 ATCTTCTACATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTACTGCAACATT 534
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
Db 535 CCTGGCTGTACTACTTGGCTACCACTACATCAGTCTATATGAAGGATGTGAAGGTCCAG 594
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
Db 595 CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCAGTACCAAGAAATTAATGTG 654
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 655 GACCAGGCTCCGGCTCTGTGCTCTCATCTGGAGGTGGCGACCAAGTCTGGCTCCAG 714
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
Db 715 GTGATGGGAGGAGGAGCGTAATGGACTCTATGCTGTAATGACATGACTCCACCTTC 774
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 775 ACAGGCTTTCTCTACCATGACCAAC 804

RESULT 9
CQ715267
LOCUS CQ715267 4510 bp DNA linear PAT 03-FEB-2004
DEFINITION Sequence 1201 from Patent WO02068579.
ACCESSION CQ715267
VERSION CQ715267.1 GI:42276124
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Venter,C.J., Adams,M.C., Li,P.W. and Myers,E.W.
Kits, such as nucleic acid arrays, comprising a majority of humaxons or transcripts, for detecting expression and other uses thereof
Patent: WO 02068579-A 1201 06-SEP-2002;
PE Corporation (NY) (US)
Location/Qualifiers
source 1. .4510
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Alignment Scores:
Pred. No.: 3.29e-73 Length: 4510
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x CQ715267 (1-4510)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
Db 358 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 417
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db 418 ATCTTCTACATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTACTGCAACATT 477
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
Db 478 CCTGGCTGTACTACTTTCCTTACCACTACAGTCTATATGAAGATGTGAAGTCCAG 537
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
Db 538 CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCAGTACCAAGAAATTAATGTG 597
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 598 GACCAGGCTCCGGCTCTGTGCTCTCATCTGGAGGTGGCGACCAAGTCTGGCTCCAG 657
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
Db 658 GTGATGGGAGGAGGAGCGTAATGGACTCTATGCTGTAATGACATGACTCCACCTTC 717
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 718 ACAGGCTTTCTCTCTACCATGACCAAC 747

RESULT 10
AR138194
LOCUS AR138194 4517 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 9 from patent US 6197930.
ACCESSION AR138194
VERSION AR138194.1 GI:14479703
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 4517)
AUTHORS Sheppard,P.O. and Humes,J.M.
TITLE Adipocyte-specific protein homologs
JOURNAL Patent: US 6197930-A 9 06-MAR-2001;
FEATURES Location/Qualifiers
source 1. .4517
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Alignment Scores:
 Pred. No.: 3.3e-73 Length: 4517
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AR138194 (1-4517)

QY 1 PheSerValGlyLeuGluThrValThrIleProAsnMetProIleArgPheThrIlys 20
 Db 369 TTCAGTGTGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 428

QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 429 ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCACACTGCAACATT 488

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 489 CCTGGGCTGTACTACTTTGGCTACCAATCAGCAATCAGAGTCTATATGAAGGATGTGAAGGTCAGC 548

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 549 CTCTTCAGAGGACAGAGGCTATGCTTCCACTATGATCAGTACCAAGAAATAATGTG 608

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
 Db 609 GACCAGGCTCCGGCTCTGTGCTCTGCTGATCTGGAGGTGGCGGACCAAGTCTGGCTCCAG 668

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnSerThrPhe 120
 Db 669 GTGTATGGGAGAGAGCGTAAATGACTCTATGCTGATAATGACAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 729 ACAGGCTTCTCTCTACCATGACACCAAC 758

RESULT 12
 AR337311
 LOCUS 4517 bp DNA linear PAT 17-AUG-2003
 DEFINITION Sequence 5 from patent US 6566332.
 ACCESSION AR337311
 VERSION AR337311.1 GI:33723295
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 4517)
 AUTHORS Fruebis, J., Erickson, M.R., Yen, F. and Bihain, B.
 TITLE OBG3 globular head and uses thereof for decreasing body mass
 JOURNAL Patent: US 6566332-A 5 20-MAY-2003;
 FEATURES
 1. .4517
 Location/Qualifiers
 source
 /organism="unknown"
 /mol_type="genomic DNA"

ORIGIN
 Alignment Scores:
 Pred. No.: 3.3e-73 Length: 4517
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AR337311 (1-4517)

QY 1 PheSerValGlyLeuGluThrValThrIleProAsnMetProIleArgPheThrIlys 20
 Db 369 TTCAGTGTGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 428

QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 429 ATCTTCTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCACACTGCAACATT 488

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 489 CCTGGGCTGTACTACTTTGGCTACCAATCAGCAATCAGAGTCTATATGAAGGATGTGAAGGTCAGC 548

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 549 CTCTTCAGAGGACAGAGGCTATGCTTCCACTATGATCAGTACCAAGAAATAATGTG 608

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
 Db 609 GACCAGGCTCCGGCTCTGTGCTCTGCTGATCTGGAGGTGGCGGACCAAGTCTGGCTCCAG 668

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnSerThrPhe 120
 Db 669 GTGTATGGGAGAGAGCGTAAATGACTCTATGCTGATAATGACAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 729 ACAGGCTTCTCTCTACCATGACACCAAC 758

RESULT 11
 AR255755
 LOCUS 4517 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 9 from patent US 6482612.
 ACCESSION AR255755
 VERSION AR255755.1 GI:27304874
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 4517)
 AUTHORS Sheppard, P.O. and Humes, J.M.
 TITLE Adipocyte-specific protein homologs
 JOURNAL Patent: US 6482612-A 9 19-NOV-2002;
 FEATURES
 1. .4517
 Location/Qualifiers
 source
 /organism="unknown"
 /mol_type="genomic DNA"

ORIGIN
 Alignment Scores:
 Pred. No.: 3.3e-73 Length: 4517
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AR255755 (1-4517)

QY 1 PheSerValGlyLeuGluThrValThrIleProAsnMetProIleArgPheThrIlys 20
 Db 369 TTCAGTGTGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 428

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnSerThrPhe 120
 Db 669 GTGTATGGGAGGAGAGCGTAATGGACTATGCTGTAATAGCAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 729 ACAGGCTTCTCTCTACATGACACCAAC 758

RESULT 13
 LOCUS AR343651 4517 bp DNA linear PAT 17-AUG-2003
 DEFINITION Sequence 5 from patent US 6579852.
 ACCESSION AR343651
 VERSION AR343651.1 GI:33739445
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 4517)
 AUTHORS Fruebis, J., Erickson, M.R., Yen-Potin, F. and Bihain, B.
 TITLE OB93 globular head and uses thereof for decreasing body mass
 JOURNAL Patent: US 6579852-A 5 17-JUN-2003;
 FEATURES
 Location/Qualifiers
 1..4517
 /organism="unknown"
 /mol_type="genomic DNA"
 source

ORIGIN
 Alignment Scores:
 Pred. No.: 3.3e-73 Length: 4517
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AR343651 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 369 TTCAGTGTGGGATGGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 428

QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 429 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCACCTGCAACATT 488

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer 60
 Db 489 CCTGGGCTGTACTCTTGGCTTACCATCATGATGCTATATGAAGGATGGAAGTCAGC 548

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 549 CTCCTCAAGAGGACAGGCTATGCTCTACCTATGATCATGATGATGATGATGATGATG 608

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 609 GACCAGGCTCCGGCTCTGTCTCTGCTCATCTGGAGTGGGGCCACCAAGTCTGGCTCCAG 668

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
 Db 669 GTGTATGGGAGGAGAGCGTAATGGACTATGCTGTAATAGCAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 729 ACAGGCTTCTCTCTACCATGACACCAAC 758

RESULT 14
 LOCUS AX195211 4517 bp DNA linear PAT 28-AUG-2001
 DEFINITION Sequence 5 from Patent WO0151645.
 ACCESSION AX195211
 VERSION AX195211.1 GI:15385772

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
 Db 669 GTGTATGGGAGGAGAGCGTAATGGACTATGCTGTAATAGCAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 729 ACAGGCTTCTCTCTACCATGACACCAAC 758

RESULT 15
 LOCUS AX335029 4517 bp DNA linear PAT 09-JAN-2002
 DEFINITION Sequence 5538 from Patent WO0194629.
 ACCESSION AX335029
 VERSION AX335029.1 GI:18125748
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 MAMMALIA; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
 Horrigan, S., Soppet, D.R., and Weaver, Z.
 TITLE Cancer gene determination and therapeutic screening using signature
 JOURNAL Gene sets
 Patent: WO 0194629-A 5538 13-DEC-2001;
 Avalon Pharmaceuticals (US)

KEYWORDS

Homo sapiens (human)

SOURCE

Homo sapiens

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Bihain, B., Erickson, M.R., Fruebis, J. and Yen-Potin, F.

OB93 globular head and uses thereof for decreasing body mass

Patent: WO 0151645-A 5 19-JUL-2001;

JOURNAL

GENSET (FR)

FEATURES

Location/Qualifiers

1..4517

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

ORIGIN

Alignment Scores:

Pred. No.: 3.3e-73 Length: 4517

Score: 708.00 Matches: 130

Percent Similarity: 100.00% Conservative: 0

Best Local Similarity: 100.00% Mismatches: 0

Query Match: 100.00% Indels: 0

DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AX195211 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20

Db 369 TTCAGTGTGGGATGGAGACTTACGTTACTATCCCAACATGCCATTCGCTTTACCAAG 428

QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40

Db 429 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCACCTGCAACATT 488

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer 60

Db 489 CCTGGGCTGTACTCTTGGCTTACCATCATGATGCTATATGAAGGATGGAAGTCAGC 548

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80

Db 549 CTCCTCAAGAGGACAGGCTATGCTCTACCTATGATCATGATGATGATGATGATGATG 608

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100

Db 609 GACCAGGCTCCGGCTCTGTCTCTGCTCATCTGGAGTGGGGCCACCAAGTCTGGCTCCAG 668

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120

Db 669 GTGTATGGGAGGAGAGCGTAATGGACTATGCTGTAATAGCAATGACTCCACCTTC 728

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130

Db 729 ACAGGCTTCTCTCTACCATGACACCAAC 758

FEATURES
source Location/Qualifiers
1..4517
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Alignment Scores:
Pred. No.: 3.3e-73 Length: 4517
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-10-072-159-11 (1-130) x AX335029 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 369 TTCAGTGTGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 428
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 429 ATCTTCTACAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCACCTGCAACATT 488
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
DB 489 CCTGGGCTGTACTACTTTCCTACCAATCAGAGTCTATATGAGGATGTGAGGTCAGC 548
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 549 CTCTTCAAGAAAGGACCAAGGCTATGCTCTTCACCTATGATCAGTACCCAGGAAAATAATGTG 608
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
DB 609 GACCAGGCTCCGGCTCTGTGCTCTTCATCTGGAGTGGGCGACCAAGTCTGGCTCCAG 668
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
DB 669 GTGTATGGGAGAGGAGCGGTAATGGACTCTATGCTGATAATGACAAATGACTCCACCTTC 728
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 729 ACAGGCTTTCTCTCTACCATGACCAAC 758

Search completed: December 3, 2004, 11:40:39
Job time : 2362 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: December 3, 2004, 10:55:53 ; Search time 396 Seconds
(without alignments)
1803.853 Million cell updates/sec

Title: US-10-072-159-11

Perfect score: 708
Sequence: 1 FSVGLTYVTPNPIRFTK.....YADNDNSTFTGFLLYHDIN 130

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 3594831 seqs, 2747406616 residues

Total number of hits satisfying chosen parameters: 7389662

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-O=/cgn2_1/USPTO_spool_p/US10072159/runat_02122004_142306_15619/app_query.fasta_1.327
-DB=Published_Applications_NA -QFMT=fastp -SUFFIX=p2n.rnpb -MINMATCH=0.1
-LOOPEXT=0 -LOOPEXT=0 -UNITS=bites -START=1 -END=1 -MATRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100
-MAXLEN=2000000000 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0
-NCPU=6 -ICPU=3 -NO MAP -LARGEQUERY -NEG SCORE=0 -WAIT -DSPBLOCK=100
-LONGLOG -DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5
-FGAPO=6 -FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
2: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq.*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
6: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq.*
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq.*
12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq.*
16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq.*
17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq.*
18: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq.*
19: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq.*
20: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
21: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB ID	Description
1	708	100.0	492	15	US-10-325-717-16
2	708	100.0	537	15	US-10-325-717-65
3	708	100.0	564	15	US-10-325-717-15
4	708	100.0	582	15	US-10-325-717-14
5	708	100.0	735	15	US-10-325-717-9
6	708	100.0	742	16	US-10-379-747-13
7	708	100.0	754	16	US-10-379-747-9
8	708	100.0	778	16	US-10-379-747-11
9	708	100.0	783	16	US-10-379-747-5
10	708	100.0	1550	15	US-10-411-120-19
11	708	100.0	4517	9	US-09-776-976-5
12	708	100.0	4517	9	US-09-758-065-5
13	708	100.0	4517	9	US-09-909-547-5
14	708	100.0	4517	9	US-09-964-824A-235
15	708	100.0	4517	15	US-10-231-814-5
16	708	100.0	4517	15	US-10-197-293-9
17	708	100.0	4517	16	US-10-285-833-5
18	708	100.0	4545	15	US-10-376-460-5
19	708	100.0	4545	16	US-10-379-747-7
20	708	100.0	20966	9	US-09-776-976-7
21	708	100.0	20966	9	US-09-758-055-7
22	708	100.0	20966	9	US-09-909-547-7
23	708	100.0	20966	15	US-10-231-814-7
24	708	100.0	20966	15	US-10-376-460-1
25	708	100.0	20966	16	US-10-285-833-7
26	703	99.3	537	15	US-10-325-717-63
27	703	99.3	537	15	US-10-325-717-68
28	702	99.2	537	15	US-10-325-717-82
29	702	99.2	537	15	US-10-325-717-67
30	700	98.9	537	15	US-10-325-717-66
31	699	98.7	537	15	US-10-325-717-69
32	699	98.7	537	15	US-10-325-717-70
33	699	98.7	537	15	US-10-325-717-71
34	699	98.7	537	15	US-10-325-717-71
35	655	92.5	1276	9	US-09-776-976-3
36	655	92.5	1276	9	US-09-758-055-3
37	655	92.5	1276	9	US-09-909-547-3
38	655	92.5	1276	15	US-10-231-814-3
39	655	92.5	1276	16	US-10-285-833-3
40	649	91.7	933	16	US-10-379-747-45
41	645	91.1	1152	9	US-09-776-976-1
42	645	91.1	1152	9	US-09-758-055-1
43	645	91.1	1152	9	US-09-909-547-1
44	645	91.1	1152	15	US-10-231-814-1
45	645	91.1	1152	16	US-10-285-833-1

ALIGNMENTS

RESULT 1

US-10-325-717-16
; Sequence 16, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbourn
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bogues, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25

; PRIOR APPLICATION NUMBER: US 60/343,482
 ; PRIOR FILING DATE: 2001-12-21
 ; NUMBER OF SEQ ID NOS: 115
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 16
 ; LENGTH: 492
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: apM1 (82-244) coding sequence
 US-10-325-717-16

Alignment Scores:
 Pred. No.: 1,246-88 Length: 492
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-325-717-15 (1-492)

Qy 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 100 TTCAGTGTGGGATTTGGAGACTTACGTTACTATCCCAACATCGCCATTTCGCTTTACCAAG 159
 Qy 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 160 ATCTTCTACATCAGCAAAACCACTATGATGCTCCATGGTAATTCATCGCAACATT 219
 Qy 41 ProGlyLeuTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 220 CCTGGCTGTACTACTTTCCTACCAATCAGATCTATATGAGGATGTGAAGGTGAGC 279
 Qy 61 LeuPheLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 280 CTCCTTCAAGAGGACAGGCTATGCTTCCTATGATATCAGTACCAAGAAATAATG 339
 Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 340 GACCAGGCTCCGGCTCTGCTCTGATCTGGAGGTGGGACCAAGTCTGGCTCCAG 399
 Qy 101 ValTyrGlyGluGlyLysGlnGluArgGlnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
 Db 400 GTGTATGGGAGGAGGAGCGTAAATGACTCTATGCTGATAATGACAATGACTCCACCTTC 459
 Qy 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 460 ACAGGCTTTCTTCTCTACCATGACACCAAC 489

RESULT 2

US-10-325-717-65
 ; Sequence 65, Application US/10325717
 ; Publication No. US20030176328A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rasmussen, Poul Baad
 ; APPLICANT: Andersen, Kim Vilbour
 ; APPLICANT: Pedersen, Anders Hjelholt
 ; APPLICANT: Schambye, Hans Thalsgaard
 ; APPLICANT: Halkier, Torben
 ; APPLICANT: Bognes, Are
 ; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
 ; FILE REFERENCE: 0251us610
 ; CURRENT APPLICATION NUMBER: US/10/325,717
 ; PRIOR FILING DATE: 2002-12-20
 ; PRIOR APPLICATION NUMBER: US 60/412,169
 ; PRIOR FILING DATE: 2002-09-20
 ; PRIOR APPLICATION NUMBER: US 60/394,117
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/375,492
 ; PRIOR FILING DATE: 2002-04-25
 ; PRIOR APPLICATION NUMBER: US 60/343,482
 ; PRIOR FILING DATE: 2001-12-21

; NUMBER OF SEQ ID NOS: 115
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 65
 ; LENGTH: 537
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic construct encoding Y111N-apM1 (82-244)
 US-10-325-717-65

Alignment Scores:
 Pred. No.: 1,416-88 Length: 537
 Score: 708.00 Matches: 130
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-325-717-65 (1-537)

Qy 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 Db 145 TTCAGTGTGGGATTTGGAGACTTACGTTACTATCCCAACATCGCCATTTCGCTTTACCAAG 204
 Qy 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 205 ATCTTCTACATCAGCAAAACCACTATGATGCTCCATGGTAATTCATCGCAACATT 264
 Qy 41 ProGlyLeuTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
 Db 265 CCTGGCTGTACTACTTTCCTACCAATCAGATCTATATGAGGATGTGAAGGTGAGC 324
 Qy 61 LeuPheLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
 Db 325 CTCCTTCAAGAGGACAGGCTATGCTTCCTATGATATCAGTACCAAGAAATAATG 384
 Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 385 GACCAGGCTCCGGCTCTGCTCTGATCTGGAGGTGGGACCAAGTCTGGCTCCAG 444
 Qy 101 ValTyrGlyGluGlyLysGlnGluArgGlnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
 Db 445 GTGTATGGGAGGAGGAGCGTAAATGACTCTATGCTGATAATGACAATGACTCCACCTTC 504
 Qy 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 Db 505 ACAGGCTTTCTTCTCTACCATGACACCAAC 534

RESULT 3

US-10-325-717-15
 ; Sequence 15, Application US/10325717
 ; Publication No. US20030176328A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rasmussen, Poul Baad
 ; APPLICANT: Andersen, Kim Vilbour
 ; APPLICANT: Pedersen, Anders Hjelholt
 ; APPLICANT: Schambye, Hans Thalsgaard
 ; APPLICANT: Halkier, Torben
 ; APPLICANT: Bognes, Are
 ; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
 ; FILE REFERENCE: 0251us610
 ; CURRENT APPLICATION NUMBER: US/10/325,717
 ; PRIOR FILING DATE: 2002-12-20
 ; PRIOR APPLICATION NUMBER: US 60/412,169
 ; PRIOR FILING DATE: 2002-09-20
 ; PRIOR APPLICATION NUMBER: US 60/394,117
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/375,492
 ; PRIOR FILING DATE: 2002-04-25
 ; PRIOR APPLICATION NUMBER: US 60/343,482
 ; PRIOR FILING DATE: 2001-12-21
 ; NUMBER OF SEQ ID NOS: 115
 ; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 15
; LENGTH: 564
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apM1(58-244) coding sequence
US-10-325-717-15

Alignment Scores:
Pred. No.: 1,52e-88 Length: 564
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-325-717-15 (1-564)

```
Qy 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
Db 172 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 231
Qy 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db 232 ATCTTCTACATACAGAAACCACTATGATGGCTCCACTGGTAAATTCCTACTGCAACATT 291
Qy 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
Db 292 CCTGGCTGTACTACTTGGCTACACATCAGATCTATATGAAGGATGTGAAGGTGAGC 351
Qy 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
Db 352 CTCTTCAAGAGGACAGGCTATGCTTCCATCTATGATCAGTACCAAGGAAATATATGTG 411
Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 412 GACCAAGGCTCCGGCTCTGTCTCTGATCTGGAGGTGGCGACCAAGTCTGGCTCCAG 471
Qy 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
Db 472 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGATGATGATGATGATGATGATGATG 531
Qy 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 532 ACAGGCTTCTCTCTACCATGACACCAAC 561
```

RESULT 4

US-10-325-717-14
; Sequence 14, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 582

; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: apM1(52-244) coding sequence
US-10-325-717-14

Alignment Scores:
Pred. No.: 1,59e-88 Length: 582
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-325-717-14 (1-582)

```
Qy 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
Db 190 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 249
Qy 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db 250 ATCTTCTACATACAGAAACCACTATGATGGCTCCACTGGTAAATTCCTACTGCAACATT 309
Qy 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
Db 310 CCTGGCTGTACTACTTGGCTACACATCAGATCTATATGAAGGATGTGAAGGTGAGC 369
Qy 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
Db 370 CTCTTCAAGAGGACAGGCTATGCTTCCATCTATGATCAGTACCAAGGAAATATATGTG 429
Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 430 GACCAAGGCTCCGGCTCTGTCTCTGATCTGGAGGTGGCGACCAAGTCTGGCTCCAG 489
Qy 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
Db 490 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGATGATGATGATGATGATGATGATG 549
Qy 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 550 ACAGGCTTCTCTCTACCATGACACCAAC 579
```

RESULT 5

US-10-325-717-9
; Sequence 9, Application US/10325717
; Publication No. US20030176328A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Poul Baad
; APPLICANT: Andersen, Kim Vilbour
; APPLICANT: Pedersen, Anders Hjelholt
; APPLICANT: Schambye, Hans Thalsgaard
; APPLICANT: Halkier, Torben
; APPLICANT: Bognes, Are
; TITLE OF INVENTION: Adiponectin Fragments and Conjugates
; FILE REFERENCE: 0251us610
; CURRENT APPLICATION NUMBER: US/10/325,717
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/412,169
; PRIOR FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/394,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/375,492
; PRIOR FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US 60/343,482
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 735
; TYPE: DNA
; ORGANISM: Homo sapiens

FEATURE:
OTHER INFORMATION: apM1 (1-244) coding sequence
US-10-325-717-9

Alignment Scores:
Pred. No.: 2-26e-88 Length: 735
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservatives: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-325-717-9 (1-735)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrIys 20
DB 343 TTCAAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCAATCGCTTTACCAAG 402
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 403 ATCTTCTACAATCAGCAAAACCACTATGATGCTCCACTGGTAATTCCTGCAACATT 462
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValIysValSer 60
DB 463 CTGGGCTGTACTACTTTCCTCCACCATCAGCTCTATATGAGGATGTGAAGTCCAGC 522
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 523 CTCCTCAAGAGACAGAGCTATGCTTCTCACTATGATCAGTACCAAGAAATATATGTG 582
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 583 GACCAGGCTCCGGCTCTGCTCTCGCATCTGGAGTGGGGCCACCAAGTCTGGCTCCAG 642
QY 101 ValTyrGlyGluGlyGluArgGlnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
DB 643 GTGTATGGGAGAGAGAGGCTAATGAGCTCTATGCTATGATGATAATGACATGCCACCTC 702
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 703 ACAGGCTTTCTTCTCTACCATGACACCAAC 732

RESULT 6

US-10-379-747-13
Sequence 13, Application US/10379747
Publication No. US20040023874A1
GENERAL INFORMATION:
APPLICANT: Burgess, Catherine E.;
APPLICANT: Chant, John S.;
APPLICANT: Chaudhuri, Amitabha ;
APPLICANT: Edinger, Shlomit R.;
APPLICANT: Gangolli, Esha A.;
APPLICANT: Malyankar, Uriel M.;
APPLICANT: Miller, Charles E.;
APPLICANT: Ooi, Chean Eng.;
APPLICANT: Ort, Tatiana A.;
APPLICANT: Patturajan, Meera ;
APPLICANT: Rastelli, Luca ;
APPLICANT: Rieger, Daniel K.;
APPLICANT: Shinkets, Richard A.;
APPLICANT: Zerhusen, Bryan D.
TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
FILE REFERENCE: 21402-568B
CURRENT APPLICATION NUMBER: US/10/379,747
PRIOR FILING DATE: 2003-03-05
PRIOR FILING DATE: 2002-03-15
PRIOR APPLICATION NUMBER: 60/365,034
PRIOR FILING DATE: 2002-03-21
PRIOR APPLICATION NUMBER: 60/365,477
PRIOR FILING DATE: 2002-03-19
NUMBER OF SEQ ID NOS: 45
SOFTWARE: Curasequid version 0.1

SEQ ID NO 13
LENGTH: 742
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: CDS
LOCATION: (11)..(709)
US-10-379-747-13
Alignment Scores:
Pred. No.: 2-29e-88 Length: 742
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservatives: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 16 Gaps: 0

US-10-072-159-11 (1-130) x US-10-379-747-13 (1-742)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrIys 20
DB 320 TTCAAGTGGGATGGAGACTTACGTTACTATCCCAACATGCCCAATCGCTTTACCAAG 379
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 380 ATCTTCTACAATCAGCAAAACCACTATGATGCTCCACTGGTAATTCCTGCAACATT 439
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValIysValSer 60
DB 440 CTGGGCTGTACTACTTTCCTCCACCATCAGCTCTATATGAGGATGTGAAGTCCAGC 499
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 500 CTCCTCAAGAGACAGAGCTATGCTTCTCACTATGATCAGTACCAAGAAATATATGTG 559
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 560 GACCAGGCTCCGGCTCTGCTCTCGCATCTGGAGTGGGGCCACCAAGTCTGGCTCCAG 619
QY 101 ValTyrGlyGluGlyGluArgGlnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
DB 620 GTGTATGGGAGAGAGAGGCTAATGAGCTCTATGCTATGATGATAATGACATGCCACCTTC 679
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 680 ACAGGCTTTCTTCTCTACCATGACACCAAC 709

RESULT 7

US-10-379-747-9
Sequence 9, Application US/10379747
Publication No. US20040023874A1
GENERAL INFORMATION:
APPLICANT: Burgess, Catherine E.;
APPLICANT: Chant, John S.;
APPLICANT: Chaudhuri, Amitabha ;
APPLICANT: Edinger, Shlomit R.;
APPLICANT: Gangolli, Esha A.;
APPLICANT: Malyankar, Uriel M.;
APPLICANT: Miller, Charles E.;
APPLICANT: Ooi, Chean Eng.;
APPLICANT: Ort, Tatiana A.;
APPLICANT: Patturajan, Meera ;
APPLICANT: Rastelli, Luca ;
APPLICANT: Rieger, Daniel K.;
APPLICANT: Shinkets, Richard A.;
APPLICANT: Zerhusen, Bryan D.
TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
FILE REFERENCE: 21402-568B
CURRENT APPLICATION NUMBER: US/10/379,747
PRIOR FILING DATE: 2003-03-05
PRIOR FILING DATE: 2002-03-15
PRIOR APPLICATION NUMBER: 60/365,034
PRIOR FILING DATE: 2002-03-21
PRIOR APPLICATION NUMBER: 60/365,420

```
; PRIOR FILING DATE: 2002-03-21
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 9
; LENGTH: 754
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (14)...(745)
US-10-379-747-9

Alignment Scores:
Pred. No.: 2,35e-88      Length: 754
Score: 708.00           Matches: 130
Percent Similarity: 100.00%  Conservative: 0
Best Local Similarity: 100.00%  Mismatches: 0
Query Match: 100.00%      Indels: 0
DB: 16                  Gaps: 0

US-10-072-159-11 (1-130) x US-10-379-747-9 (1-754)

QY 1 PheSerValGlyLeuGluThrTyrValThrileProAsnMetProIleArgPheThrLys 20
DB 356 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 415
QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 416 ATCTTCAACAATCAGCAAAACCACTATGATGCTCCACCTGCTAAATCCACTGCAACATT 475
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
DB 476 CCTGGGCTGTACTACTTTGGCTACCAATCAGCTATATGAAGGATGTGAAGGTGAGC 535
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 536 CTCCTCAGAGGACAGGCTATGCTCTTCCCTATGATGATGATGATGATGATGATGATG 595
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
DB 596 GACCAAGGCTCCGGCTCTGTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 655
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
DB 656 GGTATGGGAGGAGAGCGTAATGGACTCTATGCTGATATGATGATGATGATGATGATG 715
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 716 ACAGGCTTTCTTCTTCTACCATGACACCAAC 745

RESULT 8
US-10-379-747-11
; Sequence 11, Application US/10379747
; Publication No. US20040023874A1
; GENERAL INFORMATION:
; APPLICANT: Burgess, Catherine E.;
; APPLICANT: Chant, John S.;
; APPLICANT: Chaudhuri, Amitabha ;
; APPLICANT: Edinger, Shlomit R.;
; APPLICANT: Gangolli, Bsha A.;
; APPLICANT: Malyankar, Uriel M.;
; APPLICANT: Miller, Charles E.;
; APPLICANT: Ooi, Chean Eng;
; APPLICANT: Patturajan, Meera ;
; APPLICANT: Rastelli, Luca ;
; APPLICANT: Rieger, Daniel K.;
; APPLICANT: Shimkets, Richard A.;
; APPLICANT: Zerhusen, Bryan D.
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-568B
```

```
; CURRENT APPLICATION NUMBER: US/10/379,747
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/365,034
; PRIOR FILING DATE: 2002-03-15
; PRIOR APPLICATION NUMBER: 60/366,420
; PRIOR FILING DATE: 2002-03-21
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 11
; LENGTH: 778
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (17)...(766)
US-10-379-747-11

Alignment Scores:
Pred. No.: 2,46e-88      Length: 778
Score: 708.00           Matches: 130
Percent Similarity: 100.00%  Conservative: 0
Best Local Similarity: 100.00%  Mismatches: 0
Query Match: 100.00%      Indels: 0
DB: 16                  Gaps: 0

US-10-072-159-11 (1-130) x US-10-379-747-11 (1-778)

QY 1 PheSerValGlyLeuGluThrTyrValThrileProAsnMetProIleArgPheThrLys 20
DB 377 TTCAGTGTGGGATTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG 436
QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 437 ATCTTCAACAATCAGCAAAACCACTATGATGCTCCACTGGTAAATTCACCTGCAACATT 496
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
DB 497 CCTGGGCTGTACTACTTTGGCTACCAATCAGCTATATGAGGATGTGAAGGTGAGC 556
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 557 CTCCTCAGAGGACAGGCTATGCTCTTCCCTATGATGATGATGATGATGATGATGATG 616
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
DB 617 GACCAAGGCTCCGGCTCTGTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 676
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAspSerThrPhe 120
DB 677 GTGTATGGGAGGAGAGCGTAATGGACTCTATGCTGATATGATGATGATGATGATGATG 736
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 737 ACAGGCTTTCTTCTTCTACCATGACACCAAC 766
```

```
RESULT 9
US-10-379-747-5
; Sequence 5, Application US/10379747
; Publication No. US20040023874A1
; GENERAL INFORMATION:
; APPLICANT: Burgess, Catherine E.;
; APPLICANT: Chant, John S.;
; APPLICANT: Chaudhuri, Amitabha ;
; APPLICANT: Edinger, Shlomit R.;
; APPLICANT: Gangolli, Bsha A.;
; APPLICANT: Malyankar, Uriel M.;
; APPLICANT: Miller, Charles E.;
; APPLICANT: Ooi, Chean Eng;
; APPLICANT: Patturajan, Meera ;
; APPLICANT: Rastelli, Luca ;
```

; APPLICANT: Rieger, Daniel K.;
 ; APPLICANT: Shimkets, Richard A.;
 ; APPLICANT: Zerhusen, Bryan D.
 ; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
 ; FILE REFERENCES: 21402-568B
 ; CURRENT APPLICATION NUMBER: US/10/379,747
 ; CURRENT FILING DATE: 2003-03-05
 ; PRIOR APPLICATION NUMBER: 60/365,034
 ; PRIOR FILING DATE: 2002-03-15
 ; PRIOR APPLICATION NUMBER: 60/366,420
 ; PRIOR FILING DATE: 2002-03-21
 ; PRIOR APPLICATION NUMBER: 60/365,477
 ; PRIOR FILING DATE: 2002-03-19
 ; NUMBER OF SEQ ID NOS: 45
 ; SOFTWARE: CuraseqList version 0.1
 ; SEQ ID NO 5
 ; LENGTH: 783
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: CDS
 ; LOCATION: (12)..(743)
 US-10-379-747-5

Alignment Scores:

Pred. No.:	2,498-88	Length:	783
Score:	708.00	Matches:	130
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	16	Gaps:	0

US-10-072-159-11 (1-130) x US-10-379-747-5 (1-783)

Qy	1	PheserValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys	20
Db	354	TTCAAGTGTGGGATTTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG	413
Qy	21	IlePheTyrAsnGlnGlnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle	40
Db	414	ATCTTCTCAATCAGCAAAACCACTATGATGCTCCCTGCTGTAATTCACATGCAACATT	473
Qy	41	ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer	60
Db	474	CCTGGGCTGTACTTCTTCCCTACCAATCAGATCTATATGAGGATGTGAAGGTCCAG	533
Qy	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80
Db	534	CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCATGACAGCAAAATTAATGTG	593
Qy	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln	100
Db	594	GACCAAGGCTCCGGCTCTGTCTCTGCTATGAGGTGGGACCAAGTCTGGCTCCAG	653
Qy	101	ValTyrGlyGluGlyGluArgHisGlyLeuTyrAlaAspAsnAspSerThrPhe	120
Db	654	GTGTATGGGAGGAGGAGGCTAATGGACTCTATGCTGTAATGACAAATTAATGTG	713
Qy	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130
Db	714	ACAGGCTTTCTTCTTACCATGACACCAAC	743

RESULT 10

US-10-411-120-19
 ; Sequence 19, Application US/10411120
 ; Publication No. US20030224425A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Blondel et al.
 ; TITLE OF INVENTION: ACRP-30-like Polynucleotides, Polypeptides, and Antibodies
 ; FILE REFERENCE: FT316P1
 ; CURRENT APPLICATION NUMBER: US/10/411,120
 ; CURRENT FILING DATE: 2003-04-11
 ; PRIOR APPLICATION NUMBER: 60/328,419

; PRIOR FILING DATE: 2001-10-12
 ; PRIOR APPLICATION NUMBER: PCT/US02/32432
 ; PRIOR FILING DATE: 2002-10-11
 ; NUMBER OF SEQ ID NOS: 107
 ; SOFTWARE: PatentIn ver. 3.2
 ; SEQ ID NO 19
 ; LENGTH: 1550
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; LOCATION: (1547)..(1547)
 ; OTHER INFORMATION: n equals a,t,g, or c
 US-10-411-120-19

Alignment Scores:

Pred. No.:	6,96e-88	Length:	1550
Score:	708.00	Matches:	130
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	15	Gaps:	0

US-10-072-159-11 (1-130) x US-10-411-120-19 (1-1550)

Qy	1	PheserValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys	20
Db	384	TTCAAGTGTGGGATTTGGAGACTTACGTTACTATCCCAACATGCCCATTCGCTTTACCAAG	443
Qy	21	IlePheTyrAsnGlnGlnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle	40
Db	444	ATCTTCTCAATCAGCAAAACCACTATGATGCTCCCTGCTGTAATTCACATGCAACATT	503
Qy	41	ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer	60
Db	504	CCTGGGCTGTACTTCTTCCCTACCAATCAGATCTATATGAGGATGTGAAGGTCCAG	563
Qy	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80
Db	564	CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCATGACCAAGAAATTAATGTG	623
Qy	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln	100
Db	624	GACCAAGGCTCCGGCTCTGTCTCTGCTATGAGGTGGGACCAAGTCTGGCTCCAG	683
Qy	101	ValTyrGlyGluGlyGluArgHisGlyLeuTyrAlaAspAsnAspSerThrPhe	120
Db	684	GTGTATGGGAGGAGGAGGCTAATGGACTCTATGCTGTAATGACAAATTAATGTG	743
Qy	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130
Db	744	ACAGGCTTTCTTCTTACCATGACACCAAC	773

RESULT 11

US-09-776-976-5
 ; Sequence 5, Application US/09776976
 ; Patent No. US20020037849A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Fruebis, Joachim
 ; APPLICANT: Erickson, Mary Ruth
 ; APPLICANT: Yen, Frances
 ; APPLICANT: Bihain, Bernard
 ; TITLE OF INVENTION: CBG3 Globular Head and Uses Thereof for Decreasing Body Mass
 ; FILE REFERENCE: 76.US4.REG
 ; CURRENT APPLICATION NUMBER: US/09/776,976
 ; CURRENT FILING DATE: 2001-02-05
 ; PRIOR APPLICATION NUMBER: US 09/758,055
 ; PRIOR FILING DATE: 2001-01-10
 ; PRIOR APPLICATION NUMBER: US 60/176,228
 ; PRIOR FILING DATE: 2000-01-14
 ; PRIOR APPLICATION NUMBER: US 60/198,087
 ; PRIOR FILING DATE: 2000-04-13
 ; PRIOR APPLICATION NUMBER: US 60/299,881

Length: 4517
Matches: 130

Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 9 Gaps: 0

US-10-072-159-11 (1-130) x US-09-909-547-5 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 369 TTCAGTGTGGGATTGGAGACTTACGTACTATCCCAACATGCCCATTCGCTTTTACCAG 428
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 429 ATCTTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTGCAACATT 488
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer 60
DB 489 CTTGGGCTGTACTTTCCTACCAATCAGTCTATATGAGGATGTGAGGTCCAGC 548
QY 61 LeuPheLysAspLysAlaMetLeupheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 549 CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCAGTACCAAGGAAATTAATGTG 608
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 609 GACCAGGCTCCGGCTCTGTCTCTGTCATCTGGAGGTGGGCGACCAAGTCTGGCTCCAG 668
QY 101 ValTyrGlyGluGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
DB 669 GTGTATGGGAGGAGGAGGCTATGAGTCTATGCTGATGATGATGATGATGATGATGATG 728
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 729 ACAGGCTTTCTCTCTACCATGACACCAAC 758

RESULT 14

US-09-964-824A-235
; Sequence 235, Application US/09964824A
; Patent No. US20020102531A1
; GENERAL INFORMATION:
; APPLICANT: Horrihan, Stephen
; TITLE OF INVENTION: Cancer Gene Determination and Therapeutic Screening Using Signatu
; TITLE OF INVENTION: Sets
; FILE REFERENCE: 689290-73
; CURRENT APPLICATION NUMBER: US/09/964,824A
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: US/60/236,033
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236,032
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236,028
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 583
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 235
; LENGTH: 4517
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-964-824A-235

Alignment Scores:
Pred. No.: 3,49e-87 Length: 4517
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 9 Gaps: 0

US-10-072-159-11 (1-130) x US-09-964-824A-235 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 369 TTCAGTGTGGGATTGGAGACTTACGTACTATCCCAACATGCCCATTCGCTTTTACCAG 428

QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 429 ATCTTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTGCAACATT 488
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer 60
DB 489 CTTGGGCTGTACTTTCCTACCAATCAGTCTATATGAGGATGTGAGGTCCAGC 548
QY 61 LeuPheLysAspLysAlaMetLeupheThrTyrAspGlnTyrGlnGluAsnVal 80
DB 549 CTCTTCAAGAGGACAGGCTATGCTCTTCACTATGATCAGTACCAAGGAAATTAATGTG 608
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 609 GACCAGGCTCCGGCTCTGTCTCTGTCATCTGGAGGTGGGCGACCAAGTCTGGCTCCAG 668
QY 101 ValTyrGlyGluGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
DB 669 GTGTATGGGAGGAGGAGGCTATGAGTCTATGCTGATGATGATGATGATGATGATGATG 728
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 729 ACAGGCTTTCTCTCTACCATGACACCAAC 758

RESULT 15

US-10-231-814-5
; Sequence 5, Application US/10231814
; Publication No. US20030100500A1
; GENERAL INFORMATION:
; APPLICANT: Fruebis, Joachim
; APPLICANT: Erickson, Mary Ruth
; APPLICANT: Yen, Frances
; APPLICANT: Bihain, Bernard
; TITLE OF INVENTION: OB3 Globular Head and Uses Thereof for Decreasing Body Mass
; FILE REFERENCE: 76.USA.REG
; CURRENT APPLICATION NUMBER: US/10/231,814
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US/05/758,055
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 60/176,228
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/198,087
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: US 60/299,881
; PRIOR FILING DATE: 2000-09-01
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patent.pm
; SEQ ID NO 5
; LENGTH: 4517
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-231-814-5

Alignment Scores:
Pred. No.: 3,49e-87 Length: 4517
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 15 Gaps: 0

US-10-072-159-11 (1-130) x US-10-231-814-5 (1-4517)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 369 TTCAGTGTGGGATTGGAGACTTACGTACTATCCCAACATGCCCATTCGCTTTTACCAG 428
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 429 ATCTTACAAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTGCAACATT 488
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValSer 60

Db	489	CTGGGCTGTACTCTTTGGCTTACCATCATCAGCTATATGAGGATGTGAGATGCACG	548
Qy	61	LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal	80
Db	549	CTCTTCAGAAAGGACAGGGCTATGCTCTTCACCTATCATCAGTACCAGGAAAAATATGTG	608
Qy	81	AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln	100
Db	609	GACCAGGCCCTCCGGCTCTGTGCTCTGCATCTGGAGGTGGGACCAAGTCTGGCTCCAG	668
Qy	101	ValTyrGlyGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnSerThrPhe	120
Db	669	GTGTATGGGAGGAGACGCTAATGGACTCTATGCTGATTAATGACAAATGACTCCACTTC	728
Qy	121	ThrGlyPheLeuLeuTyrHisAspThrAsn	130
Db	729	ACAGGCTTTCTCTCTACCATGACCAAC	758

Search completed: December 3, 2004, 12:38:49
Job time : 401 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: December 3, 2004, 09:59:48 ; Search time 2971 Seconds

(without alignments)
1594.468 Million cell updates/sec

Title: US-10-072-159-11

Perfect score: 708

Sequence: 1 FSVGLTYTIPNPIRFTK.....YADNDNDSTFTGFLLYHDTN 130

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q=/CGM2_1/USPTO_spool_p/US10072159/runat_02122004_142305_15575/app_query.fasta_1.327
-DB=EST -QFMT=fastcap -SUFFIX=p2n.rst -MINWATCH=0.1 -LOOPCT=0 -LOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US10072159 -CGCN 1.1 5180 @runat_02122004_142305_15575 -NCPU=6 -ICPU=3
-NO WMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPOP=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : EST:*

1: gb_est1:*
2: gb_est2:*
3: gb_hic:*
4: gb_est3:*
5: gb_est4:*
6: gb_est5:*
7: gb_est6:*
8: gb_gss1:*
9: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	708	100.0	1842	3	BC054496 Homo sapi
2	708	100.0	3591	3	BC036509 Homo sapi
3	661	93.4	610	2	AW915595 EST346899
4	661	93.4	857	7	CO389083 AGENCOURT
5	655	92.5	523	5	BX519230 BX519230
6	655	92.5	552	2	BE625509 uu19e06.Y
7	655	92.5	566	1	AA028544 ml18b08.r
8	655	92.5	921	3	AK003138 Mus muscu
9	655	92.5	1158	3	AK041214 Mus muscu

C	10	652	92.1	605	4	BM384395
	11	647	91.4	545	1	AI158610
	12	638	90.1	1465	3	BC078720
	13	637	90.0	543	1	AI105446
	14	636	89.8	577	5	BQ189822
	15	634	89.5	811	1	AA763396
	16	634	89.5	905	1	AI747241
	17	609	86.0	921	1	AA673154
	18	604	85.3	508	1	AA493090
	19	582	82.2	885	5	BQ876848
	20	574	81.1	856	5	BQ876848
	21	568	80.2	491	7	CF931240
	22	568	80.2	830	7	CF931240
	23	558	78.8	468	2	AW988554
	24	558	78.8	634	7	CO384703
	25	556	78.5	600	1	AA960123
	26	555	78.4	694	2	BB225356
	27	551	77.8	786	7	CO400150
	28	549	77.5	438	1	AA061943
	29	548	77.4	486	2	BE626169
	30	544.5	76.9	585	1	AI323469
	31	537	75.8	468	2	AW911832
	32	537	75.8	470	2	AW986727
	33	537	75.8	519	2	BE478076
	34	533	75.3	707	4	BG872725
	35	510	72.0	433	1	AI407605
	36	501	70.8	758	6	CF345349
	37	501	70.8	787	6	CF345350
	38	496	70.1	445	1	AI171410
	39	492	69.5	867	7	CF376220
	40	490	69.2	406	4	BG090627
	41	475.5	67.2	766	7	CO387981
	42	470	66.4	811	7	CK794688
	43	467.5	66.0	825	1	AI645984
	44	462	65.3	625	1	AA451292
	45	457	64.5	698	5	EX862914

ALIGNMENTS

RESULT 1

BC054496

LOCUS

DEFINITION

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

BC054496

JOURNAL
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
12477932
2 (bases 1 to 1842)
Strausberg, R.
Direct Submission
Submitted (01-JUL-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: Dr. James R. Lupski
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: <http://www-shgc.stanford.edu>
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAK Plate: 98 Row: m Column: 9
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 4757759
This clone has the following problem: retained intron.

FEATURES
source
1..1842
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6192794"
/tissue_type="Peripheral Nervous System, sympathetic
trunk"
/clone_lib="Lupski_sympathetic_trunk"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"

ORIGIN
Alignment Scores:
Pred. No.: 5,748-80 Length: 1842
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 3 Gaps: 0

US-10-072-159-11 (1-130) x BC054496 (1-1842)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 368 TTCAGTGGGATTGGAGACTTACGTACTATCCCAACATGCCATTCGCTTACCAAG 427

QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 428 ATCTTCTCAATCAGCAAAACCACTATGATGGCTCCACTGGTAAATTCCTGCAACATT 487

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
DB 488 CTGGGCTGTACTTGTGCTTACCATCATCAGTCTATATGAAGGATGGAAGGTGAGC 547

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnAsnVal 80
DB 548 CTCTTCAAGAGGACCAAGGCTATCTCTTACCTATGATCAGTACCAAGAAATATGIG 607

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
DB 608 GACCAGGCTCCGGCTCTGTCCTCTGATCTGAGGTGGGCGACCAAGTCTGGCTCCAG 667

QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120

Db 668 GTGTATGGGGAAGGAGCGTAATGGACTCTATCTGATATGCAATGACTCCACCTTC 727

QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
DB 728 ACAGGCTTCTTCTCTTACCATGACACCAAC 757

RESULT 2
BC036509/c 3591 bp mRNA linear HTC 04-MAR-2003
LOCUS Homo sapiens, clone IMAGE:5266441, mRNA.
DEFINITION BC036509
VERSION BC036509.1 GI:23242690
KEYWORDS HTC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 3591)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (09-AUG-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>
COMMENT Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: Miklos Pakovits, M.D., Ph.D.
cDNA Library Preparation: Michael J. Brownstein (NHGRI) & Shiraki
Toshiyuki and Piero Carninci (RIKEN)
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
<http://www.systemsbio.org>
contact: anadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kerteman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAK Plate: 73 Row: o Column: 22
This clone has the following problem: retained intron.

FEATURES
source
1..3591
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5266441"
/tissue_type="Testis"
/clone_lib="NIH MGC_97"
/lab_host="DH10B"
/note="Vector: pBluescript"

ORIGIN
Alignment Scores:
Pred. No.: 1,348-79 Length: 3591
Score: 708.00 Matches: 130
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 3 Gaps: 0

US-10-072-159-11 (1-130) x BC036509 (1-3591)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
DB 1948 TTCAGTGGGATTGGAGACTTACGTACTATCCCAACATGCCATTCGCTTACCAAG 1889

QY 21 IlePheTyrAsnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
DB 1888 ATCTTCTCAATCAGCAAAACCACTATGATGGCTCCACTGCTAAATTCCTGCAACATT 1829

QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60

```

Db      1828  CCTGGCTGTACTACTTTGGCTACCACATCATCAGCTATATGAAGGTGTGAAGTCAGC 1769
Qy      61  LeuPheLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
1768  CTCCTTCAAGAGGACGAGCTATGCTCTTCCATCATGATCATGATCAGTACCAGGAAATAATGTG 1709
Qy      81  AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
1708  GACCAAGGCTCCGGCTCTGTGCTCTGTCATCTGAGGTGGCGACCAAGTCTGGCTCCAG 1649
Qy      101  ValTyrGlyGluGlyGluAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
1648  GTGTATGGGAGGAGAGCGTAATGAGCTATGCTGATATGATGATCAATGACTCCACCTTC 1589
Qy      121  ThrGlyPheLeuLeuTyrHisAspThrAsn 130
1588  ACAGGCTTCTCTCTACCATGACACCAAC 1559

RESULT 3
LOCUS   AW915595
DEFINITION EST346899 Normalized rat embryo, Bento Soares Rattus sp. cDNA clone
          RGIC17 5' end, mRNA sequence.
ACCESSION AW915595
VERSION   AW915595.1 GI:8081296
KEYWORDS EST.
SOURCE   Rattus sp.
ORGANISM Rattus sp.
          Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
          Rattus.
REFERENCE 1 (bases 1 to 610)
AUTHORS  Lee, N.H., Glodek, A., Chandra, I., Mason, T.M., Quackenbush, J.,
          Kerlavage, A.R. and Adams, M.D.
TITLE    Rat Genome Project: Generation of a Rat EST (EST) Catalog & Rat
          Gene Index
JOURNAL  Unpublished (1999)
COMMENT  Contact: Lee, NH
          The Institute for Genomic Research
          9712, Medical Center Drive, Rockville, MD 20850, USA
          Tel: (301)-838-3529
          Fax: (301)-838-0208
          Email: nhlee@igrr.org
          This clone is available through the ATCC, contact the ATCC
          tel#703-365-2700 for further information
          Seq primer: M13 Reverse.

FEATURES             Location/Qualifiers
     source           1..610
                     /organism="Rattus sp."
                     /mol_type="mRNA"
                     /db_xref="taxon:10118"
                     /clone="RGIC17"
                     /dev_stages="embryo 8, 12, 18 dpc"
                     /clone_lib="Normalized rat embryo, Bento Soares"
                     /note="Vector: pT7T3pac; Site_1: EcoRI; Site_2: NotI"

ORIGIN
Alignment Scores:
Pred. No.:      1.59e-74      Length:      610
Score:          661.00      Matches:    120
Percent Similarity: 96.9%      Conservative: 6
Best Local Similarity: 92.31%      Mismatches:  4
Query Match:    93.36%      Indels:     0
DB:             2           Gaps:        0

US-10-072-159-11 (1-130) x AW915595 (1-610)
Qy      1  PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrIys 20
Db      58  TTCACGTAGGGCTGGAGCCCGCTCACTGTCCTCCATGTCTCCATCGTCTTACTAAG 117
Qy      21  IlePheTyrAsnGlnGluAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40

```

```

Db      118  ATCTTCTACACCAACAGCAATCATTTAGCGGACGACACTGGCAATTCCTCACTGCACATT 177
Qy      41  ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
178  CCGGGGCTCTTACTACTTTTCTTACCACATCAGGTTGTACATGAAGGATGTGAAGTGAGC 237
Qy      61  LeuPheLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
238  CTCTTCAAGAGGACGAGGGGCTTCTTCTTCCCTAGCACCATGATCAGGAAAAATGTG 297
Qy      81  AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGln 100
298  GACCAAGGCTCTGGCTCCATGCTCTTCCATCTGGAGGTGGGAGACCAAGTCTGGCTCCAA 357
Qy      101  ValTyrGlyGluGlyGluAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
358  GTGTATGGGAGGAGGACCAATGAGCTCTATGCAATATGTCATGACTCTACATT 417
Qy      121  ThrGlyPheLeuLeuTyrHisAspThrAsn 130
418  ACAGGCTTCTCTTCTTACCATGATACCAAC 447

RESULT 4
LOCUS   CO389083
DEFINITION AGENCOURT_26621565 NIH_MGC_253 Rattus norvegicus cDNA clone
          IMAGE:7304566 5', mRNA sequence.
ACCESSION CO389083
VERSION   CO389083.1 GI:49496574
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE   Rattus norvegicus
ORGANISM Rattus norvegicus
          Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
          Rattus.
REFERENCE 1 (bases 1 to 857)
AUTHORS  NIH-MGC http://mgi.nhl.nih.gov/.
          National Institutes of Health, Mammalian Gene Collection (MGC)
          Unpublished (1999)
          Contact: Daniela S. Gerhard, Ph.D.
          Office of Cancer Genomics
          National Cancer Institute / NIH
          Bldg. 31 Rm10A07 Bethesda, MD 20892
          Email: cgabbs-f@mail.nih.gov
          Tissue Procurement: Drs. Josef Lazar & Howard Jacob, Medical
          College of Wisconsin
          cDNA Library Preparation: Express Genomics
          DNA Sequencing by: The I.M.A.G.E. Consortium (LNL)
          Clone distribution: MGC clone distribution information can be
          found through the I.M.A.G.E. Consortium/LNL at:
          http://image.llnl.gov
          Plate: LLAM15341 row: f column: 20
          High quality sequence stop: 644.
          Location/Qualifiers
     source           1..857
                     /organism="Rattus norvegicus"
                     /mol_type="mRNA"
                     /db_xref="taxon:10116"
                     /clone="IMAGE:7304566"
                     /tissue_type="Ovary - Brown Norway Line 3 Age 8 weeks.
                     Tissues were snap-frozen and transferred in -70c. RNase
                     free the entire procedure."
                     /lab_host="DH10B Tona"
                     /clone_lib="NIH_MGC_253"
                     /note="Organ: ovary; Vector: pExpress-1; Site_1: EcoRV;
                     Site_2: NotI; RNA obtained from female animals at 8 wk
                     old. Tissues were snap-frozen and kept at -80C for two
                     days before RNA extraction and purification (TRI-reagent
                     method). cDNA was primed using oligo-dT primer:
                     5'-PGACTAGTCTAGATCGGAGCGGCCCTT-3' and cloned into
                     the EcoRV/NotI sites of pExpress-1. Size-selection >1.25kb
                     resulted in an average insert size of 1.5 Kb. This primary

```

library is normalized (non-normalized primary library is NIH_MGC_252) and was constructed by Express Genomics (Frederick, MD). Note: this is a NIH_MGC library."

ORIGIN

Alignment Scores:
 Pred. No.: 2,45e-74 Length: 857
 Score: 661.00 Matches: 120
 Percent Similarity: 96.92% Conservative: 6
 Best Local Similarity: 92.31% Mismatches: 4
 Query Match: 93.36% Indels: 0
 DB: 7 Gaps: 0

US-10-072-159-11 (1-130) x C0389083 (1-857)

Qy 1 PheSerValGlyLeuGluThrTyValThrIleProAsnMetProIleArgPheThrLys 20
 Db 69 TTCAAGGCTAGGCTGGAGACCGCGTCACTGCCCAATGTTCCCATTCGCTTACTAAG 128
 Qy 21 IlePheTyAsnGlnGlnAsnHisTyAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 129 ATCTTCTACCAACCAAGAAATCATATGACGGCAGCAGTGGCAATTCCTACGCAACATT 188
 Qy 41 ProGlyLeuTyTyPheAlaTyHisIleThrValTyMetLysAspValLysValSer 60
 Db 189 CCGGGGCTCTACTACTTCTTCTACCAATCATCGGTGTACATGAAGATGTGAAGTGAGC 248
 Qy 61 LeuPheLysAspLysAlaMetLeuPheThrTyAspGlnTyGlnGluAsnVal 80
 Db 249 CTCCTCAAGAGACAAAGCCGTTCTTCCCTACGACCATGATATCAGAAATAATGTG 308
 Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 309 GACCAAGCTCTGGCTCCATGCTCTCCATCTGGAGTGGAGACCAAGTCTGGCTCCA 368
 Qy 101 ValTyGlyGluGlyGluArgGlnGlyLeuTyAlaAspAsnAspAsnAspSerThrPhe 120
 Db 369 GTGTATGGGAGGAGGACCAATGAGCTCTATGAGATAATGTCAATGACTCTACATT 428
 Qy 121 ThrGlyPheLeuLeuTyHisAspThrAsn 130
 Db 429 ACAGGCTTCTTCTTCTACCATGATACCAAC 458

RESULT 5

BX519230 523 bp mRNA linear EST 27-JUN-2003
 LOCUS BX519230 Soares mammary gland NMLMG Mus musculus cDNA clone
 DEFINITION IMAGE:3372418 5', similar to gb:U37222 Mus musculus 30kDa adipocyte
 complement-related protein Acrp30 (MOUSE);, mRNA sequence.

ACCESSION BX519230.1 GI:32300580
 VERSION EST.
 KEYWORDS Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 523)
 Heil, O., Ebert, L., Neubert, P., Peters, M., Radelof, U., Schneider, D.
 and Korn, B.
 Mouse Unigeneset - RZPD2
 Unpublished (2003)

TITLE

JOURNAL

COMMENT

RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
 Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
 RZPD; IMAGE:3372418 5', similar to gb:U37222 Mus musculus 30kDa adipocyte
 complement-related protein Acrp30 (MOUSE);, mRNA sequence.
 Mouse Unigeneset - RZPD2 (RZPDLIB No.981)
 http://www.rzpd.de/Cli/ResponseLibNo=981
 bin/showLib.pl.cgi/ResponseLibNo=981 Contact: Ina Rolfs
 RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
 Heubnerweg 6, D-14059 Berlin, Germany
 Tel: +49 30 32639 101
 Fax: +49 30 32639 111
 www.rzpd.de

This clone is available royalty-free from RZPD;
 contact RZPD (clone@rzpd.de) for further information. Seq primer:
 T7, Primer sequence: TAATACGACTCACTATAGG.

FEATURES

source

1..523

Location/Qualifiers
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="IMAGE:3372418 5', similar to gb:U37222 Mus musculus 30kDa adipocyte
 complement-related protein Acrp30 (MOUSE);, mRNA sequence."
 /sex="female (lactating)"
 /tissue_type="mammary gland"
 /lab_host="DH10B"
 /clone_lib="Soares mammary gland NMLMG"
 /notes="Vector: pT73D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from mammary
 gland tissue from a lactating female, and was then primed
 with a Not I - cligo(dT) primer. Double-stranded cDNA was
 ligated to Eco RI adaptors (Pharmacia), digested with Not
 I and cloned into the Not I and Eco RI sites of the
 modified pT73 vector. Library is normalized. Library
 was constructed by Bento Soares and M. Fatima Bonaldo."

ORIGIN

Alignment Scores:
 Pred. No.: 7.75e-74 Length: 523
 Score: 655.00 Matches: 119
 Percent Similarity: 96.92% Conservative: 7
 Best Local Similarity: 91.54% Mismatches: 4
 Query Match: 92.51% Indels: 0
 DB: 5 Gaps: 0

US-10-072-159-11 (1-130) x BX519230 (1-523)

Qy 1 PheSerValGlyLeuGluThrTyValThrIleProAsnMetProIleArgPheThrLys 20
 Db 88 TTCAGTGTGGGCTGGAGACCGCGTCACTGCCCAATGTTCCCATTCGCTTACTAAG 147
 Qy 21 IlePheTyAsnGlnGlnAsnHisTyAspGlySerThrGlyLysPheHisCysAsnIle 40
 Db 148 ATCTTCTACCAACCAAGAAATCATATGACGGCAGCAGTGGCAATTCCTACGCAACATT 207
 Qy 41 ProGlyLeuTyTyPheAlaTyHisIleThrValTyMetLysAspValLysValSer 60
 Db 208 CCGGGGCTCTACTACTTCTTCTACCAATCATCGGTGTACATGAAGATGTGAAGTGAGC 267
 Qy 61 LeuPheLysAspLysAlaMetLeuPheThrTyAspGlnTyGlnGluAsnVal 80
 Db 268 CTCCTCAAGAGACAAAGCCGTTCTTCCCTACGACCATGATATCAGAAATAATGTG 327
 Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
 Db 328 GACCAAGCTCTGGCTCCATGCTCTCCATCTGGAGTGGAGACCAAGTCTGGCTCCA 387
 Qy 101 ValTyGlyGluGlyGluArgGlnGlyLeuTyAlaAspAsnAspAspSerThrPhe 120
 Db 388 GTGTATGGGAGTGGAGACCAATGAGCTCTATGAGATAATGTCAATGACTCTACATT 447
 Qy 121 ThrGlyPheLeuLeuTyHisAspThrAsn 130
 Db 448 ACTGGCTTCTTCTTCTACCATGATACCAAC 477

RESULT 6

BX625509 552 bp mRNA linear EST 24-AUG-2000
 LOCUS BX625509 Soares mammary gland NMLMG Mus musculus cDNA clone
 DEFINITION IMAGE:3372418 5', similar to gb:U37222 Mus musculus 30kDa adipocyte
 complement-related protein Acrp30 (MOUSE);, mRNA sequence.
 ACCESSION BX625509
 VERSION EST.
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 552)
 REFERENCE NCI-CCAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 JOURNAL Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-re@mail.nih.gov
 This clone is available royalty-free through LLNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 MGI:1082022
 Seq primer: -40RP from Gibco
 High quality sequence stop: 486.
 Location/Qualifiers
 1..552
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="IMAGE:3372418"
 /sex="female (lactating)"
 /tissue_type="mammary gland"
 /lab_host="DH10B"
 /clone_lib="Soares mammary gland NMLMG"
 /note="Vector: pT73D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from mammary
 gland tissue from a lactating female, and was then primed
 with a Not I - oligo(dT) primer. Double-stranded cDNA was
 ligated to Eco RI adaptors (Pharmacia), digested with Not
 I and cloned into the Not I and Eco RI sites of the
 modified pT73 vector. Library is normalized. Library
 was constructed by Bento Soares and M. Fatima Bonaldo."

FEATURES

source

ORIGIN

Alignment Scores:
 Pred. No.: 8,296-74 Length: 552
 Score: 655.00 Matches: 119
 Percent Similarity: 96.92% Conservative: 7
 Best Local Similarity: 91.54% Mismatches: 4
 Query Match: 92.51% Indels: 0
 DB: 2 Gaps: 0

US-10-072-159-11 (1-130) x BE262509 (1-552)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
 DB 97 TTCAGTGTGGGTGGAGACCGCGTCACTGTCCCAATGACCAATTCGTTTACTAAG 156
 QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyPheHisCysAsnIle 40
 DB 157 ATCTTCTACACCAACAGCAATCATATGACGGCAGCACTGGCAAGTTCCTACTGCAACATT 216
 QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetIleAspValIleValSer 60
 DB 217 CCGGAGCTCTACTCTCTTCACATCATACCGGTGTACATGAAGATGTGAAGTGAGC 276
 QY 61 LeuPheLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGlnAsnVal 80
 DB 277 CTCTTCAAGAGGACCAAGCGCGTCTCTTCCCTACGACCAAGTATCAGAAAGATGTG 336
 QY 81 AspGlnAlaSerGlySerValLeuLeuHisIleuValGlyAspGlnValTyrIleuGln 100
 DB 337 GACCAAGGCTCTGGTCTGTGCTCTCCATCTGGAGGTGGAGACCAAGTCTGCTCCAG 396
 QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspAsnSerThrPhe 120
 DB 397 GTGTATGGGTGGGACCAACATGAGTCTATGCAGATACGTCACGACTCTACATT 456
 QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
 DB 457 ACTGGCTTCTCTCTACCATGATACCAAC 486

RESULT 7

AA028544

LOCUS

DEFINITION

AA028544 566 bp mRNA linear EST 11-SEP-1996
 m11808.r1 Soares mouse p3NNF19.5 Mus musculus cDNA clone
 IMAGE:463863 5' similar to gb:U37222 Mus musculus 30kDa adipocyte
 complement-related protein Acrp30 (MOUSE);, mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

ORIGIN

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

ORIGIN

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

ORIGIN

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

ORIGIN

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

ORIGIN

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Db 476 ATCTTACACACAGATCATTTATGACGAGCAGCTGGCAAGTCTTACTGCAACATT 535
Qy 41 ProGlyLeuTyrPheAlaTyrHisIleThrValTyrMetIysAspValSer 60
Db 536 CCGGGACTCTACTACTTCTCTTACCAACATCAGCGGTACATGAAGATGGAAGTGAGC 595
Qy 61 LeuPheIysAspIysAlaMetLeuPheThrTyrAspGlnTyrClnGluAsnVal 80
Db 596 CTCTTCAAGAGACAGAGCGGCTCTCTTCACTACGACGATACGAGAAAGATGTG 555
Qy 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 656 GACCAGGCTCTGGCTGTGTCTCTCCATCTGAGGTGGAGACCAAGTCTGGCTCCAG 715
Qy 101 ValTyrClyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
Db 716 GTGTATGGGATGGGACCAAGTGGACTCTATGCAGATAACGTCACGACTCTACATT 775
Qy 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 776 ACTGGCTTCTCTCTACCATGATACCAAC 805
RESULT 10
BM384395/c
LOCUS
DEFINITION BM384395 605 bp mRNA linear EST 17-JAN-2002
UI-R-CN1-cj-n-e-02-0-UI.s1 UI-R-CN1 Rattus norvegicus cDNA clone
UI-R-CN1-cj-n-e-02-0-UI 3', mRNA sequence.
ACCESSION BM384395
VERSION BM384395.1 GI:18194448
KEYWORDS ESR.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 605)
Bonaldo,M.F., Lemmon,G. and Soares,M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6 (9), 791-806 (1996)
97044477
889548
Contact: Soares, MB
Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: bento-soares@iowa.edu
The sequence contained an oligo-dT track that was present in the
oligonucleotide that was used to prime the synthesis of first
strand cDNA and therefore this may represent a bonafide poly A
tail. The sequence tag present in the cDNA between the NotI site
and the oligo-dT track served to identify it as a clone from the
normalized brown adipose library cDNA Library Preparation: M.B.
Soares Lab Clone distribution: clones will be available through
Research Genetics (www.reagen.com) The following repetitive
elements were found in this cDNA sequence: 1-25,
>POLY A#Simple_repeat
Seq primer: M13 Forward
POLYA=Yes.
FEATURES
Location/Qualifiers
1..605
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/clone="UI-R-CN1-cj-n-e-02-0-UI"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"
/clone_lib="UI-R-CN1"
/note="Vector: pRT3D-Pac (Pharmacia) with a modified

polylinker; Site 1: Not I; Site 2: Eco RI; The UI-R-CN1 library is a subtracted library derived from the following pool of seven normalized rat libraries: normalized rat seminal vesicles, normalized rat penis, normalized rat bladder, normalized rat cervix, normalized rat brown adipose, normalized rat fundus, and normalized rat salivary gland. It was constructed according to the procedure described by Bonaldo, Lemmon & Soares (Genome Research Genome 6: 791-806, 1996). For construction of the CN1 library, plasmid DNA from the pool of normalized libraries was electroporated into competent bacteria for the production of single-stranded circular DNA. This was then used as a tracer in a subtractive hybridization with a driver (PCR amplified inserts from a plasmid DNA template preparation) comprising: a) a pool of about 34,000 clones from the Rat Unigene Set corresponding to plates R-5-AA-NN excluding plates R-5-MM and MN. This pool represented 40% of the final driver population. b) a pool of about 29,000 clones from subtracted libraries CA0 and CA1 corresponding to plates R-CA0-AWV through R-CA0-AXS, R-CA0-AZX through R-CA0-BAZ, R-CA0-BFE through R-CA0-BHI, R-CA0-BJS, R-CA0-BKE, R-CA0-BKG-H, R-CA0-BKG-K, R-CA0-BKP through R-CA0-BKS, R-CA0-BKU-V, R-CA0-BLY through R-CA0-BNA, R-CA0-EMC through R-CA0-EME, R-CA0-BNS, R-CA0-BOB through R-CA0-BPG, R-CA0-BPA through R-CA0-BPG, R-CA1-BBA through R-CA1-BDA, R-CA1-BHZ through R-CA1-BJF, R-CA1-BJR, R-CA1-BUT through R-CA1-BKB, R-CA1-BKD, R-CA1-BKF, R-CA1-BKT, R-CA1-BUF, R-CA1-BUL, R-CA1-BLN through R-CA1-BLN, R-CA1-BLS, R-CA1-BLU-V, R-CA1-BNR, and R-CA1-BLE. The resulting pool represented 20% of the final driver population. c) a pool of about 15,000 clones from non-normalized libraries CS0s, CT0s, CU0s, CW0s, CX0s and normalized libraries CS0, CT0, CU0, CW0, and CX0 corresponding to plates R-CS0s-CD through R-CS0s-CBO, R-CT0s-CAM through R-CT0s-CAX, R-CU0s-CCP through R-CU0s-CCA, R-CW0s-CCB through R-CW0s-CCM, R-CX0s-CCN through R-CX0s-CCX, R-CS0-BSD, R-CS0-BTD through R-CS0-BTV, R-CS0-BVM, R-CT0-BTW through R-CT0-BUP, R-CT0-BVN, R-CU0-BUQ through R-CU0-BVL, R-CW0-BVU through R-CW0-BVP, R-CW0-BXN through R-CW0-BXO, R-CX0-BWQ through R-CX0-BXM. The resulting pool represented 5% of the final driver population. d) a pool of about 5,000 clones from non-normalized eye library CV0 and 4,000 from normalized eye library CV1) corresponding to plates R-CV0-BRH through R-CV0-BRR, R-CV1-BRS through R-CV1-BSC, R-CV1-BSE through R-CV1-BTC, and R-CV1-BVO through R-CV1-BVU. This pool represented about 5% of the final driver population. e) A pool of about 10,000 clones from subtracted library BS2, BV0 and BV0p (7-9.5 kb cDNA library fraction from rat whole embryo), and BX0 (0.5-7kb cDNA library fraction from rat whole embryo) corresponding to plates R-BS2-BDB through R-BS2-BFB, R-BV0-ANK through R-BV0-ANR, R-BV0p-AOI through R-BV0p-AOX, and R-BX0-AQY through R-BX0-ASH. The resulting pool represented 5% of the final driver population. f) a pool of about 7,000 clones from the seven non-normalized libraries that make up the tracer including CY0, CZ0, DA0, DB0, DC0, DD0, and DE0 corresponding to plates R-CY0-BXP through R-CY0-BXZ, R-CZ0-EVA through R-CZ0-EYI, R-CZ0-BZB-C, R-DA0-BYJ through R-DA0-BYP, R-DA0-BZ1 through R-DA0-BZH, R-DB0-BYQ through R-DB0-BZA, R-DC0-BZ1 through R-DC0-BZQ, R-DD0-BYQ through R-DD0-BZA, R-DD0-BZB through R-DD0-BZC, R-DD0-BZB-C, and R-DE0-CAB through R-DE0-CAL. The resulting pool represented about 10% of the final driver population. g) a pool of about 2,000 clones from the pool of normalized libraries, CN0, that makes up the tracer. The corresponding plates are R-CN0-BKW through R-CN0-BLD, R-CN0-BLG, R-CN0-BLP through R-CN0-BLR, R-CN0-BLT, R-CN0-BUN-X, R-CN0-BWB, and R-CN0-BMF through R-CN0-BML. This pool represented 5% of the final driver population. h) a pool of the 28 most abundant clones in the CN0 pool corresponding to the following addresses: bkx-a-09-0-UI, bkx-b-09-0-UI, bkx-b-11-0-UI, bkx-b-10-0-UI,

Db 247 GACGAGGCTCTGGCTCTGCTCTCCATCTGGAGGTGGAGACCAAGTCTGGCTCCAG 306

QY 101 valtyrGlyGluGluArgAnGlyLeuTyRAlaAspAsnAspSerThrPhe 120

Db 307 GTGTATGGGATGGGACCAACATGACTCTATGCAGATAACGTCAACGACTCTACATT 366

QY 121 ThrGlyPheLeuLeuTyRHisAspThrAsn 130

Db 367 ACTGGCTTCTCTCTACCATGATACCAAC 396

RESULT 12

BC078720 1465 bp mRNA linear HTC 03-AUG-2004

LOCUS Rattus norvegicus cDNA clone IMAGE:7109244, containing frame-shift errors.

DEFINITION BC078720

ACCESSION BC078720.1 GI:50927299

VERSION BC078720

KEYWORDS Rattus norvegicus (Norway rat)

SOURCE Rattus norvegicus

ORGANISM Rattus norvegicus

REFERENCE 1 (bases 1 to 1465)

AUTHORS Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, A.K., Moore, S.I., Max, S.I., Wang, J., Hsieh, P., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, A.A., Rabin, G.M., Hong, L., Scapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Schencki, F.E., Brownstein, M.J., Usdin, T.B., Loquellano, N.A., Peters, G.J., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahy, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickinson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalusz, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

TITLE Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

PUBMED 12477932

REFERENCE 2 (bases 1 to 1465)

AUTHORS Director MGC Project.

TITLE Direct Submission

JOURNAL Submitted (02-AUG-2004) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>

COMMENT Contact: MGC help desk

Email: cgaps-remail.nih.gov

Tissue Procurement: Howard Jacobs

CNA Library Preparation: Express Genomics

CNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Sequencing Group at the Stanford Human Genome Center, Stanford University School of Medicine, Stanford, CA 94305

Web site: <http://www-shgc.stanford.edu>

Contact: (Dickson, Mark) mcd@paxil.stanford.edu

Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAC Plate: 181 Row: 1 Column: 7

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 21426808

This clone has the following problem: frame shifted.

Location/Qualifiers

source 1.1465

/organism="Rattus norvegicus"

/mol_type="mRNA"

/db_xref="taxon:10116"

/clone="IMAGE:7109244"

/tissue_type="Kidney, rat (Brown Norway)"

/clone_lib="NIH_MGC_235"

/lab_host="DH10B"

/note="Vector: pExpress1"

ORIGIN

Alignment Scores: 4,41e-71 Length: 1465

Pred. No.: 638.00 Matches: 120

Score: 96.92% Conservative: 6

Percent Similarity: 92.31% Mismatches: 4

Best Local Similarity: 90.11% Indels: 1

Query Match: 3 Gaps: 0

DB:

US-10-072-159-11 (1-130) x BC078720 (1-1465).

QY 1 PheSerValGlyLeuGluThrTyRValThrIleProAsnMetProIleArgPheThrLys 20

Db 383 TTCAGCGTAGGGCTGGAGACCGCGTCACTGTCCCAATGTCCCATTCGCTTTACTAAG 442

QY 21 IlePheTyRAsnGlnGlnAsnHisTyRAspGlySerThrGlyLysPheHisCysAsnIle 40

Db 443 ATCTTCTACAAACCAACAGATCATTAATGCGGAGAGCTGGCAATTCCTACTGCACATT 502

QY 41 ProGlyLeuTyRValPheAlaTyRHisIleThrValTyRMetLysAspValLysValSer 60

Db 503 CCGGGCTCTACTACTTCTTCTCCACCATCACGGTGTACATGAAGGATGTGAAGTGCAGC 562

QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyRAspGlnTyRValGlnGluAsnVal 80

Db 563 CTCTTCAAGAGGAGGAGCGGCTCTCTTCCCTACCGAGGATATCAGGAAAAA-AATGTG 621

QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100

Db 622 GACAGGCTCTGGCTCTCATCTCTCTCACTGGAGGTGGAGACCAAGTCTGGCTCCAA 681

QY 101 ValTyRValGlyGluGluArgAsnGlyLeuTyRAlaAspAsnAspSerThrPhe 120

Db 682 GTGTATGGGAGGAGGAGCAACATGGACTCTATGCAGATAATGCAATGACTCTACATT 741

QY 121 ThrGlyPheLeuLeuTyRHisAspThrAsn 130

Db 742 ACAGGCTTCTCTCTACCATGATACCAAC 771

RESULT 13

LOCUS A1105446/c

DEFINITION R21214735 Normalized rat kidney, Bonto Soares Rattus sp. cDNA clone EST214735 3' end; mRNA sequence.

ACCESSION A1105446

VERSION A1105446.1 GI:3709525

KEYWORDS EST.

SOURCE Rattus sp.

ORGANISM Rattus sp.

REFERENCE 1 (bases 1 to 543)

AUTHORS Lee, N.H., Glodex, A., Chandra, I., Mason, T.M., Quackenbush, J., Kerlavage, A.R. and Adams, M.D.

TITLE Rat Genome Project: Generation of a Rat EST (EST) Catalog & Rat Gene Index

JOURNAL Unpublished (1998)

COMMENT Other ESTs: TC52707

Contact: Lee, NH

The Institute for Genomic Research

9712, Medical Center Drive, Rockville, MD 20850, USA

Tel: (301)-838-3529

BEST AVAILABLE COPY

Fax: (301)-838-0208
Email: mhlee@igr.org
Seq primer: M13-21

FEATURES

source

Location/Qualifiers
1..543
/organism="Rattus sp."
/mol_type="mRNA"
/db_xref="ATCC (inhost):2030555"
/db_xref="taxon:10118"
/clone="RK18K49"
/clone_lib="Normalized rat kidney, Bento Soares"
/note="Organ: Kidney; Vector: pT73Pac; Site 1: EcoRI;
Site 2: NotI"

ORIGIN

Alignment Scores:
Pred. No.: 1,69e-71 Length: 543
Score: 637.00 Matches: 115
Percent Similarity: 96.80% Conservatives: 6
Best Local Similarity: 92.00% Mismatches: 4
Query Match: 89.97% Indels: 0
DB: 1 Gaps: 0

US-10-072-159-11 (1-130) x A1105446 (1-543)

QY 6 GluThrTyrValThrIleProAsnMetProIleArgPheThrLysIlePheTyrAsnGln 25
DB 529 GAGACCGCGTCACGTGCCCAATGTTCCCATTCGCTTACTAGATCTTCTACAACCA 470
QY 26 GlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIleProGlyLeuTyrTyr 45
DB 469 CAGATCATATGACGGCAGCACTGGCAATTCCTGCACTGCACATTCGGGGCTCTACTAC 410
QY 46 PheAlaTyrHisIleThrValTyrMetLysAspValLysValSerLeuPheLysAsp 65
DB 409 TTTTCTTACCACATCACGCTGTACATGAAGATGTGAAGTGAGGCTCTTCAAGAGGAC 350
QY 66 LysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnValAspGlnAlaSerGly 85
DB 349 AAGCGGTCTCTTCCCTACACAGATATCAGGAAAAATGTGGACCGCTCTGTGC 290
QY 86 SerValLeuLeuHisLeuGluValGlyAspGlnValTyrLeuGlnValTyrGlyGluGly 105
DB 289 TCCATGCTCTCCATCTGAGGTGGAGACCAAGTCTGGCTCCAAGTGTATGGGAGGG 230
QY 106 GluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPheThrGlyPheLeuLeu 125
DB 229 GACACAAAGGACTCTATGCAGATAATGTCAATGACTCTACATTACAGGCTTCTTCTC 170
QY 126 TyrHisAspThrAsn 130
DB 169 TACCATGATACCAAC 155

RESULT 14
BQ189822/c
LOCUS
DEFINITION
Rattus norvegicus (Norway rat)
VERSION
BQ189822.1 GI:20365373
KEYWORDS
EST.
ACCESSION
BQ189822
UI-R-CN1-cjn-e-02-0-UI-s3 UI-R-CN1 Rattus norvegicus cDNA clone
UI-R-CN1-cjn-e-02-0-UI 3', mRNA sequence.

577 bp mRNA linear EST 30-APR-2002
Rattus norvegicus (Norway rat)
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

1 (bases 1 to 577)
REFERENCE
AUTHORS
TITLE
Normalization and subtraction: two approaches to facilitate gene
discovery
JOURNAL
Genome Res. 6 (9), 791-806 (1996)
MEDLINE
9704477
PUBMED
889548

Contact: Soares, MS

Coordinated Laboratory for Computational Genomics

University of Iowa
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565

Email: bento-soares@uiowa.edu

The sequence contained an oligo-dT track that was present in the oligonucleotide that was used to prime the synthesis of first strand cDNA and therefore this may represent a bonafide poly A tail. The sequence tag present in the cDNA between the NotI site and the oligo-dT track served to identify it as a clone from the normalized brown adipose library cDNA Library Preparation: M.B. Soares Lab Clone distribution: clones will be available through Research Genetics (www.resgen.com)

Seq primer: M13 Forward

PODIA=Yes.

FEATURES

Location/Qualifiers

1..577
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/clone="UI-R-CN1-cjn-e-02-0-UI"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"
/clone_lib="UI-R-CN1"
/notes="Vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site 1: Not-I; Site 2: Eco RI; The UI-R-CN1 library is a subtracted library derived from the following pool of seven normalized rat libraries: normalized rat seminal vesicles, normalized rat penis, normalized rat bladder, normalized rat cervix, normalized rat brown adipose, normalized rat fundus, and normalized rat salivary gland. It was constructed according to the procedures described by Bonaldo, Lennon & Soares (Genome Research Genome 6: 791-806, 1996). For construction of the CN1 library, plasmid DNA from the pool of normalized libraries was electroporated into competent bacteria for the production of single-stranded circular DNA. This was then used as a tracer in a subtractive hybridization with a driver (PCR amplified inserts from a plasmid DNA template preparation) comprising: a) a pool of about 34,000 clones from the Rat Unigene Set corresponding to plates R-5-AA-NN excluding plates R-5-MM and MN. This pool represented 40% of the final driver population. b) a pool of about 29,000 clones from subtracted libraries CA0 and CA1 corresponding to plates R-CA0-AW through R-CA0-AXS, R-CA0-AZX through R-CA0-BAZ, R-CA0-BFE through R-CA0-BHY, R-CA0-BJS, R-CA0-BKE, R-CA0-BKG-M, R-CA0-BKT-K, R-CA0-BKP through R-CA0-BKS, R-CA0-BKU-V, R-CA0-BLY through R-CA0-BWA, R-CA0-BWC through R-CA0-BWE, R-CA0-BNS, R-CA0-BOB through R-CA0-BOU, R-CA0-BPA through R-CA0-BPG, R-CA0-BBA through R-CA1-BDA, R-CA1-BHZ through R-CA1-BJF, R-CA1-BJR, R-CA1-BJT through R-CA1-BKB, R-CA1-BKD, R-CA1-BKF, R-CA1-BKI, R-CA1-BKT, R-CA1-BLF, R-CA1-BLH through R-CA1-BLN, R-CA1-BLS, R-CA1-BLU-V, R-CA1-BNR, and R-CA1-BLE. The resulting pool represented 20% of the final driver population. c) a pool of about 15,000 clones from non-normalized libraries CS0, CT0, CU0, CW0, and CX0 and normalized libraries CS0, CT0, CU0, CW0, and CX0 corresponding to plates R-CT0s-CAX, R-CU0s-CBP through R-CU0s-CCA, R-CW0s-CCB through R-CW0s-CCM, R-CX0s-CCN through R-CX0s-CCX, R-CS0-BSD, R-CS0-BTD through R-CS0-BTV, R-CS0-BVM, R-CT0-BTW through R-CT0-BUP, R-CT0-BVN, R-CU0-BUQ through R-CU0-BVL, R-CW0-BVU through R-CW0-BWP, R-CW0-BXN through R-CW0-BXO, R-CX0-BMQ through R-CX0-BMW. The resulting pool represented 5% of the final driver population. d) a pool of about 5,000 clones (1,000 from non-normalized eye library CV0 and 4,000 from normalized eye library CV1) corresponding to plates R-CV0-SRH through R-CV0-BRR, R-CV1-BRS through R-CV1-BSC,

DB: 1 Gaps: 0

US-10-072-159-11 (1-130) x AA763396 (1-811)

QY 1 PheSerValGlyLeuGluThrTyrValThrIleProAsnMetProIleArgPheThrLys 20
Db 57 TTCAAGTGGGGTGGAGCCG-GTCACATGTTCCCAATGTACCCATGGCTTTACTAAG 115
QY 21 IlePheTyrAsnGlnGlnAsnHisTyrAspGlySerThrGlyLysPheHisCysAsnIle 40
Db 116 ATCTTCTACCAACCAACAGAAATCATTATGACGGCAGCAGCTGGCAAGTTCTACTGCAACATT 175
QY 41 ProGlyLeuTyrTyrPheAlaTyrHisIleThrValTyrMetLysAspValLysValSer 60
Db 176 CCGGACTCTACTACTCTCTTACCAATCAGCTGATGATGAAAGATGTAAGGTGAGC 235
QY 61 LeuPheLysLysAspLysAlaMetLeuPheThrTyrAspGlnTyrGlnGluAsnVal 80
Db 236 CTCTTCAAGAAGACAAAGGCGTCTCTTCCCTACGACCATATCAGAAAGATGTG 295
QY 81 AspGlnAlaSerGlySerValLeuLeuHisLeuGluValGlyAspGlnValTrpLeuGln 100
Db 296 GACCAGGCTCTGGCTCTGTGTCTCTCCATCTGGAGGTGGAGACCAAGTCTGGCTCCAG 355
QY 101 ValTyrGlyGluGlyGluArgAsnGlyLeuTyrAlaAspAsnAspSerThrPhe 120
Db 356 GTGTATGGGATGGGACCAACATATGACTCTATGCAATACGTCAACGACTTACATT 415
QY 121 ThrGlyPheLeuLeuTyrHisAspThrAsn 130
Db 416 ACTGGCTTTCTTCTTACCATGATACCAAC 445

Search completed: December 3, 2004, 12:30:23
Job time : 2981 secs

